Master Alliance Provisions Guide (MAPGuide)

Search Results For:

  • Search results for:
    • COVID-19
(Click + to show provisions)
Agreement title
Effective date
Partner type
Technology
Development stage
US Department of Defense - Moderna, COVID-19 Vaccine Supply Agreement
2020
Government
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Sanofi - Translate Bio, Influenza and COVID-19 Vaccine Collaboration & License Agreement
2020
Industry
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
NIH - GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
2020
Government
Industry
Vaccine
Preclinical
Commercialization

				GHIAA2019\MapguideSearch Object
(
    [search_parameters] => Array
        (
            [qs] => COVID-19
        )

    [filters] => Array
        (
            [text_search] => COVID-19
        )

    [child_filters] => Array
        (
        )

    [agreement_args] => 
    [provision_args] => Array
        (
            [post_type] => provision_document
            [posts_per_page] => -1
            [post__in] => Array
                (
                    [0] => 11750
                    [1] => 11749
                    [2] => 11748
                    [3] => 11747
                    [4] => 11746
                    [5] => 11745
                    [6] => 11744
                    [7] => 11743
                    [8] => 11742
                    [9] => 11741
                    [10] => 11740
                    [11] => 11724
                    [12] => 11610
                    [13] => 11609
                    [14] => 11606
                    [15] => 11605
                    [16] => 11604
                    [17] => 11618
                    [18] => 11613
                    [19] => 11611
                    [20] => 11602
                    [21] => 11617
                    [22] => 11616
                    [23] => 11614
                    [24] => 11607
                    [25] => 11361
                    [26] => 11360
                    [27] => 11359
                    [28] => 11358
                    [29] => 11357
                    [30] => 11356
                    [31] => 11354
                    [32] => 11353
                    [33] => 11351
                    [34] => 11350
                    [35] => 11349
                    [36] => 11347
                    [37] => 11348
                    [38] => 11346
                    [39] => 11345
                    [40] => 11337
                    [41] => 11336
                    [42] => 11335
                    [43] => 11334
                    [44] => 11333
                    [45] => 11331
                    [46] => 11330
                    [47] => 11329
                    [48] => 11328
                    [49] => 11327
                    [50] => 11260
                    [51] => 11259
                    [52] => 11258
                    [53] => 11257
                    [54] => 11256
                    [55] => 11255
                    [56] => 11254
                    [57] => 11252
                    [58] => 11251
                    [59] => 11250
                    [60] => 11248
                    [61] => 11247
                    [62] => 11145
                    [63] => 11144
                    [64] => 11143
                    [65] => 11142
                    [66] => 11141
                    [67] => 11140
                    [68] => 11139
                    [69] => 11138
                    [70] => 11137
                    [71] => 11136
                    [72] => 11135
                    [73] => 11111
                    [74] => 11019
                    [75] => 11021
                    [76] => 11023
                    [77] => 11028
                    [78] => 11029
                    [79] => 11018
                    [80] => 11031
                    [81] => 11020
                    [82] => 11032
                    [83] => 11026
                    [84] => 11030
                    [85] => 11022
                    [86] => 10998
                    [87] => 10997
                    [88] => 10995
                    [89] => 9090
                    [90] => 9089
                    [91] => 9088
                    [92] => 9087
                    [93] => 9086
                    [94] => 9083
                    [95] => 9082
                    [96] => 9081
                    [97] => 9080
                    [98] => 9079
                    [99] => 9078
                    [100] => 9077
                    [101] => 9076
                    [102] => 9073
                    [103] => 9072
                    [104] => 9071
                    [105] => 9070
                    [106] => 9069
                    [107] => 9068
                    [108] => 9067
                    [109] => 9066
                    [110] => 9065
                    [111] => 9064
                    [112] => 9063
                    [113] => 9062
                    [114] => 9061
                    [115] => 8462
                    [116] => 8447
                    [117] => 8314
                    [118] => 8313
                    [119] => 8312
                    [120] => 8311
                    [121] => 8192
                    [122] => 8191
                    [123] => 8190
                    [124] => 8157
                    [125] => 8152
                    [126] => 8151
                    [127] => 8150
                    [128] => 8143
                    [129] => 8142
                    [130] => 8131
                    [131] => 8130
                    [132] => 8129
                    [133] => 8051
                    [134] => 5808
                    [135] => 5782
                    [136] => 5653
                    [137] => 5652
                    [138] => 5620
                    [139] => 5619
                    [140] => 5618
                    [141] => 5617
                    [142] => 5616
                    [143] => 5615
                    [144] => 5614
                    [145] => 5612
                    [146] => 5611
                    [147] => 5610
                    [148] => 5609
                    [149] => 5608
                    [150] => 5599
                    [151] => 5596
                    [152] => 5595
                    [153] => 5594
                    [154] => 5593
                    [155] => 5592
                    [156] => 5591
                    [157] => 5429
                    [158] => 5123
                    [159] => 5122
                    [160] => 5121
                    [161] => 5120
                    [162] => 5119
                    [163] => 5118
                    [164] => 5117
                    [165] => 5116
                    [166] => 5115
                    [167] => 5114
                    [168] => 5113
                    [169] => 5112
                    [170] => 5111
                    [171] => 4808
                    [172] => 4807
                    [173] => 4806
                    [174] => 4805
                    [175] => 4804
                    [176] => 4802
                    [177] => 4801
                    [178] => 4800
                    [179] => 4798
                    [180] => 4797
                    [181] => 4796
                    [182] => 4661
                    [183] => 4147
                    [184] => 4601
                    [185] => 4148
                    [186] => 4223
                    [187] => 4222
                    [188] => 4221
                    [189] => 4220
                    [190] => 4219
                    [191] => 4218
                    [192] => 4217
                    [193] => 4216
                    [194] => 4215
                    [195] => 4214
                    [196] => 4213
                    [197] => 4212
                    [198] => 4210
                    [199] => 4209
                    [200] => 4205
                    [201] => 4204
                    [202] => 4201
                    [203] => 4200
                    [204] => 4161
                    [205] => 4159
                    [206] => 4158
                    [207] => 4157
                    [208] => 4156
                    [209] => 4155
                    [210] => 4154
                    [211] => 4153
                    [212] => 4152
                    [213] => 4151
                    [214] => 4150
                    [215] => 4149
                    [216] => 4146
                    [217] => 4141
                    [218] => 4140
                    [219] => 4139
                    [220] => 4138
                    [221] => 4137
                    [222] => 4136
                    [223] => 4135
                    [224] => 4134
                    [225] => 4133
                    [226] => 4131
                    [227] => 4130
                    [228] => 4129
                    [229] => 4128
                    [230] => 4058
                    [231] => 4054
                    [232] => 4051
                    [233] => 4050
                    [234] => 4047
                    [235] => 4046
                    [236] => 4045
                    [237] => 4043
                    [238] => 4042
                    [239] => 4041
                    [240] => 4040
                    [241] => 4038
                    [242] => 4036
                    [243] => 4035
                    [244] => 4032
                    [245] => 4029
                    [246] => 4028
                    [247] => 4024
                    [248] => 4022
                    [249] => 4021
                    [250] => 4020
                    [251] => 4017
                    [252] => 4016
                    [253] => 4014
                    [254] => 4013
                    [255] => 4011
                    [256] => 4009
                    [257] => 4007
                    [258] => 4006
                    [259] => 4004
                    [260] => 4003
                    [261] => 4002
                    [262] => 4001
                    [263] => 3997
                    [264] => 3869
                    [265] => 3886
                    [266] => 3884
                    [267] => 3883
                    [268] => 3882
                    [269] => 3881
                    [270] => 3880
                    [271] => 3878
                    [272] => 3877
                    [273] => 3876
                    [274] => 3875
                    [275] => 3874
                    [276] => 3873
                    [277] => 3870
                    [278] => 3863
                    [279] => 3861
                    [280] => 3860
                    [281] => 3859
                    [282] => 3858
                    [283] => 3857
                    [284] => 3856
                    [285] => 3855
                    [286] => 3854
                    [287] => 3852
                    [288] => 3851
                    [289] => 3849
                    [290] => 3848
                    [291] => 3847
                    [292] => 3846
                    [293] => 3812
                    [294] => 3810
                    [295] => 3809
                    [296] => 3808
                    [297] => 3807
                    [298] => 3806
                    [299] => 3805
                    [300] => 3804
                    [301] => 3803
                    [302] => 3802
                    [303] => 3801
                    [304] => 3800
                    [305] => 3799
                    [306] => 3798
                    [307] => 3797
                    [308] => 3796
                    [309] => 3792
                    [310] => 3791
                    [311] => 3789
                    [312] => 3788
                    [313] => 3786
                    [314] => 3784
                    [315] => 3783
                    [316] => 3782
                    [317] => 3781
                    [318] => 3778
                    [319] => 3765
                    [320] => 3764
                    [321] => 3758
                    [322] => 3741
                    [323] => 3696
                    [324] => 3495
                    [325] => 3493
                    [326] => 3436
                    [327] => 3434
                    [328] => 3433
                    [329] => 3431
                    [330] => 3430
                    [331] => 3428
                    [332] => 3427
                    [333] => 3426
                    [334] => 3424
                    [335] => 3422
                    [336] => 3421
                    [337] => 3420
                    [338] => 3372
                    [339] => 3370
                    [340] => 3368
                    [341] => 3366
                    [342] => 3364
                    [343] => 3361
                    [344] => 3360
                    [345] => 3356
                    [346] => 3354
                    [347] => 3352
                    [348] => 3221
                    [349] => 3220
                    [350] => 3219
                    [351] => 3218
                    [352] => 3217
                    [353] => 3215
                    [354] => 3127
                    [355] => 3126
                    [356] => 3125
                    [357] => 3123
                    [358] => 3122
                    [359] => 3121
                    [360] => 3120
                    [361] => 3119
                    [362] => 2956
                    [363] => 2961
                    [364] => 2965
                    [365] => 2947
                    [366] => 2960
                    [367] => 2964
                    [368] => 2958
                    [369] => 2949
                    [370] => 2957
                    [371] => 2962
                    [372] => 2945
                    [373] => 2909
                    [374] => 2908
                    [375] => 2907
                    [376] => 2893
                    [377] => 2892
                    [378] => 2890
                    [379] => 2889
                    [380] => 2885
                    [381] => 2824
                    [382] => 2822
                    [383] => 2820
                    [384] => 2744
                    [385] => 2749
                    [386] => 2748
                    [387] => 2743
                    [388] => 2742
                    [389] => 2741
                    [390] => 2739
                    [391] => 2737
                    [392] => 2736
                    [393] => 2734
                    [394] => 2543
                    [395] => 2540
                    [396] => 2541
                    [397] => 2542
                    [398] => 2544
                    [399] => 2545
                    [400] => 2547
                    [401] => 2549
                    [402] => 2553
                    [403] => 2457
                    [404] => 2461
                    [405] => 2462
                    [406] => 2463
                    [407] => 2464
                    [408] => 2465
                    [409] => 2466
                    [410] => 2467
                    [411] => 2470
                    [412] => 2473
                    [413] => 2474
                    [414] => 2475
                    [415] => 2476
                    [416] => 2477
                    [417] => 2479
                    [418] => 2481
                    [419] => 2482
                    [420] => 2471
                    [421] => 2452
                    [422] => 2450
                    [423] => 2449
                    [424] => 2448
                    [425] => 2444
                    [426] => 2443
                    [427] => 2442
                    [428] => 2441
                    [429] => 2426
                    [430] => 2424
                    [431] => 11750
                    [432] => 11749
                    [433] => 11748
                    [434] => 11747
                    [435] => 11746
                    [436] => 11745
                    [437] => 11744
                    [438] => 11743
                    [439] => 11742
                    [440] => 11741
                    [441] => 11740
                    [442] => 11724
                    [443] => 11610
                    [444] => 11609
                    [445] => 11606
                    [446] => 11605
                    [447] => 11604
                    [448] => 11618
                    [449] => 11613
                    [450] => 11611
                    [451] => 11602
                    [452] => 11617
                    [453] => 11616
                    [454] => 11614
                    [455] => 11607
                    [456] => 11361
                    [457] => 11360
                    [458] => 11359
                    [459] => 11358
                    [460] => 11357
                    [461] => 11356
                    [462] => 11354
                    [463] => 11353
                    [464] => 11351
                    [465] => 11350
                    [466] => 11349
                    [467] => 11347
                    [468] => 11348
                    [469] => 11346
                    [470] => 11345
                    [471] => 11337
                    [472] => 11336
                    [473] => 11335
                    [474] => 11334
                    [475] => 11333
                    [476] => 11331
                    [477] => 11330
                    [478] => 11329
                    [479] => 11328
                    [480] => 11327
                    [481] => 11260
                    [482] => 11259
                    [483] => 11258
                    [484] => 11257
                    [485] => 11256
                    [486] => 11255
                    [487] => 11254
                    [488] => 11252
                    [489] => 11251
                    [490] => 11250
                    [491] => 11248
                    [492] => 11247
                    [493] => 11145
                    [494] => 11144
                    [495] => 11143
                    [496] => 11142
                    [497] => 11141
                    [498] => 11140
                    [499] => 11139
                    [500] => 11138
                    [501] => 11137
                    [502] => 11136
                    [503] => 11135
                    [504] => 11111
                    [505] => 11019
                    [506] => 11021
                    [507] => 11023
                    [508] => 11028
                    [509] => 11029
                    [510] => 11018
                    [511] => 11031
                    [512] => 11020
                    [513] => 11032
                    [514] => 11026
                    [515] => 11030
                    [516] => 11022
                    [517] => 10998
                    [518] => 10997
                    [519] => 10995
                    [520] => 9090
                    [521] => 9089
                    [522] => 9088
                    [523] => 9087
                    [524] => 9086
                    [525] => 9083
                    [526] => 9082
                    [527] => 9081
                    [528] => 9080
                    [529] => 9079
                    [530] => 9078
                    [531] => 9077
                    [532] => 9076
                    [533] => 9073
                    [534] => 9072
                    [535] => 9071
                    [536] => 9070
                    [537] => 9069
                    [538] => 9068
                    [539] => 9067
                    [540] => 9066
                    [541] => 9065
                    [542] => 9064
                    [543] => 9063
                    [544] => 9062
                    [545] => 9061
                    [546] => 8462
                    [547] => 8447
                    [548] => 8314
                    [549] => 8313
                    [550] => 8312
                    [551] => 8311
                    [552] => 8192
                    [553] => 8191
                    [554] => 8190
                    [555] => 8157
                    [556] => 8152
                    [557] => 8151
                    [558] => 8150
                    [559] => 8143
                    [560] => 8142
                    [561] => 8131
                    [562] => 8130
                    [563] => 8129
                    [564] => 8051
                    [565] => 5808
                    [566] => 5782
                    [567] => 5653
                    [568] => 5652
                    [569] => 5620
                    [570] => 5619
                    [571] => 5618
                    [572] => 5617
                    [573] => 5616
                    [574] => 5615
                    [575] => 5614
                    [576] => 5612
                    [577] => 5611
                    [578] => 5610
                    [579] => 5609
                    [580] => 5608
                    [581] => 5599
                    [582] => 5596
                    [583] => 5595
                    [584] => 5594
                    [585] => 5593
                    [586] => 5592
                    [587] => 5591
                    [588] => 5429
                    [589] => 5123
                    [590] => 5122
                    [591] => 5121
                    [592] => 5120
                    [593] => 5119
                    [594] => 5118
                    [595] => 5117
                    [596] => 5116
                    [597] => 5115
                    [598] => 5114
                    [599] => 5113
                    [600] => 5112
                    [601] => 5111
                    [602] => 4808
                    [603] => 4807
                    [604] => 4806
                    [605] => 4805
                    [606] => 4804
                    [607] => 4802
                    [608] => 4801
                    [609] => 4800
                    [610] => 4798
                    [611] => 4797
                    [612] => 4796
                    [613] => 4661
                    [614] => 4147
                    [615] => 4601
                    [616] => 4148
                    [617] => 4223
                    [618] => 4222
                    [619] => 4221
                    [620] => 4220
                    [621] => 4219
                    [622] => 4218
                    [623] => 4217
                    [624] => 4216
                    [625] => 4215
                    [626] => 4214
                    [627] => 4213
                    [628] => 4212
                    [629] => 4210
                    [630] => 4209
                    [631] => 4205
                    [632] => 4204
                    [633] => 4201
                    [634] => 4200
                    [635] => 4161
                    [636] => 4159
                    [637] => 4158
                    [638] => 4157
                    [639] => 4156
                    [640] => 4155
                    [641] => 4154
                    [642] => 4153
                    [643] => 4152
                    [644] => 4151
                    [645] => 4150
                    [646] => 4149
                    [647] => 4146
                    [648] => 4141
                    [649] => 4140
                    [650] => 4139
                    [651] => 4138
                    [652] => 4137
                    [653] => 4136
                    [654] => 4135
                    [655] => 4134
                    [656] => 4133
                    [657] => 4131
                    [658] => 4130
                    [659] => 4129
                    [660] => 4128
                    [661] => 4058
                    [662] => 4054
                    [663] => 4051
                    [664] => 4050
                    [665] => 4047
                    [666] => 4046
                    [667] => 4045
                    [668] => 4043
                    [669] => 4042
                    [670] => 4041
                    [671] => 4040
                    [672] => 4038
                    [673] => 4036
                    [674] => 4035
                    [675] => 4032
                    [676] => 4029
                    [677] => 4028
                    [678] => 4024
                    [679] => 4022
                    [680] => 4021
                    [681] => 4020
                    [682] => 4017
                    [683] => 4016
                    [684] => 4014
                    [685] => 4013
                    [686] => 4011
                    [687] => 4009
                    [688] => 4007
                    [689] => 4006
                    [690] => 4004
                    [691] => 4003
                    [692] => 4002
                    [693] => 4001
                    [694] => 3997
                    [695] => 3869
                    [696] => 3886
                    [697] => 3884
                    [698] => 3883
                    [699] => 3882
                    [700] => 3881
                    [701] => 3880
                    [702] => 3878
                    [703] => 3877
                    [704] => 3876
                    [705] => 3875
                    [706] => 3874
                    [707] => 3873
                    [708] => 3870
                    [709] => 3863
                    [710] => 3861
                    [711] => 3860
                    [712] => 3859
                    [713] => 3858
                    [714] => 3857
                    [715] => 3856
                    [716] => 3855
                    [717] => 3854
                    [718] => 3852
                    [719] => 3851
                    [720] => 3849
                    [721] => 3848
                    [722] => 3847
                    [723] => 3846
                    [724] => 3812
                    [725] => 3810
                    [726] => 3809
                    [727] => 3808
                    [728] => 3807
                    [729] => 3806
                    [730] => 3805
                    [731] => 3804
                    [732] => 3803
                    [733] => 3802
                    [734] => 3801
                    [735] => 3800
                    [736] => 3799
                    [737] => 3798
                    [738] => 3797
                    [739] => 3796
                    [740] => 3792
                    [741] => 3791
                    [742] => 3789
                    [743] => 3788
                    [744] => 3786
                    [745] => 3784
                    [746] => 3783
                    [747] => 3782
                    [748] => 3781
                    [749] => 3778
                    [750] => 3765
                    [751] => 3764
                    [752] => 3758
                    [753] => 3741
                    [754] => 3696
                    [755] => 3495
                    [756] => 3493
                    [757] => 3436
                    [758] => 3434
                    [759] => 3433
                    [760] => 3431
                    [761] => 3430
                    [762] => 3428
                    [763] => 3427
                    [764] => 3426
                    [765] => 3424
                    [766] => 3422
                    [767] => 3421
                    [768] => 3420
                    [769] => 3372
                    [770] => 3370
                    [771] => 3368
                    [772] => 3366
                    [773] => 3364
                    [774] => 3361
                    [775] => 3360
                    [776] => 3356
                    [777] => 3354
                    [778] => 3352
                    [779] => 3221
                    [780] => 3220
                    [781] => 3219
                    [782] => 3218
                    [783] => 3217
                    [784] => 3215
                    [785] => 3127
                    [786] => 3126
                    [787] => 3125
                    [788] => 3123
                    [789] => 3122
                    [790] => 3121
                    [791] => 3120
                    [792] => 3119
                    [793] => 2956
                    [794] => 2961
                    [795] => 2965
                    [796] => 2947
                    [797] => 2960
                    [798] => 2964
                    [799] => 2958
                    [800] => 2949
                    [801] => 2957
                    [802] => 2962
                    [803] => 2945
                    [804] => 2909
                    [805] => 2908
                    [806] => 2907
                    [807] => 2893
                    [808] => 2892
                    [809] => 2890
                    [810] => 2889
                    [811] => 2885
                    [812] => 2824
                    [813] => 2822
                    [814] => 2820
                    [815] => 2744
                    [816] => 2749
                    [817] => 2748
                    [818] => 2743
                    [819] => 2742
                    [820] => 2741
                    [821] => 2739
                    [822] => 2737
                    [823] => 2736
                    [824] => 2734
                    [825] => 2543
                    [826] => 2540
                    [827] => 2541
                    [828] => 2542
                    [829] => 2544
                    [830] => 2545
                    [831] => 2547
                    [832] => 2549
                    [833] => 2553
                    [834] => 2457
                    [835] => 2461
                    [836] => 2462
                    [837] => 2463
                    [838] => 2464
                    [839] => 2465
                    [840] => 2466
                    [841] => 2467
                    [842] => 2470
                    [843] => 2473
                    [844] => 2474
                    [845] => 2475
                    [846] => 2476
                    [847] => 2477
                    [848] => 2479
                    [849] => 2481
                    [850] => 2482
                    [851] => 2471
                    [852] => 2452
                    [853] => 2450
                    [854] => 2449
                    [855] => 2448
                    [856] => 2444
                    [857] => 2443
                    [858] => 2442
                    [859] => 2441
                    [860] => 2426
                    [861] => 2424
                    [862] => 3910
                    [863] => 3909
                    [864] => 3908
                    [865] => 3907
                    [866] => 3906
                    [867] => 3904
                    [868] => 3903
                    [869] => 3901
                    [870] => 3900
                    [871] => 3899
                    [872] => 3898
                    [873] => 3897
                    [874] => 3896
                    [875] => 3895
                    [876] => 3892
                    [877] => 3891
                    [878] => 3406
                    [879] => 2873
                    [880] => 2872
                    [881] => 2870
                    [882] => 2869
                    [883] => 2867
                )

        )

    [text_agreement_args] => Array
        (
            [post_type] => agreement
            [posts_per_page] => -1
            [s] => COVID-19
        )

    [text_provision_args] => Array
        (
            [post_type] => provision_document
            [posts_per_page] => -1
            [s] => COVID-19
        )

    [agreement_ids] => Array
        (
        )

    [agreement_q_rslts] => 
    [provision_q_rslts] => 
    [text_agreement_q_rslts] => WP_Query Object
        (
            [query] => Array
                (
                    [post_type] => agreement
                    [posts_per_page] => -1
                    [s] => COVID-19
                )

            [query_vars] => Array
                (
                    [post_type] => agreement
                    [posts_per_page] => -1
                    [s] => COVID-19
                    [error] => 
                    [m] => 
                    [p] => 0
                    [post_parent] => 
                    [subpost] => 
                    [subpost_id] => 
                    [attachment] => 
                    [attachment_id] => 0
                    [name] => 
                    [pagename] => 
                    [page_id] => 0
                    [second] => 
                    [minute] => 
                    [hour] => 
                    [day] => 0
                    [monthnum] => 0
                    [year] => 0
                    [w] => 0
                    [category_name] => 
                    [tag] => 
                    [cat] => 
                    [tag_id] => 
                    [author] => 
                    [author_name] => 
                    [feed] => 
                    [tb] => 
                    [paged] => 0
                    [meta_key] => 
                    [meta_value] => 
                    [preview] => 
                    [sentence] => 
                    [title] => 
                    [fields] => 
                    [menu_order] => 
                    [embed] => 
                    [category__in] => Array
                        (
                        )

                    [category__not_in] => Array
                        (
                        )

                    [category__and] => Array
                        (
                        )

                    [post__in] => Array
                        (
                        )

                    [post__not_in] => Array
                        (
                        )

                    [post_name__in] => Array
                        (
                        )

                    [tag__in] => Array
                        (
                        )

                    [tag__not_in] => Array
                        (
                        )

                    [tag__and] => Array
                        (
                        )

                    [tag_slug__in] => Array
                        (
                        )

                    [tag_slug__and] => Array
                        (
                        )

                    [post_parent__in] => Array
                        (
                        )

                    [post_parent__not_in] => Array
                        (
                        )

                    [author__in] => Array
                        (
                        )

                    [author__not_in] => Array
                        (
                        )

                    [search_columns] => Array
                        (
                        )

                    [orderby] => title
                    [order] => ASC
                    [suppress_filters] => 
                    [ignore_sticky_posts] => 
                    [cache_results] => 1
                    [update_post_term_cache] => 1
                    [update_menu_item_cache] => 
                    [lazy_load_term_meta] => 1
                    [update_post_meta_cache] => 1
                    [nopaging] => 1
                    [comments_per_page] => 50
                    [no_found_rows] => 
                    [search_terms_count] => 1
                    [search_terms] => Array
                        (
                            [0] => COVID-19
                        )

                    [search_orderby_title] => Array
                        (
                            [0] => wpry_posts.post_title LIKE '{88db1a056eb1b0b033c16b964afd6ab740ee6e6030748f9f5394ebc17067a339}COVID-19{88db1a056eb1b0b033c16b964afd6ab740ee6e6030748f9f5394ebc17067a339}'
                        )

                )

            [tax_query] => WP_Tax_Query Object
                (
                    [queries] => Array
                        (
                        )

                    [relation] => AND
                    [table_aliases:protected] => Array
                        (
                        )

                    [queried_terms] => Array
                        (
                        )

                    [primary_table] => wpry_posts
                    [primary_id_column] => ID
                )

            [meta_query] => WP_Meta_Query Object
                (
                    [queries] => Array
                        (
                        )

                    [relation] => 
                    [meta_table] => 
                    [meta_id_column] => 
                    [primary_table] => 
                    [primary_id_column] => 
                    [table_aliases:protected] => Array
                        (
                        )

                    [clauses:protected] => Array
                        (
                        )

                    [has_or_relation:protected] => 
                )

            [date_query] => 
            [request] => SELECT  DISTINCT wpry_posts.*
			 FROM wpry_posts  INNER JOIN wpry_postmeta AS a ON ( a.post_id = wpry_posts.ID ) LEFT JOIN wpry_postmeta AS b ON ( (( b.post_id = a.post_id )) AND (( b.meta_key LIKE CONCAT( '\_', a.meta_key ) )) ) LEFT JOIN wpry_posts AS c ON ( ( c.post_name = b.meta_value ) AND ( c.post_type = 'acf-field' ) AND (( c.post_content LIKE '%:"text"%' ) OR ( c.post_content LIKE '%:"textarea"%' ) OR ( c.post_content LIKE '%:"wysiwyg"%' ) OR ( c.post_content LIKE '%:"checkbox"%' )) ) 
			 WHERE 1=1  AND ( ( ( b.meta_id IS NOT NULL ) AND ( c.ID IS NOT NULL ) AND ( a.meta_value LIKE '%COVID-19%' ) ) OR ( ( wpry_posts.post_title LIKE '%COVID-19%' ) OR ( wpry_posts.post_content LIKE '%COVID-19%' ) OR ( wpry_posts.post_excerpt LIKE '%COVID-19%' ) ) )  AND ((wpry_posts.post_type = 'agreement' AND (wpry_posts.post_status = 'publish' OR wpry_posts.post_status = 'acf-disabled')))
			 
			 ORDER BY wpry_posts.post_title ASC
			 
            [posts] => Array
                (
                    [0] => WP_Post Object
                        (
                            [ID] => 2438
                            [post_author] => 5
                            [post_date] => 2021-01-19 06:43:39
                            [post_date_gmt] => 2021-01-19 06:43:39
                            [post_content] => 
                            [post_title] => BARDA - Moderna, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-barda-agreement-contract-no-75a50122c00034-for-development-of-an-mrna-vaccine-for-sars-cov-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-09-15 12:05:25
                            [post_modified_gmt] => 2021-09-15 12:05:25
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=2438
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [1] => WP_Post Object
                        (
                            [ID] => 4207
                            [post_author] => 5
                            [post_date] => 2022-03-02 11:38:41
                            [post_date_gmt] => 2022-03-02 11:38:41
                            [post_content] => 
                            [post_title] => Biological E - Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-03-02 11:38:51
                            [post_modified_gmt] => 2022-03-02 11:38:51
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=4207
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [2] => WP_Post Object
                        (
                            [ID] => 4126
                            [post_author] => 5
                            [post_date] => 2022-01-28 13:33:11
                            [post_date_gmt] => 2022-01-28 13:33:11
                            [post_content] => 
                            [post_title] => CEPI - Dynavax, COVID-19 Material Reservation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-dynavax-covid-19-material-reservation-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-01-28 13:33:11
                            [post_modified_gmt] => 2022-01-28 13:33:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=4126
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [3] => WP_Post Object
                        (
                            [ID] => 2882
                            [post_author] => 6
                            [post_date] => 2021-05-14 14:03:29
                            [post_date_gmt] => 2021-05-14 14:03:29
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-09-15 11:58:31
                            [post_modified_gmt] => 2021-09-15 11:58:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=2882
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [4] => WP_Post Object
                        (
                            [ID] => 8049
                            [post_author] => 5
                            [post_date] => 2022-12-12 08:37:47
                            [post_date_gmt] => 2022-12-12 08:37:47
                            [post_content] => 
                            [post_title] => CEPI - VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-12 08:37:47
                            [post_modified_gmt] => 2022-12-12 08:37:47
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=8049
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [5] => WP_Post Object
                        (
                            [ID] => 4794
                            [post_author] => 5
                            [post_date] => 2022-05-23 13:54:39
                            [post_date_gmt] => 2022-05-23 13:54:39
                            [post_content] => 
                            [post_title] => CSIC - MPP (C-TAP), COVID-19 Diagnostic, Patent & Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 11:53:50
                            [post_modified_gmt] => 2023-09-18 11:53:50
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=4794
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [6] => WP_Post Object
                        (
                            [ID] => 11245
                            [post_author] => 5
                            [post_date] => 2023-09-18 08:29:10
                            [post_date_gmt] => 2023-09-18 08:29:10
                            [post_content] => 
                            [post_title] => CSIC - MPP (C-TAP), COVID-19 Vaccine, Patent and Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 08:29:10
                            [post_modified_gmt] => 2023-09-18 08:29:10
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=11245
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [7] => WP_Post Object
                        (
                            [ID] => 3817
                            [post_author] => 6
                            [post_date] => 2021-09-15 10:46:18
                            [post_date_gmt] => 2021-09-15 10:46:18
                            [post_content] => 
                            [post_title] => CureVac - GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-and-gsk-collaboration-and-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-11 12:16:37
                            [post_modified_gmt] => 2022-10-11 12:16:37
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=3817
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [8] => WP_Post Object
                        (
                            [ID] => 3117
                            [post_author] => 6
                            [post_date] => 2021-06-03 14:15:12
                            [post_date_gmt] => 2021-06-03 14:15:12
                            [post_content] => 
                            [post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-09-15 12:00:38
                            [post_modified_gmt] => 2021-09-15 12:00:38
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=3117
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [9] => WP_Post Object
                        (
                            [ID] => 2538
                            [post_author] => 5
                            [post_date] => 2021-03-12 13:41:11
                            [post_date_gmt] => 2021-03-12 13:41:11
                            [post_content] => 
                            [post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => advance-purchase-agreement-for-the-production-purchase-and-supply-of-a-covid-19-vaccine-in-the-european-union-with-astrazeneca
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-09-15 12:05:41
                            [post_modified_gmt] => 2021-09-15 12:05:41
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=2538
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [10] => WP_Post Object
                        (
                            [ID] => 2468
                            [post_author] => 5
                            [post_date] => 2021-02-25 15:15:43
                            [post_date_gmt] => 2021-02-25 15:15:43
                            [post_content] => 
                            [post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => advance-purchase-agreement-for-the-development-production-advance-purchase-and-supply-of-a-covid-19-vaccine-for-eu-member-states-with-curevac
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-09-15 12:00:56
                            [post_modified_gmt] => 2021-09-15 12:00:56
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=2468
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [11] => WP_Post Object
                        (
                            [ID] => 3419
                            [post_author] => 6
                            [post_date] => 2021-07-01 01:45:34
                            [post_date_gmt] => 2021-07-01 01:45:34
                            [post_content] => 
                            [post_title] => Fiocruz - AstraZeneca, COVID-19 Technological Order Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-11-10 18:22:02
                            [post_modified_gmt] => 2021-11-10 18:22:02
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=3419
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [12] => WP_Post Object
                        (
                            [ID] => 3843
                            [post_author] => 5
                            [post_date] => 2021-11-05 10:54:08
                            [post_date_gmt] => 2021-11-05 10:54:08
                            [post_content] => 
                            [post_title] => Fiocruz - AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-11-05 10:54:08
                            [post_modified_gmt] => 2021-11-05 10:54:08
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=3843
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [13] => WP_Post Object
                        (
                            [ID] => 5586
                            [post_author] => 5
                            [post_date] => 2022-08-11 09:34:02
                            [post_date_gmt] => 2022-08-11 09:34:02
                            [post_content] => 
                            [post_title] => Gates Foundation - Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => bmgf-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-11 09:37:27
                            [post_modified_gmt] => 2022-08-11 09:37:27
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=5586
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [14] => WP_Post Object
                        (
                            [ID] => 5589
                            [post_author] => 5
                            [post_date] => 2022-08-11 09:35:21
                            [post_date_gmt] => 2022-08-11 09:35:21
                            [post_content] => 
                            [post_title] => Gates Foundation - Icosavax, COVID-19 Vaccine Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-11 09:35:21
                            [post_modified_gmt] => 2022-08-11 09:35:21
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=5589
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [15] => WP_Post Object
                        (
                            [ID] => 4142
                            [post_author] => 5
                            [post_date] => 2022-02-01 18:56:28
                            [post_date_gmt] => 2022-02-01 18:56:28
                            [post_content] => 
                            [post_title] => Gavi Alliance - Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-02-02 07:30:00
                            [post_modified_gmt] => 2022-02-02 07:30:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=4142
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [16] => WP_Post Object
                        (
                            [ID] => 11343
                            [post_author] => 5
                            [post_date] => 2023-10-10 08:51:06
                            [post_date_gmt] => 2023-10-10 08:51:06
                            [post_content] => 
                            [post_title] => Medigen - MPP (C-TAP), COVID-19 Vaccine, Patent and Know How License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-10-11 15:25:05
                            [post_modified_gmt] => 2023-10-11 15:25:05
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=11343
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [17] => WP_Post Object
                        (
                            [ID] => 3867
                            [post_author] => 5
                            [post_date] => 2021-11-18 12:26:40
                            [post_date_gmt] => 2021-11-18 12:26:40
                            [post_content] => 
                            [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-11-18 12:26:40
                            [post_modified_gmt] => 2021-11-18 12:26:40
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=3867
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [18] => WP_Post Object
                        (
                            [ID] => 9058
                            [post_author] => 5
                            [post_date] => 2023-03-06 11:20:36
                            [post_date_gmt] => 2023-03-06 11:20:36
                            [post_content] => 
                            [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-08 11:33:14
                            [post_modified_gmt] => 2023-03-08 11:33:14
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=9058
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [19] => WP_Post Object
                        (
                            [ID] => 9074
                            [post_author] => 5
                            [post_date] => 2023-03-07 13:56:00
                            [post_date_gmt] => 2023-03-07 13:56:00
                            [post_content] => 
                            [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-07 13:56:00
                            [post_modified_gmt] => 2023-03-07 13:56:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=9074
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [20] => WP_Post Object
                        (
                            [ID] => 11600
                            [post_author] => 5
                            [post_date] => 2024-01-25 08:39:06
                            [post_date_gmt] => 2024-01-25 08:39:06
                            [post_content] => 
                            [post_title] => MPP (C-TAP) - Biotech Africa, COVID-19 Diagnostic, Patent & Material Sublicense Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-c-tap-biotech-africa-covid-19-diagnostic-patent-material-sublicense-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-01-25 08:39:06
                            [post_modified_gmt] => 2024-01-25 08:39:06
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=11600
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [21] => WP_Post Object
                        (
                            [ID] => 11722
                            [post_author] => 5
                            [post_date] => 2024-04-11 07:44:47
                            [post_date_gmt] => 2024-04-11 07:44:47
                            [post_content] => 
                            [post_title] => NIAID - AbCellera, COVID-19 Exclusive Patent License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => niaid-abcellera-covid-19-exclusive-patent-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-11 07:44:47
                            [post_modified_gmt] => 2024-04-11 07:44:47
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=11722
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [22] => WP_Post Object
                        (
                            [ID] => 11016
                            [post_author] => 5
                            [post_date] => 2023-08-23 06:56:23
                            [post_date_gmt] => 2023-08-23 06:56:23
                            [post_content] => 
                            [post_title] => NIH - Fluidigm, COVID-19 Diagnostic Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => 11016
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-24 09:11:35
                            [post_modified_gmt] => 2023-08-24 09:11:35
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=11016
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [23] => WP_Post Object
                        (
                            [ID] => 5110
                            [post_author] => 5
                            [post_date] => 2022-06-29 11:57:22
                            [post_date_gmt] => 2022-06-29 11:57:22
                            [post_content] => 
                            [post_title] => NIH – MPP (C-TAP), COVID-19 Technologies, Patent and Biological Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 11:58:40
                            [post_modified_gmt] => 2023-09-18 11:58:40
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=5110
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [24] => WP_Post Object
                        (
                            [ID] => 3794
                            [post_author] => 5
                            [post_date] => 2021-09-10 08:02:49
                            [post_date_gmt] => 2021-09-10 08:02:49
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-02-20 13:22:55
                            [post_modified_gmt] => 2023-02-20 13:22:55
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=3794
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [25] => WP_Post Object
                        (
                            [ID] => 4026
                            [post_author] => 5
                            [post_date] => 2021-12-21 11:36:17
                            [post_date_gmt] => 2021-12-21 11:36:17
                            [post_content] => 
                            [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-11 12:21:01
                            [post_modified_gmt] => 2022-10-11 12:21:01
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=4026
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [26] => WP_Post Object
                        (
                            [ID] => 3213
                            [post_author] => 6
                            [post_date] => 2021-06-28 12:04:36
                            [post_date_gmt] => 2021-06-28 12:04:36
                            [post_content] => 
                            [post_title] => Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-09-15 12:03:12
                            [post_modified_gmt] => 2021-09-15 12:03:12
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=3213
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [27] => WP_Post Object
                        (
                            [ID] => 2420
                            [post_author] => 5
                            [post_date] => 2020-12-14 14:59:07
                            [post_date_gmt] => 2020-12-14 14:59:07
                            [post_content] => 
                            [post_title] => Sanofi - Translate Bio, Influenza and COVID-19 Vaccine Collaboration & License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => collaboration-and-license-agreement-between-sanofi-pasteur-inc-sanofi-and-translate-bio-ma-inc-translate-bio-or-tb-and-first-amendment-co
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-11 12:21:49
                            [post_modified_gmt] => 2022-10-11 12:21:49
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=2420
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [28] => WP_Post Object
                        (
                            [ID] => 2943
                            [post_author] => 6
                            [post_date] => 2021-05-28 13:48:32
                            [post_date_gmt] => 2021-05-28 13:48:32
                            [post_content] => 
                            [post_title] => UK Secretary of State - AstraZeneca, COVID-19 Vaccine Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-09-15 12:12:31
                            [post_modified_gmt] => 2021-09-15 12:12:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=2943
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [29] => WP_Post Object
                        (
                            [ID] => 11325
                            [post_author] => 5
                            [post_date] => 2023-09-25 16:05:58
                            [post_date_gmt] => 2023-09-25 16:05:58
                            [post_content] => 
                            [post_title] => University of Chile - MPP (C-TAP), COVID-19 Diagnostic Material & Know-How License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => university-of-chile-mpp-c-tap-covid-19-diagnostic-material-know-how-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-26 10:26:26
                            [post_modified_gmt] => 2023-09-26 10:26:26
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=11325
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [30] => WP_Post Object
                        (
                            [ID] => 2817
                            [post_author] => 5
                            [post_date] => 2021-04-16 11:58:45
                            [post_date_gmt] => 2021-04-16 11:58:45
                            [post_content] => 
                            [post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-06-23 06:24:06
                            [post_modified_gmt] => 2022-06-23 06:24:06
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=2817
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [31] => WP_Post Object
                        (
                            [ID] => 11109
                            [post_author] => 5
                            [post_date] => 2023-09-01 06:30:03
                            [post_date_gmt] => 2023-09-01 06:30:03
                            [post_content] => 
                            [post_title] => US Department of Defense - Inovio, COVID-19 Vaccine Delivery Device, Other Transaction Prototype Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => u-s-department-of-defense-inovio-covid-19-vaccine-delivery-device-other-transaction-prototype-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-04 15:45:40
                            [post_modified_gmt] => 2023-09-04 15:45:40
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=11109
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [32] => WP_Post Object
                        (
                            [ID] => 3776
                            [post_author] => 5
                            [post_date] => 2021-09-09 11:24:04
                            [post_date_gmt] => 2021-09-09 11:24:04
                            [post_content] => 
                            [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-09-15 12:12:55
                            [post_modified_gmt] => 2021-09-15 12:12:55
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=3776
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [33] => WP_Post Object
                        (
                            [ID] => 2446
                            [post_author] => 5
                            [post_date] => 2021-01-19 09:42:42
                            [post_date_gmt] => 2021-01-19 09:42:42
                            [post_content] => 
                            [post_title] => US Department of Defense - Moderna, COVID-19 Vaccine Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => award-contract-no-w911qy20c0100-by-and-between-modernatx-inc-and-the-department-of-defense
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-09-15 12:03:43
                            [post_modified_gmt] => 2021-09-15 12:03:43
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=2446
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [34] => WP_Post Object
                        (
                            [ID] => 2732
                            [post_author] => 5
                            [post_date] => 2021-03-23 15:54:07
                            [post_date_gmt] => 2021-03-23 15:54:07
                            [post_content] => 
                            [post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-us-army-statement-of-work-for-rapid-wf10-advanced-research-development-to-large-scale-manufacturing-of-nvx-cov-2373-as-a-vaccine-for-sars-cov-2-coronavirus-under-the-base-agreemen
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-09-15 12:18:39
                            [post_modified_gmt] => 2021-09-15 12:18:39
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=2732
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [35] => WP_Post Object
                        (
                            [ID] => 2455
                            [post_author] => 5
                            [post_date] => 2021-02-25 15:19:51
                            [post_date_gmt] => 2021-02-25 15:19:51
                            [post_content] => 
                            [post_title] => US Department of Defense - Sanofi, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-09-15 12:13:19
                            [post_modified_gmt] => 2021-09-15 12:13:19
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=2455
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [36] => WP_Post Object
                        (
                            [ID] => 3348
                            [post_author] => 5
                            [post_date] => 2021-06-30 13:13:40
                            [post_date_gmt] => 2021-06-30 13:13:40
                            [post_content] => 
                            [post_title] => US Government - Ology Bioservices, COVID-19 Plasmid Procurement Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 13:46:12
                            [post_modified_gmt] => 2022-10-12 13:46:12
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=3348
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                )

            [post_count] => 37
            [current_post] => -1
            [before_loop] => 1
            [in_the_loop] => 
            [post] => WP_Post Object
                (
                    [ID] => 2438
                    [post_author] => 5
                    [post_date] => 2021-01-19 06:43:39
                    [post_date_gmt] => 2021-01-19 06:43:39
                    [post_content] => 
                    [post_title] => BARDA - Moderna, COVID-19 Vaccine Development Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => moderna-barda-agreement-contract-no-75a50122c00034-for-development-of-an-mrna-vaccine-for-sars-cov-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-09-15 12:05:25
                    [post_modified_gmt] => 2021-09-15 12:05:25
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=agreement&p=2438
                    [menu_order] => 0
                    [post_type] => agreement
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [comment_count] => 0
            [current_comment] => -1
            [found_posts] => 37
            [max_num_pages] => 0
            [max_num_comment_pages] => 0
            [is_single] => 
            [is_preview] => 
            [is_page] => 
            [is_archive] => 1
            [is_date] => 
            [is_year] => 
            [is_month] => 
            [is_day] => 
            [is_time] => 
            [is_author] => 
            [is_category] => 
            [is_tag] => 
            [is_tax] => 
            [is_search] => 1
            [is_feed] => 
            [is_comment_feed] => 
            [is_trackback] => 
            [is_home] => 
            [is_privacy_policy] => 
            [is_404] => 
            [is_embed] => 
            [is_paged] => 
            [is_admin] => 
            [is_attachment] => 
            [is_singular] => 
            [is_robots] => 
            [is_favicon] => 
            [is_posts_page] => 
            [is_post_type_archive] => 1
            [query_vars_hash:WP_Query:private] => fa702f1eb60e9370db031867225caff5
            [query_vars_changed:WP_Query:private] => 1
            [thumbnails_cached] => 
            [allow_query_attachment_by_filename:protected] => 
            [stopwords:WP_Query:private] => Array
                (
                    [0] => about
                    [1] => an
                    [2] => are
                    [3] => as
                    [4] => at
                    [5] => be
                    [6] => by
                    [7] => com
                    [8] => for
                    [9] => from
                    [10] => how
                    [11] => in
                    [12] => is
                    [13] => it
                    [14] => of
                    [15] => on
                    [16] => or
                    [17] => that
                    [18] => the
                    [19] => this
                    [20] => to
                    [21] => was
                    [22] => what
                    [23] => when
                    [24] => where
                    [25] => who
                    [26] => will
                    [27] => with
                    [28] => www
                )

            [compat_fields:WP_Query:private] => Array
                (
                    [0] => query_vars_hash
                    [1] => query_vars_changed
                )

            [compat_methods:WP_Query:private] => Array
                (
                    [0] => init_query_flags
                    [1] => parse_tax_query
                )

        )

    [text_provision_q_rslts] => WP_Query Object
        (
            [query] => Array
                (
                    [post_type] => provision_document
                    [posts_per_page] => -1
                    [s] => COVID-19
                )

            [query_vars] => Array
                (
                    [post_type] => provision_document
                    [posts_per_page] => -1
                    [s] => COVID-19
                    [error] => 
                    [m] => 
                    [p] => 0
                    [post_parent] => 
                    [subpost] => 
                    [subpost_id] => 
                    [attachment] => 
                    [attachment_id] => 0
                    [name] => 
                    [pagename] => 
                    [page_id] => 0
                    [second] => 
                    [minute] => 
                    [hour] => 
                    [day] => 0
                    [monthnum] => 0
                    [year] => 0
                    [w] => 0
                    [category_name] => 
                    [tag] => 
                    [cat] => 
                    [tag_id] => 
                    [author] => 
                    [author_name] => 
                    [feed] => 
                    [tb] => 
                    [paged] => 0
                    [meta_key] => 
                    [meta_value] => 
                    [preview] => 
                    [sentence] => 
                    [title] => 
                    [fields] => 
                    [menu_order] => 
                    [embed] => 
                    [category__in] => Array
                        (
                        )

                    [category__not_in] => Array
                        (
                        )

                    [category__and] => Array
                        (
                        )

                    [post__in] => Array
                        (
                        )

                    [post__not_in] => Array
                        (
                        )

                    [post_name__in] => Array
                        (
                        )

                    [tag__in] => Array
                        (
                        )

                    [tag__not_in] => Array
                        (
                        )

                    [tag__and] => Array
                        (
                        )

                    [tag_slug__in] => Array
                        (
                        )

                    [tag_slug__and] => Array
                        (
                        )

                    [post_parent__in] => Array
                        (
                        )

                    [post_parent__not_in] => Array
                        (
                        )

                    [author__in] => Array
                        (
                        )

                    [author__not_in] => Array
                        (
                        )

                    [search_columns] => Array
                        (
                        )

                    [suppress_filters] => 
                    [ignore_sticky_posts] => 
                    [cache_results] => 1
                    [update_post_term_cache] => 1
                    [update_menu_item_cache] => 
                    [lazy_load_term_meta] => 1
                    [update_post_meta_cache] => 1
                    [nopaging] => 1
                    [comments_per_page] => 50
                    [no_found_rows] => 
                    [search_terms_count] => 1
                    [search_terms] => Array
                        (
                            [0] => COVID-19
                        )

                    [search_orderby_title] => Array
                        (
                            [0] => wpry_posts.post_title LIKE '{88db1a056eb1b0b033c16b964afd6ab740ee6e6030748f9f5394ebc17067a339}COVID-19{88db1a056eb1b0b033c16b964afd6ab740ee6e6030748f9f5394ebc17067a339}'
                        )

                    [order] => DESC
                )

            [tax_query] => WP_Tax_Query Object
                (
                    [queries] => Array
                        (
                        )

                    [relation] => AND
                    [table_aliases:protected] => Array
                        (
                        )

                    [queried_terms] => Array
                        (
                        )

                    [primary_table] => wpry_posts
                    [primary_id_column] => ID
                )

            [meta_query] => WP_Meta_Query Object
                (
                    [queries] => Array
                        (
                        )

                    [relation] => 
                    [meta_table] => 
                    [meta_id_column] => 
                    [primary_table] => 
                    [primary_id_column] => 
                    [table_aliases:protected] => Array
                        (
                        )

                    [clauses:protected] => Array
                        (
                        )

                    [has_or_relation:protected] => 
                )

            [date_query] => 
            [request] => SELECT  DISTINCT wpry_posts.*
			 FROM wpry_posts  INNER JOIN wpry_postmeta AS a ON ( a.post_id = wpry_posts.ID ) LEFT JOIN wpry_postmeta AS b ON ( (( b.post_id = a.post_id )) AND (( b.meta_key LIKE CONCAT( '\_', a.meta_key ) )) ) LEFT JOIN wpry_posts AS c ON ( ( c.post_name = b.meta_value ) AND ( c.post_type = 'acf-field' ) AND (( c.post_content LIKE '%:"text"%' ) OR ( c.post_content LIKE '%:"textarea"%' ) OR ( c.post_content LIKE '%:"wysiwyg"%' ) OR ( c.post_content LIKE '%:"checkbox"%' )) ) 
			 WHERE 1=1  AND ( ( ( b.meta_id IS NOT NULL ) AND ( c.ID IS NOT NULL ) AND ( a.meta_value LIKE '%COVID-19%' ) ) OR ( ( wpry_posts.post_title LIKE '%COVID-19%' ) OR ( wpry_posts.post_content LIKE '%COVID-19%' ) OR ( wpry_posts.post_excerpt LIKE '%COVID-19%' ) ) )  AND ((wpry_posts.post_type = 'provision_document' AND (wpry_posts.post_status = 'publish' OR wpry_posts.post_status = 'acf-disabled')))
			 
			 ORDER BY wpry_posts.post_title LIKE '{88db1a056eb1b0b033c16b964afd6ab740ee6e6030748f9f5394ebc17067a339}COVID-19{88db1a056eb1b0b033c16b964afd6ab740ee6e6030748f9f5394ebc17067a339}' DESC, wpry_posts.post_date DESC
			 
            [posts] => Array
                (
                    [0] => WP_Post Object
                        (
                            [ID] => 11750
                            [post_author] => 5
                            [post_date] => 2024-04-11 10:21:23
                            [post_date_gmt] => 2024-04-11 10:21:23
                            [post_content] => 
                            [post_title] => NIAID – AbCellera, COVID-19 Exclusive Patent License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => niaid-abcellera-covid-19-exclusive-patent-license-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-11 11:41:21
                            [post_modified_gmt] => 2024-04-11 11:41:21
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11750
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [1] => WP_Post Object
                        (
                            [ID] => 11749
                            [post_author] => 5
                            [post_date] => 2024-04-11 10:01:28
                            [post_date_gmt] => 2024-04-11 10:01:28
                            [post_content] => 
                            [post_title] => NIAID – AbCellera, COVID-19 Exclusive Patent License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => niaid-abcellera-covid-19-exclusive-patent-license-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-11 11:41:05
                            [post_modified_gmt] => 2024-04-11 11:41:05
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11749
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [2] => WP_Post Object
                        (
                            [ID] => 11748
                            [post_author] => 5
                            [post_date] => 2024-04-11 09:57:21
                            [post_date_gmt] => 2024-04-11 09:57:21
                            [post_content] => 
                            [post_title] => NIAID – AbCellera, COVID-19 Exclusive Patent License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => niaid-abcellera-covid-19-exclusive-patent-license-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-11 11:40:50
                            [post_modified_gmt] => 2024-04-11 11:40:50
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11748
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [3] => WP_Post Object
                        (
                            [ID] => 11747
                            [post_author] => 5
                            [post_date] => 2024-04-11 09:54:19
                            [post_date_gmt] => 2024-04-11 09:54:19
                            [post_content] => 
                            [post_title] => NIAID – AbCellera, COVID-19 Exclusive Patent License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => niaid-abcellera-covid-19-exclusive-patent-license-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-11 11:40:37
                            [post_modified_gmt] => 2024-04-11 11:40:37
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11747
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [4] => WP_Post Object
                        (
                            [ID] => 11746
                            [post_author] => 5
                            [post_date] => 2024-04-11 09:49:49
                            [post_date_gmt] => 2024-04-11 09:49:49
                            [post_content] => 
                            [post_title] => NIAID – AbCellera, COVID-19 Exclusive Patent License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => niaid-abcellera-covid-19-exclusive-patent-license-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-11 11:39:04
                            [post_modified_gmt] => 2024-04-11 11:39:04
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11746
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [5] => WP_Post Object
                        (
                            [ID] => 11745
                            [post_author] => 5
                            [post_date] => 2024-04-11 09:44:15
                            [post_date_gmt] => 2024-04-11 09:44:15
                            [post_content] => 
                            [post_title] => NIAID – AbCellera, COVID-19 Exclusive Patent License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => niaid-abcellera-covid-19-exclusive-patent-license-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-11 11:39:36
                            [post_modified_gmt] => 2024-04-11 11:39:36
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11745
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [6] => WP_Post Object
                        (
                            [ID] => 11744
                            [post_author] => 5
                            [post_date] => 2024-04-11 09:20:26
                            [post_date_gmt] => 2024-04-11 09:20:26
                            [post_content] => 
                            [post_title] => NIAID – AbCellera, COVID-19 Exclusive Patent License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => niaid-abcellera-covid-19-exclusive-patent-license-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-11 11:39:50
                            [post_modified_gmt] => 2024-04-11 11:39:50
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11744
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [7] => WP_Post Object
                        (
                            [ID] => 11743
                            [post_author] => 5
                            [post_date] => 2024-04-11 09:11:35
                            [post_date_gmt] => 2024-04-11 09:11:35
                            [post_content] => 
                            [post_title] => NIAID – AbCellera, COVID-19 Exclusive Patent License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => niaid-abcellera-covid-19-exclusive-patent-license-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-11 11:39:22
                            [post_modified_gmt] => 2024-04-11 11:39:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11743
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [8] => WP_Post Object
                        (
                            [ID] => 11742
                            [post_author] => 5
                            [post_date] => 2024-04-11 08:51:35
                            [post_date_gmt] => 2024-04-11 08:51:35
                            [post_content] => 
                            [post_title] => NIAID - AbCellera, COVID-19 Exclusive Patent License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => niaid-abcellera-covid-19-exclusive-patent-license-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-11 11:38:49
                            [post_modified_gmt] => 2024-04-11 11:38:49
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11742
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [9] => WP_Post Object
                        (
                            [ID] => 11741
                            [post_author] => 5
                            [post_date] => 2024-04-11 08:26:17
                            [post_date_gmt] => 2024-04-11 08:26:17
                            [post_content] => 
                            [post_title] => NIAID - AbCellera, COVID-19 Exclusive Patent License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => niaid-abcellera-covid-19-exclusive-patent-license-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-11 11:38:34
                            [post_modified_gmt] => 2024-04-11 11:38:34
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11741
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [10] => WP_Post Object
                        (
                            [ID] => 11740
                            [post_author] => 5
                            [post_date] => 2024-04-11 08:08:15
                            [post_date_gmt] => 2024-04-11 08:08:15
                            [post_content] => 
                            [post_title] => NIAID - AbCellera, COVID-19 Exclusive Patent License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => niaid-abcellera-covid-19-exclusive-patent-license-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-11 11:40:23
                            [post_modified_gmt] => 2024-04-11 11:40:23
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11740
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [11] => WP_Post Object
                        (
                            [ID] => 11724
                            [post_author] => 5
                            [post_date] => 2024-04-11 07:44:23
                            [post_date_gmt] => 2024-04-11 07:44:23
                            [post_content] => 
                            [post_title] => NIAID - AbCellera, COVID-19 Exclusive Patent License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => niaid-abcellera-covid-19-exclusive-patent-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-11 11:40:05
                            [post_modified_gmt] => 2024-04-11 11:40:05
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11724
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [12] => WP_Post Object
                        (
                            [ID] => 11610
                            [post_author] => 5
                            [post_date] => 2024-01-25 09:11:37
                            [post_date_gmt] => 2024-01-25 09:11:37
                            [post_content] => 
                            [post_title] => MPP (C-TAP) - Biotech Africa, COVID-19 Diagnostic, Patent & Material Sublicense Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-c-tap-biotech-africa-covid-19-diagnostic-patent-material-sublicense-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-01-25 09:11:37
                            [post_modified_gmt] => 2024-01-25 09:11:37
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11610
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [13] => WP_Post Object
                        (
                            [ID] => 11609
                            [post_author] => 5
                            [post_date] => 2024-01-25 09:10:44
                            [post_date_gmt] => 2024-01-25 09:10:44
                            [post_content] => 
                            [post_title] => MPP (C-TAP) - Biotech Africa, COVID-19 Diagnostic, Patent & Material Sublicense Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-c-tap-biotech-africa-covid-19-diagnostic-patent-material-sublicense-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-01-25 09:10:44
                            [post_modified_gmt] => 2024-01-25 09:10:44
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11609
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [14] => WP_Post Object
                        (
                            [ID] => 11606
                            [post_author] => 5
                            [post_date] => 2024-01-25 09:10:25
                            [post_date_gmt] => 2024-01-25 09:10:25
                            [post_content] => 
                            [post_title] => MPP (C-TAP) - Biotech Africa, COVID-19 Diagnostic, Patent & Material Sublicense Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-c-tap-biotech-africa-covid-19-diagnostic-patent-material-sublicense-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-01-25 09:10:25
                            [post_modified_gmt] => 2024-01-25 09:10:25
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11606
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [15] => WP_Post Object
                        (
                            [ID] => 11605
                            [post_author] => 5
                            [post_date] => 2024-01-25 09:10:18
                            [post_date_gmt] => 2024-01-25 09:10:18
                            [post_content] => 
                            [post_title] => MPP (C-TAP) - Biotech Africa, COVID-19 Diagnostic, Patent & Material Sublicense Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-c-tap-biotech-africa-covid-19-diagnostic-patent-material-sublicense-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-01-25 09:35:04
                            [post_modified_gmt] => 2024-01-25 09:35:04
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11605
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [16] => WP_Post Object
                        (
                            [ID] => 11604
                            [post_author] => 5
                            [post_date] => 2024-01-25 09:10:10
                            [post_date_gmt] => 2024-01-25 09:10:10
                            [post_content] => 
                            [post_title] => MPP (C-TAP) - Biotech Africa, COVID-19 Diagnostic, Patent & Material Sublicense Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-c-tap-biotech-africa-covid-19-diagnostic-patent-material-sublicense-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-01-25 09:10:10
                            [post_modified_gmt] => 2024-01-25 09:10:10
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11604
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [17] => WP_Post Object
                        (
                            [ID] => 11618
                            [post_author] => 5
                            [post_date] => 2024-01-25 09:09:21
                            [post_date_gmt] => 2024-01-25 09:09:21
                            [post_content] => 
                            [post_title] => MPP (C-TAP) – Biotech Africa, COVID-19 Diagnostic, Patent & Material Sublicense Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-c-tap-biotech-africa-covid-19-diagnostic-patent-material-sublicense-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-01-25 09:09:21
                            [post_modified_gmt] => 2024-01-25 09:09:21
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11618
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [18] => WP_Post Object
                        (
                            [ID] => 11613
                            [post_author] => 5
                            [post_date] => 2024-01-25 09:08:27
                            [post_date_gmt] => 2024-01-25 09:08:27
                            [post_content] => 
                            [post_title] => MPP (C-TAP) – Biotech Africa, COVID-19 Diagnostic, Patent & Material Sublicense Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-c-tap-biotech-africa-covid-19-diagnostic-patent-material-sublicense-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-01-25 09:08:27
                            [post_modified_gmt] => 2024-01-25 09:08:27
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11613
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [19] => WP_Post Object
                        (
                            [ID] => 11611
                            [post_author] => 5
                            [post_date] => 2024-01-25 08:54:37
                            [post_date_gmt] => 2024-01-25 08:54:37
                            [post_content] => 
                            [post_title] => MPP (C-TAP) – Biotech Africa, COVID-19 Diagnostic, Patent & Material Sublicense Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-c-tap-biotech-africa-covid-19-diagnostic-patent-material-sublicense-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-01-25 08:54:37
                            [post_modified_gmt] => 2024-01-25 08:54:37
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11611
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [20] => WP_Post Object
                        (
                            [ID] => 11602
                            [post_author] => 5
                            [post_date] => 2024-01-25 08:54:11
                            [post_date_gmt] => 2024-01-25 08:54:11
                            [post_content] => 
                            [post_title] => MPP (C-TAP) - Biotech Africa, COVID-19 Diagnostic, Patent & Material Sublicense Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-c-tap-biotech-africa-covid-19-diagnostic-patent-material-sublicense-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-01-25 09:36:08
                            [post_modified_gmt] => 2024-01-25 09:36:08
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11602
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [21] => WP_Post Object
                        (
                            [ID] => 11617
                            [post_author] => 5
                            [post_date] => 2024-01-25 08:50:16
                            [post_date_gmt] => 2024-01-25 08:50:16
                            [post_content] => 
                            [post_title] => MPP (C-TAP) – Biotech Africa, COVID-19 Diagnostic, Patent & Material Sublicense Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-c-tap-biotech-africa-covid-19-diagnostic-patent-material-sublicense-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-01-25 08:50:16
                            [post_modified_gmt] => 2024-01-25 08:50:16
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11617
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [22] => WP_Post Object
                        (
                            [ID] => 11616
                            [post_author] => 5
                            [post_date] => 2024-01-25 08:45:04
                            [post_date_gmt] => 2024-01-25 08:45:04
                            [post_content] => 
                            [post_title] => MPP (C-TAP) – Biotech Africa, COVID-19 Diagnostic, Patent & Material Sublicense Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-c-tap-biotech-africa-covid-19-diagnostic-patent-material-sublicense-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-01-25 08:45:04
                            [post_modified_gmt] => 2024-01-25 08:45:04
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11616
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [23] => WP_Post Object
                        (
                            [ID] => 11614
                            [post_author] => 5
                            [post_date] => 2024-01-25 08:38:38
                            [post_date_gmt] => 2024-01-25 08:38:38
                            [post_content] => 
                            [post_title] => MPP (C-TAP) – Biotech Africa, COVID-19 Diagnostic, Patent & Material Sublicense Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-c-tap-biotech-africa-covid-19-diagnostic-patent-material-sublicense-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-01-25 08:38:38
                            [post_modified_gmt] => 2024-01-25 08:38:38
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11614
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [24] => WP_Post Object
                        (
                            [ID] => 11607
                            [post_author] => 5
                            [post_date] => 2024-01-23 14:07:35
                            [post_date_gmt] => 2024-01-23 14:07:35
                            [post_content] => 
                            [post_title] => MPP (C-TAP) - Biotech Africa, COVID-19 Diagnostic, Patent & Material Sublicense Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-c-tap-biotech-africa-covid-19-diagnostic-patent-material-sublicense-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-01-25 09:10:31
                            [post_modified_gmt] => 2024-01-25 09:10:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11607
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [25] => WP_Post Object
                        (
                            [ID] => 11361
                            [post_author] => 5
                            [post_date] => 2023-10-11 15:17:51
                            [post_date_gmt] => 2023-10-11 15:17:51
                            [post_content] => 
                            [post_title] => Medigen - MPP (C-TAP), COVID-19 Vaccine, Patent and Know How License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-15
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-10-11 16:01:11
                            [post_modified_gmt] => 2023-10-11 16:01:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11361
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [26] => WP_Post Object
                        (
                            [ID] => 11360
                            [post_author] => 5
                            [post_date] => 2023-10-11 15:03:54
                            [post_date_gmt] => 2023-10-11 15:03:54
                            [post_content] => 
                            [post_title] => Medigen - MPP (C-TAP), COVID-19 Vaccine, Patent and Know How License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-10-11 16:02:40
                            [post_modified_gmt] => 2023-10-11 16:02:40
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11360
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [27] => WP_Post Object
                        (
                            [ID] => 11359
                            [post_author] => 5
                            [post_date] => 2023-10-11 14:14:13
                            [post_date_gmt] => 2023-10-11 14:14:13
                            [post_content] => 
                            [post_title] => Medigen - MPP (C-TAP), COVID-19 Vaccine, Patent and Know How License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-10-11 16:00:13
                            [post_modified_gmt] => 2023-10-11 16:00:13
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11359
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [28] => WP_Post Object
                        (
                            [ID] => 11358
                            [post_author] => 5
                            [post_date] => 2023-10-11 13:57:27
                            [post_date_gmt] => 2023-10-11 13:57:27
                            [post_content] => 
                            [post_title] => Medigen - MPP (C-TAP), COVID-19 Vaccine, Patent and Know How License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-10-11 15:59:35
                            [post_modified_gmt] => 2023-10-11 15:59:35
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11358
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [29] => WP_Post Object
                        (
                            [ID] => 11357
                            [post_author] => 5
                            [post_date] => 2023-10-11 13:42:17
                            [post_date_gmt] => 2023-10-11 13:42:17
                            [post_content] => 
                            [post_title] => Medigen - MPP (C-TAP), COVID-19 Vaccine, Patent and Know How License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-10-11 15:59:14
                            [post_modified_gmt] => 2023-10-11 15:59:14
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11357
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [30] => WP_Post Object
                        (
                            [ID] => 11356
                            [post_author] => 5
                            [post_date] => 2023-10-11 13:32:54
                            [post_date_gmt] => 2023-10-11 13:32:54
                            [post_content] => 
                            [post_title] => Medigen - MPP (C-TAP), COVID-19 Vaccine, Patent and Know How License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-10-11 15:51:52
                            [post_modified_gmt] => 2023-10-11 15:51:52
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11356
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [31] => WP_Post Object
                        (
                            [ID] => 11354
                            [post_author] => 5
                            [post_date] => 2023-10-11 12:48:35
                            [post_date_gmt] => 2023-10-11 12:48:35
                            [post_content] => 
                            [post_title] => Medigen - MPP (C-TAP), COVID-19 Vaccine, Patent and Know How License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-10-11 15:52:44
                            [post_modified_gmt] => 2023-10-11 15:52:44
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11354
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [32] => WP_Post Object
                        (
                            [ID] => 11353
                            [post_author] => 5
                            [post_date] => 2023-10-11 12:44:32
                            [post_date_gmt] => 2023-10-11 12:44:32
                            [post_content] => 
                            [post_title] => Medigen - MPP (C-TAP), COVID-19 Vaccine, Patent and Know How License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-10-11 15:53:24
                            [post_modified_gmt] => 2023-10-11 15:53:24
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11353
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [33] => WP_Post Object
                        (
                            [ID] => 11351
                            [post_author] => 5
                            [post_date] => 2023-10-11 12:30:03
                            [post_date_gmt] => 2023-10-11 12:30:03
                            [post_content] => 
                            [post_title] => Medigen - MPP (C-TAP), COVID-19 Vaccine, Patent and Know How License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-10-11 15:56:38
                            [post_modified_gmt] => 2023-10-11 15:56:38
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11351
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [34] => WP_Post Object
                        (
                            [ID] => 11350
                            [post_author] => 5
                            [post_date] => 2023-10-10 14:05:08
                            [post_date_gmt] => 2023-10-10 14:05:08
                            [post_content] => 
                            [post_title] => Medigen - MPP (C-TAP), COVID-19 Vaccine, Patent and Know How License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-10-11 15:54:46
                            [post_modified_gmt] => 2023-10-11 15:54:46
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11350
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [35] => WP_Post Object
                        (
                            [ID] => 11349
                            [post_author] => 5
                            [post_date] => 2023-10-10 13:26:39
                            [post_date_gmt] => 2023-10-10 13:26:39
                            [post_content] => 
                            [post_title] => Medigen - MPP (C-TAP), COVID-19 Vaccine, Patent and Know How License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-10-11 15:54:08
                            [post_modified_gmt] => 2023-10-11 15:54:08
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11349
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [36] => WP_Post Object
                        (
                            [ID] => 11347
                            [post_author] => 5
                            [post_date] => 2023-10-10 13:10:51
                            [post_date_gmt] => 2023-10-10 13:10:51
                            [post_content] => 
                            [post_title] => Medigen - MPP (C-TAP), COVID-19 Vaccine, Patent and Know How License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-10-11 15:58:36
                            [post_modified_gmt] => 2023-10-11 15:58:36
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11347
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [37] => WP_Post Object
                        (
                            [ID] => 11348
                            [post_author] => 5
                            [post_date] => 2023-10-10 12:20:52
                            [post_date_gmt] => 2023-10-10 12:20:52
                            [post_content] => 
                            [post_title] => Medigen - MPP (C-TAP), COVID-19 Vaccine, Patent and Know How License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-10-11 15:52:12
                            [post_modified_gmt] => 2023-10-11 15:52:12
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11348
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [38] => WP_Post Object
                        (
                            [ID] => 11346
                            [post_author] => 5
                            [post_date] => 2023-10-10 11:44:01
                            [post_date_gmt] => 2023-10-10 11:44:01
                            [post_content] => 
                            [post_title] => Medigen - MPP (C-TAP), COVID-19 Vaccine, Patent and Know How License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-10-11 15:50:28
                            [post_modified_gmt] => 2023-10-11 15:50:28
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11346
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [39] => WP_Post Object
                        (
                            [ID] => 11345
                            [post_author] => 5
                            [post_date] => 2023-10-10 09:45:26
                            [post_date_gmt] => 2023-10-10 09:45:26
                            [post_content] => 
                            [post_title] => Medigen - MPP (C-TAP), COVID-19 Vaccine, Patent and Know How License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-10-11 15:57:28
                            [post_modified_gmt] => 2023-10-11 15:57:28
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11345
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [40] => WP_Post Object
                        (
                            [ID] => 11337
                            [post_author] => 5
                            [post_date] => 2023-09-26 13:37:20
                            [post_date_gmt] => 2023-09-26 13:37:20
                            [post_content] => 
                            [post_title] => University of Chile – MPP (C-TAP), COVID-19 Diagnostic Material & Know-How License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => university-of-chile-mpp-c-tap-covid-19-diagnostic-material-know-how-license-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 09:20:14
                            [post_modified_gmt] => 2023-09-27 09:20:14
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11337
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [41] => WP_Post Object
                        (
                            [ID] => 11336
                            [post_author] => 5
                            [post_date] => 2023-09-26 12:26:24
                            [post_date_gmt] => 2023-09-26 12:26:24
                            [post_content] => 
                            [post_title] => University of Chile – MPP (C-TAP), COVID-19 Diagnostic Material & Know-How License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => university-of-chile-mpp-c-tap-covid-19-diagnostic-material-know-how-license-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 09:19:55
                            [post_modified_gmt] => 2023-09-27 09:19:55
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11336
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [42] => WP_Post Object
                        (
                            [ID] => 11335
                            [post_author] => 5
                            [post_date] => 2023-09-26 12:23:27
                            [post_date_gmt] => 2023-09-26 12:23:27
                            [post_content] => 
                            [post_title] => University of Chile – MPP (C-TAP), COVID-19 Diagnostic Material & Know-How License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => university-of-chile-mpp-c-tap-covid-19-diagnostic-material-know-how-license-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 09:19:29
                            [post_modified_gmt] => 2023-09-27 09:19:29
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11335
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [43] => WP_Post Object
                        (
                            [ID] => 11334
                            [post_author] => 5
                            [post_date] => 2023-09-26 12:20:43
                            [post_date_gmt] => 2023-09-26 12:20:43
                            [post_content] => 
                            [post_title] => University of Chile – MPP (C-TAP), COVID-19 Diagnostic Material & Know-How License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => university-of-chile-mpp-c-tap-covid-19-diagnostic-material-know-how-license-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 09:17:25
                            [post_modified_gmt] => 2023-09-27 09:17:25
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11334
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [44] => WP_Post Object
                        (
                            [ID] => 11333
                            [post_author] => 5
                            [post_date] => 2023-09-26 10:31:42
                            [post_date_gmt] => 2023-09-26 10:31:42
                            [post_content] => 
                            [post_title] => University of Chile – MPP (C-TAP), COVID-19 Diagnostic Material & Know-How License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => university-of-chile-mpp-c-tap-covid-19-diagnostic-material-know-how-license-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 09:17:46
                            [post_modified_gmt] => 2023-09-27 09:17:46
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11333
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [45] => WP_Post Object
                        (
                            [ID] => 11331
                            [post_author] => 5
                            [post_date] => 2023-09-26 10:25:29
                            [post_date_gmt] => 2023-09-26 10:25:29
                            [post_content] => 
                            [post_title] => University of Chile - MPP (C-TAP), COVID-19 Diagnostic Material & Know-How License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => university-of-chile-mpp-c-tap-covid-19-diagnostic-material-know-how-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 09:18:47
                            [post_modified_gmt] => 2023-09-27 09:18:47
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11331
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [46] => WP_Post Object
                        (
                            [ID] => 11330
                            [post_author] => 5
                            [post_date] => 2023-09-25 16:33:25
                            [post_date_gmt] => 2023-09-25 16:33:25
                            [post_content] => 
                            [post_title] => University of Chile - MPP (C-TAP), COVID-19 Diagnostic Material & Know-How License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => university-of-chile-mpp-c-tap-covid-19-diagnostic-material-know-how-license-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 09:18:26
                            [post_modified_gmt] => 2023-09-27 09:18:26
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11330
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [47] => WP_Post Object
                        (
                            [ID] => 11329
                            [post_author] => 5
                            [post_date] => 2023-09-25 16:31:48
                            [post_date_gmt] => 2023-09-25 16:31:48
                            [post_content] => 
                            [post_title] => University of Chile - MPP (C-TAP), COVID-19 Diagnostic Material & Know-How License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => university-of-chile-mpp-c-tap-covid-19-diagnostic-material-know-how-license-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 09:18:04
                            [post_modified_gmt] => 2023-09-27 09:18:04
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11329
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [48] => WP_Post Object
                        (
                            [ID] => 11328
                            [post_author] => 5
                            [post_date] => 2023-09-25 16:22:13
                            [post_date_gmt] => 2023-09-25 16:22:13
                            [post_content] => 
                            [post_title] => University of Chile - MPP (C-TAP), COVID-19 Diagnostic Material & Know-How License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => university-of-chile-mpp-c-tap-covid-19-diagnostic-material-know-how-license-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 09:16:55
                            [post_modified_gmt] => 2023-09-27 09:16:55
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11328
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [49] => WP_Post Object
                        (
                            [ID] => 11327
                            [post_author] => 5
                            [post_date] => 2023-09-25 16:20:19
                            [post_date_gmt] => 2023-09-25 16:20:19
                            [post_content] => 
                            [post_title] => University of Chile - MPP (C-TAP), COVID-19 Diagnostic Material & Know-How License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => university-of-chile-mpp-c-tap-covid-19-diagnostic-material-know-how-license-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 09:19:08
                            [post_modified_gmt] => 2023-09-27 09:19:08
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11327
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [50] => WP_Post Object
                        (
                            [ID] => 11260
                            [post_author] => 5
                            [post_date] => 2023-09-18 11:51:39
                            [post_date_gmt] => 2023-09-18 11:51:39
                            [post_content] => 
                            [post_title] => CSIC – MPP (C-TAP), COVID-19 Vaccine, Patent and Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 11:51:39
                            [post_modified_gmt] => 2023-09-18 11:51:39
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11260
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [51] => WP_Post Object
                        (
                            [ID] => 11259
                            [post_author] => 5
                            [post_date] => 2023-09-18 11:17:07
                            [post_date_gmt] => 2023-09-18 11:17:07
                            [post_content] => 
                            [post_title] => CSIC – MPP (C-TAP), COVID-19 Vaccine, Patent and Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 11:17:07
                            [post_modified_gmt] => 2023-09-18 11:17:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11259
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [52] => WP_Post Object
                        (
                            [ID] => 11258
                            [post_author] => 5
                            [post_date] => 2023-09-18 11:14:03
                            [post_date_gmt] => 2023-09-18 11:14:03
                            [post_content] => 
                            [post_title] => CSIC – MPP (C-TAP), COVID-19 Vaccine, Patent and Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 11:14:03
                            [post_modified_gmt] => 2023-09-18 11:14:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11258
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [53] => WP_Post Object
                        (
                            [ID] => 11257
                            [post_author] => 5
                            [post_date] => 2023-09-18 10:52:07
                            [post_date_gmt] => 2023-09-18 10:52:07
                            [post_content] => 
                            [post_title] => CSIC – MPP (C-TAP), COVID-19 Vaccine, Patent and Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 11:52:21
                            [post_modified_gmt] => 2023-09-18 11:52:21
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11257
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [54] => WP_Post Object
                        (
                            [ID] => 11256
                            [post_author] => 5
                            [post_date] => 2023-09-18 10:42:58
                            [post_date_gmt] => 2023-09-18 10:42:58
                            [post_content] => 
                            [post_title] => CSIC – MPP (C-TAP), COVID-19 Vaccine, Patent and Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 10:42:58
                            [post_modified_gmt] => 2023-09-18 10:42:58
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11256
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [55] => WP_Post Object
                        (
                            [ID] => 11255
                            [post_author] => 5
                            [post_date] => 2023-09-18 10:36:46
                            [post_date_gmt] => 2023-09-18 10:36:46
                            [post_content] => 
                            [post_title] => CSIC – MPP (C-TAP), COVID-19 Vaccine, Patent and Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 10:37:13
                            [post_modified_gmt] => 2023-09-18 10:37:13
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11255
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [56] => WP_Post Object
                        (
                            [ID] => 11254
                            [post_author] => 5
                            [post_date] => 2023-09-18 09:49:03
                            [post_date_gmt] => 2023-09-18 09:49:03
                            [post_content] => 
                            [post_title] => CSIC – MPP (C-TAP), COVID-19 Vaccine, Patent and Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 09:49:03
                            [post_modified_gmt] => 2023-09-18 09:49:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11254
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [57] => WP_Post Object
                        (
                            [ID] => 11252
                            [post_author] => 5
                            [post_date] => 2023-09-18 09:45:34
                            [post_date_gmt] => 2023-09-18 09:45:34
                            [post_content] => 
                            [post_title] => CSIC – MPP (C-TAP), COVID-19 Vaccine, Patent and Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 09:45:34
                            [post_modified_gmt] => 2023-09-18 09:45:34
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11252
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [58] => WP_Post Object
                        (
                            [ID] => 11251
                            [post_author] => 5
                            [post_date] => 2023-09-18 09:38:14
                            [post_date_gmt] => 2023-09-18 09:38:14
                            [post_content] => 
                            [post_title] => CSIC – MPP (C-TAP), COVID-19 Vaccine, Patent and Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 09:38:14
                            [post_modified_gmt] => 2023-09-18 09:38:14
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11251
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [59] => WP_Post Object
                        (
                            [ID] => 11250
                            [post_author] => 5
                            [post_date] => 2023-09-18 09:35:19
                            [post_date_gmt] => 2023-09-18 09:35:19
                            [post_content] => 
                            [post_title] => CSIC – MPP (C-TAP), COVID-19 Vaccine, Patent and Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 09:35:19
                            [post_modified_gmt] => 2023-09-18 09:35:19
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11250
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [60] => WP_Post Object
                        (
                            [ID] => 11248
                            [post_author] => 5
                            [post_date] => 2023-09-18 09:31:07
                            [post_date_gmt] => 2023-09-18 09:31:07
                            [post_content] => 
                            [post_title] => CSIC – MPP (C-TAP), COVID-19 Vaccine, Patent and Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 09:31:07
                            [post_modified_gmt] => 2023-09-18 09:31:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11248
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [61] => WP_Post Object
                        (
                            [ID] => 11247
                            [post_author] => 5
                            [post_date] => 2023-09-18 09:17:13
                            [post_date_gmt] => 2023-09-18 09:17:13
                            [post_content] => 
                            [post_title] => CSIC - MPP (C-TAP), COVID-19 Vaccine, Patent and Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 09:32:09
                            [post_modified_gmt] => 2023-09-18 09:32:09
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11247
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [62] => WP_Post Object
                        (
                            [ID] => 11145
                            [post_author] => 5
                            [post_date] => 2023-09-05 12:25:49
                            [post_date_gmt] => 2023-09-05 12:25:49
                            [post_content] => 
                            [post_title] => U.S. Department of Defense – Inovio, COVID-19 Vaccine Delivery Device, Other Transaction Prototype Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => u-s-department-of-defense-inovio-covid-19-vaccine-delivery-device-other-transaction-prototype-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-05 12:25:49
                            [post_modified_gmt] => 2023-09-05 12:25:49
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11145
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [63] => WP_Post Object
                        (
                            [ID] => 11144
                            [post_author] => 5
                            [post_date] => 2023-09-05 11:51:22
                            [post_date_gmt] => 2023-09-05 11:51:22
                            [post_content] => 
                            [post_title] => U.S. Department of Defense – Inovio, COVID-19 Vaccine Delivery Device, Other Transaction Prototype Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => u-s-department-of-defense-inovio-covid-19-vaccine-delivery-device-other-transaction-prototype-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-05 11:51:22
                            [post_modified_gmt] => 2023-09-05 11:51:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11144
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [64] => WP_Post Object
                        (
                            [ID] => 11143
                            [post_author] => 5
                            [post_date] => 2023-09-05 11:36:20
                            [post_date_gmt] => 2023-09-05 11:36:20
                            [post_content] => 
                            [post_title] => U.S. Department of Defense – Inovio, COVID-19 Vaccine Delivery Device, Other Transaction Prototype Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => u-s-department-of-defense-inovio-covid-19-vaccine-delivery-device-other-transaction-prototype-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-05 11:36:20
                            [post_modified_gmt] => 2023-09-05 11:36:20
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11143
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [65] => WP_Post Object
                        (
                            [ID] => 11142
                            [post_author] => 5
                            [post_date] => 2023-09-05 11:23:35
                            [post_date_gmt] => 2023-09-05 11:23:35
                            [post_content] => 
                            [post_title] => U.S. Department of Defense – Inovio, COVID-19 Vaccine Delivery Device, Other Transaction Prototype Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => u-s-department-of-defense-inovio-covid-19-vaccine-delivery-device-other-transaction-prototype-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-05 12:14:59
                            [post_modified_gmt] => 2023-09-05 12:14:59
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11142
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [66] => WP_Post Object
                        (
                            [ID] => 11141
                            [post_author] => 5
                            [post_date] => 2023-09-05 10:28:18
                            [post_date_gmt] => 2023-09-05 10:28:18
                            [post_content] => 
                            [post_title] => U.S. Department of Defense – Inovio, COVID-19 Vaccine Delivery Device, Other Transaction Prototype Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => u-s-department-of-defense-inovio-covid-19-vaccine-delivery-device-other-transaction-prototype-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-05 12:20:34
                            [post_modified_gmt] => 2023-09-05 12:20:34
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11141
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [67] => WP_Post Object
                        (
                            [ID] => 11140
                            [post_author] => 5
                            [post_date] => 2023-09-05 09:30:03
                            [post_date_gmt] => 2023-09-05 09:30:03
                            [post_content] => 
                            [post_title] => U.S. Department of Defense – Inovio, COVID-19 Vaccine Delivery Device, Other Transaction Prototype Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => u-s-department-of-defense-inovio-covid-19-vaccine-delivery-device-other-transaction-prototype-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-05 09:30:03
                            [post_modified_gmt] => 2023-09-05 09:30:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11140
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [68] => WP_Post Object
                        (
                            [ID] => 11139
                            [post_author] => 5
                            [post_date] => 2023-09-05 08:13:21
                            [post_date_gmt] => 2023-09-05 08:13:21
                            [post_content] => 
                            [post_title] => U.S. Department of Defense – Inovio, COVID-19 Vaccine Delivery Device, Other Transaction Prototype Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => u-s-department-of-defense-inovio-covid-19-vaccine-delivery-device-other-transaction-prototype-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-05 08:13:21
                            [post_modified_gmt] => 2023-09-05 08:13:21
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11139
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [69] => WP_Post Object
                        (
                            [ID] => 11138
                            [post_author] => 5
                            [post_date] => 2023-09-05 07:25:41
                            [post_date_gmt] => 2023-09-05 07:25:41
                            [post_content] => 
                            [post_title] => U.S. Department of Defense – Inovio, COVID-19 Vaccine Delivery Device, Other Transaction Prototype Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => u-s-department-of-defense-inovio-covid-19-vaccine-delivery-device-other-transaction-prototype-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-05 09:27:47
                            [post_modified_gmt] => 2023-09-05 09:27:47
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11138
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [70] => WP_Post Object
                        (
                            [ID] => 11137
                            [post_author] => 5
                            [post_date] => 2023-09-05 06:29:43
                            [post_date_gmt] => 2023-09-05 06:29:43
                            [post_content] => 
                            [post_title] => U.S. Department of Defense – Inovio, COVID-19 Vaccine Delivery Device, Other Transaction Prototype Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => u-s-department-of-defense-inovio-covid-19-vaccine-delivery-device-other-transaction-prototype-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-05 06:29:43
                            [post_modified_gmt] => 2023-09-05 06:29:43
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11137
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [71] => WP_Post Object
                        (
                            [ID] => 11136
                            [post_author] => 5
                            [post_date] => 2023-09-04 15:29:56
                            [post_date_gmt] => 2023-09-04 15:29:56
                            [post_content] => 
                            [post_title] => U.S. Department of Defense – Inovio, COVID-19 Vaccine Delivery Device, Other Transaction Prototype Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => u-s-department-of-defense-inovio-covid-19-vaccine-delivery-device-other-transaction-prototype-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-01-11 09:24:14
                            [post_modified_gmt] => 2024-01-11 09:24:14
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11136
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [72] => WP_Post Object
                        (
                            [ID] => 11135
                            [post_author] => 5
                            [post_date] => 2023-09-04 14:52:10
                            [post_date_gmt] => 2023-09-04 14:52:10
                            [post_content] => 
                            [post_title] => U.S. Department of Defense - Inovio, COVID-19 Vaccine Delivery Device, Other Transaction Prototype Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => u-s-department-of-defense-inovio-covid-19-vaccine-delivery-device-other-transaction-prototype-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-04 15:30:23
                            [post_modified_gmt] => 2023-09-04 15:30:23
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11135
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [73] => WP_Post Object
                        (
                            [ID] => 11111
                            [post_author] => 5
                            [post_date] => 2023-09-01 07:10:42
                            [post_date_gmt] => 2023-09-01 07:10:42
                            [post_content] => 
                            [post_title] => U.S. Department of Defense - Inovio, COVID-19 Vaccine Delivery Device, Other Transaction Prototype Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => u-s-department-of-defense-inovio-covid-19-vaccine-delivery-device-other-transaction-prototype-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-12 11:06:43
                            [post_modified_gmt] => 2023-09-12 11:06:43
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11111
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [74] => WP_Post Object
                        (
                            [ID] => 11019
                            [post_author] => 5
                            [post_date] => 2023-08-24 08:13:46
                            [post_date_gmt] => 2023-08-24 08:13:46
                            [post_content] => 
                            [post_title] => NIH - Fluidigm, COVID-19 Diagnostic Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-fluidigm-covid-19-diagnostic-development-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-24 08:13:46
                            [post_modified_gmt] => 2023-08-24 08:13:46
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11019
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [75] => WP_Post Object
                        (
                            [ID] => 11021
                            [post_author] => 5
                            [post_date] => 2023-08-24 08:11:05
                            [post_date_gmt] => 2023-08-24 08:11:05
                            [post_content] => 
                            [post_title] => NIH - Fluidigm, COVID-19 Diagnostic Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-fluidigm-covid-19-diagnostic-development-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-24 08:11:05
                            [post_modified_gmt] => 2023-08-24 08:11:05
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11021
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [76] => WP_Post Object
                        (
                            [ID] => 11023
                            [post_author] => 5
                            [post_date] => 2023-08-24 08:10:08
                            [post_date_gmt] => 2023-08-24 08:10:08
                            [post_content] => 
                            [post_title] => NIH - Fluidigm, COVID-19 Diagnostic Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-fluidigm-covid-19-diagnostic-development-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-24 08:10:08
                            [post_modified_gmt] => 2023-08-24 08:10:08
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11023
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [77] => WP_Post Object
                        (
                            [ID] => 11028
                            [post_author] => 5
                            [post_date] => 2023-08-24 08:08:50
                            [post_date_gmt] => 2023-08-24 08:08:50
                            [post_content] => 
                            [post_title] => NIH - Fluidigm, COVID-19 Diagnostic Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-fluidigm-covid-19-diagnostic-development-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-24 08:08:50
                            [post_modified_gmt] => 2023-08-24 08:08:50
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11028
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [78] => WP_Post Object
                        (
                            [ID] => 11029
                            [post_author] => 5
                            [post_date] => 2023-08-24 08:07:41
                            [post_date_gmt] => 2023-08-24 08:07:41
                            [post_content] => 
                            [post_title] => NIH - Fluidigm, COVID-19 Diagnostic Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-fluidigm-covid-19-diagnostic-development-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-24 08:07:41
                            [post_modified_gmt] => 2023-08-24 08:07:41
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11029
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [79] => WP_Post Object
                        (
                            [ID] => 11018
                            [post_author] => 5
                            [post_date] => 2023-08-24 08:05:11
                            [post_date_gmt] => 2023-08-24 08:05:11
                            [post_content] => 
                            [post_title] => NIH - Fluidigm, COVID-19 Diagnostic Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-fluidigm-covid-19-diagnostic-development-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-24 08:05:11
                            [post_modified_gmt] => 2023-08-24 08:05:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11018
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [80] => WP_Post Object
                        (
                            [ID] => 11031
                            [post_author] => 5
                            [post_date] => 2023-08-24 08:04:36
                            [post_date_gmt] => 2023-08-24 08:04:36
                            [post_content] => 
                            [post_title] => NIH - Fluidigm, COVID-19 Diagnostic Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-fluidigm-covid-19-diagnostic-development-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-24 08:06:55
                            [post_modified_gmt] => 2023-08-24 08:06:55
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11031
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [81] => WP_Post Object
                        (
                            [ID] => 11020
                            [post_author] => 5
                            [post_date] => 2023-08-24 07:56:53
                            [post_date_gmt] => 2023-08-24 07:56:53
                            [post_content] => 
                            [post_title] => NIH - Fluidigm, COVID-19 Diagnostic Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-fluidigm-covid-19-diagnostic-development-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-24 07:56:53
                            [post_modified_gmt] => 2023-08-24 07:56:53
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11020
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [82] => WP_Post Object
                        (
                            [ID] => 11032
                            [post_author] => 5
                            [post_date] => 2023-08-23 13:27:36
                            [post_date_gmt] => 2023-08-23 13:27:36
                            [post_content] => 
                            [post_title] => NIH - Fluidigm, COVID-19 Diagnostic Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-fluidigm-covid-19-diagnostic-development-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-24 07:55:09
                            [post_modified_gmt] => 2023-08-24 07:55:09
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11032
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [83] => WP_Post Object
                        (
                            [ID] => 11026
                            [post_author] => 5
                            [post_date] => 2023-08-23 13:17:51
                            [post_date_gmt] => 2023-08-23 13:17:51
                            [post_content] => 
                            [post_title] => NIH - Fluidigm, COVID-19 Diagnostic Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-fluidigm-covid-19-diagnostic-development-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-24 07:50:49
                            [post_modified_gmt] => 2023-08-24 07:50:49
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11026
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [84] => WP_Post Object
                        (
                            [ID] => 11030
                            [post_author] => 5
                            [post_date] => 2023-08-23 13:10:30
                            [post_date_gmt] => 2023-08-23 13:10:30
                            [post_content] => 
                            [post_title] => NIH - Fluidigm, COVID-19 Diagnostic Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-fluidigm-covid-19-diagnostic-development-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-23 13:32:24
                            [post_modified_gmt] => 2023-08-23 13:32:24
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11030
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [85] => WP_Post Object
                        (
                            [ID] => 11022
                            [post_author] => 5
                            [post_date] => 2023-08-23 12:45:06
                            [post_date_gmt] => 2023-08-23 12:45:06
                            [post_content] => 
                            [post_title] => NIH - Fluidigm, COVID-19 Diagnostic Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-fluidigm-covid-19-diagnostic-development-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-24 09:16:00
                            [post_modified_gmt] => 2023-08-24 09:16:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11022
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [86] => WP_Post Object
                        (
                            [ID] => 10998
                            [post_author] => 5
                            [post_date] => 2023-08-11 08:59:40
                            [post_date_gmt] => 2023-08-11 08:59:40
                            [post_content] => 
                            [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-14 15:06:00
                            [post_modified_gmt] => 2023-08-14 15:06:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=10998
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [87] => WP_Post Object
                        (
                            [ID] => 10997
                            [post_author] => 5
                            [post_date] => 2023-08-11 08:41:21
                            [post_date_gmt] => 2023-08-11 08:41:21
                            [post_content] => 
                            [post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => us-army-contracting-command-via-ati-regeneron-covid-19-antibodies-large-scale-manufacturing-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-14 15:00:44
                            [post_modified_gmt] => 2023-08-14 15:00:44
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=10997
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [88] => WP_Post Object
                        (
                            [ID] => 10995
                            [post_author] => 5
                            [post_date] => 2023-08-11 07:25:45
                            [post_date_gmt] => 2023-08-11 07:25:45
                            [post_content] => 
                            [post_title] => US Government – Ology Bioservices, COVID-19 Plasmid Procurement Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => us-government-ology-bioservices-covid-19-plasmid-procurement-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-11 07:25:45
                            [post_modified_gmt] => 2023-08-11 07:25:45
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=10995
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [89] => WP_Post Object
                        (
                            [ID] => 9090
                            [post_author] => 5
                            [post_date] => 2023-03-08 10:46:30
                            [post_date_gmt] => 2023-03-08 10:46:30
                            [post_content] => 
                            [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-08 11:14:44
                            [post_modified_gmt] => 2023-03-08 11:14:44
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9090
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [90] => WP_Post Object
                        (
                            [ID] => 9089
                            [post_author] => 5
                            [post_date] => 2023-03-08 10:34:53
                            [post_date_gmt] => 2023-03-08 10:34:53
                            [post_content] => 
                            [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-08 11:24:52
                            [post_modified_gmt] => 2023-03-08 11:24:52
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9089
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [91] => WP_Post Object
                        (
                            [ID] => 9088
                            [post_author] => 5
                            [post_date] => 2023-03-08 10:31:00
                            [post_date_gmt] => 2023-03-08 10:31:00
                            [post_content] => 
                            [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-08 10:31:00
                            [post_modified_gmt] => 2023-03-08 10:31:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9088
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [92] => WP_Post Object
                        (
                            [ID] => 9087
                            [post_author] => 5
                            [post_date] => 2023-03-08 10:15:07
                            [post_date_gmt] => 2023-03-08 10:15:07
                            [post_content] => 
                            [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-08 10:15:07
                            [post_modified_gmt] => 2023-03-08 10:15:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9087
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [93] => WP_Post Object
                        (
                            [ID] => 9086
                            [post_author] => 5
                            [post_date] => 2023-03-08 09:59:11
                            [post_date_gmt] => 2023-03-08 09:59:11
                            [post_content] => 
                            [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-08 12:16:01
                            [post_modified_gmt] => 2023-03-08 12:16:01
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9086
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [94] => WP_Post Object
                        (
                            [ID] => 9083
                            [post_author] => 5
                            [post_date] => 2023-03-08 09:45:42
                            [post_date_gmt] => 2023-03-08 09:45:42
                            [post_content] => 
                            [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-08 11:15:35
                            [post_modified_gmt] => 2023-03-08 11:15:35
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9083
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [95] => WP_Post Object
                        (
                            [ID] => 9082
                            [post_author] => 5
                            [post_date] => 2023-03-08 09:34:23
                            [post_date_gmt] => 2023-03-08 09:34:23
                            [post_content] => 
                            [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-08 11:17:32
                            [post_modified_gmt] => 2023-03-08 11:17:32
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9082
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [96] => WP_Post Object
                        (
                            [ID] => 9081
                            [post_author] => 5
                            [post_date] => 2023-03-07 14:59:57
                            [post_date_gmt] => 2023-03-07 14:59:57
                            [post_content] => 
                            [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-08 11:19:49
                            [post_modified_gmt] => 2023-03-08 11:19:49
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9081
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [97] => WP_Post Object
                        (
                            [ID] => 9080
                            [post_author] => 5
                            [post_date] => 2023-03-07 14:44:45
                            [post_date_gmt] => 2023-03-07 14:44:45
                            [post_content] => 
                            [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-08 11:20:27
                            [post_modified_gmt] => 2023-03-08 11:20:27
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9080
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [98] => WP_Post Object
                        (
                            [ID] => 9079
                            [post_author] => 5
                            [post_date] => 2023-03-07 14:40:00
                            [post_date_gmt] => 2023-03-07 14:40:00
                            [post_content] => 
                            [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-05-01 14:33:10
                            [post_modified_gmt] => 2023-05-01 14:33:10
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9079
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [99] => WP_Post Object
                        (
                            [ID] => 9078
                            [post_author] => 5
                            [post_date] => 2023-03-07 14:31:51
                            [post_date_gmt] => 2023-03-07 14:31:51
                            [post_content] => 
                            [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-08 11:23:22
                            [post_modified_gmt] => 2023-03-08 11:23:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9078
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [100] => WP_Post Object
                        (
                            [ID] => 9077
                            [post_author] => 5
                            [post_date] => 2023-03-07 14:28:57
                            [post_date_gmt] => 2023-03-07 14:28:57
                            [post_content] => 
                            [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-08 11:21:30
                            [post_modified_gmt] => 2023-03-08 11:21:30
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9077
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [101] => WP_Post Object
                        (
                            [ID] => 9076
                            [post_author] => 5
                            [post_date] => 2023-03-07 14:09:37
                            [post_date_gmt] => 2023-03-07 14:09:37
                            [post_content] => 
                            [post_title] => MPP – South African Medical Research Council, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-south-african-medical-research-council-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-08 11:22:36
                            [post_modified_gmt] => 2023-03-08 11:22:36
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9076
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [102] => WP_Post Object
                        (
                            [ID] => 9073
                            [post_author] => 5
                            [post_date] => 2023-03-07 12:46:52
                            [post_date_gmt] => 2023-03-07 12:46:52
                            [post_content] => 
                            [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-08 12:18:23
                            [post_modified_gmt] => 2023-03-08 12:18:23
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9073
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [103] => WP_Post Object
                        (
                            [ID] => 9072
                            [post_author] => 5
                            [post_date] => 2023-03-07 12:24:17
                            [post_date_gmt] => 2023-03-07 12:24:17
                            [post_content] => 
                            [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-08 12:19:29
                            [post_modified_gmt] => 2023-03-08 12:19:29
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9072
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [104] => WP_Post Object
                        (
                            [ID] => 9071
                            [post_author] => 5
                            [post_date] => 2023-03-07 12:09:50
                            [post_date_gmt] => 2023-03-07 12:09:50
                            [post_content] => 
                            [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-08 12:16:59
                            [post_modified_gmt] => 2023-03-08 12:16:59
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9071
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [105] => WP_Post Object
                        (
                            [ID] => 9070
                            [post_author] => 5
                            [post_date] => 2023-03-06 18:39:51
                            [post_date_gmt] => 2023-03-06 18:39:51
                            [post_content] => 
                            [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-08 12:16:23
                            [post_modified_gmt] => 2023-03-08 12:16:23
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9070
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [106] => WP_Post Object
                        (
                            [ID] => 9069
                            [post_author] => 5
                            [post_date] => 2023-03-06 18:34:47
                            [post_date_gmt] => 2023-03-06 18:34:47
                            [post_content] => 
                            [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-08 12:15:26
                            [post_modified_gmt] => 2023-03-08 12:15:26
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9069
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [107] => WP_Post Object
                        (
                            [ID] => 9068
                            [post_author] => 5
                            [post_date] => 2023-03-06 18:20:18
                            [post_date_gmt] => 2023-03-06 18:20:18
                            [post_content] => 
                            [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-08 11:35:08
                            [post_modified_gmt] => 2023-03-08 11:35:08
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9068
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [108] => WP_Post Object
                        (
                            [ID] => 9067
                            [post_author] => 5
                            [post_date] => 2023-03-06 16:40:37
                            [post_date_gmt] => 2023-03-06 16:40:37
                            [post_content] => 
                            [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-08 11:36:48
                            [post_modified_gmt] => 2023-03-08 11:36:48
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9067
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [109] => WP_Post Object
                        (
                            [ID] => 9066
                            [post_author] => 5
                            [post_date] => 2023-03-06 15:55:39
                            [post_date_gmt] => 2023-03-06 15:55:39
                            [post_content] => 
                            [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-08 11:38:10
                            [post_modified_gmt] => 2023-03-08 11:38:10
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9066
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [110] => WP_Post Object
                        (
                            [ID] => 9065
                            [post_author] => 5
                            [post_date] => 2023-03-06 15:36:15
                            [post_date_gmt] => 2023-03-06 15:36:15
                            [post_content] => 
                            [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-08 12:13:07
                            [post_modified_gmt] => 2023-03-08 12:13:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9065
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [111] => WP_Post Object
                        (
                            [ID] => 9064
                            [post_author] => 5
                            [post_date] => 2023-03-06 15:24:23
                            [post_date_gmt] => 2023-03-06 15:24:23
                            [post_content] => 
                            [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-05-01 14:32:16
                            [post_modified_gmt] => 2023-05-01 14:32:16
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9064
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [112] => WP_Post Object
                        (
                            [ID] => 9063
                            [post_author] => 5
                            [post_date] => 2023-03-06 15:10:08
                            [post_date_gmt] => 2023-03-06 15:10:08
                            [post_content] => 
                            [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-08 12:14:56
                            [post_modified_gmt] => 2023-03-08 12:14:56
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9063
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [113] => WP_Post Object
                        (
                            [ID] => 9062
                            [post_author] => 5
                            [post_date] => 2023-03-06 15:05:13
                            [post_date_gmt] => 2023-03-06 15:05:13
                            [post_content] => 
                            [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-08 11:33:55
                            [post_modified_gmt] => 2023-03-08 11:33:55
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9062
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [114] => WP_Post Object
                        (
                            [ID] => 9061
                            [post_author] => 5
                            [post_date] => 2023-03-06 13:14:19
                            [post_date_gmt] => 2023-03-06 13:14:19
                            [post_content] => 
                            [post_title] => MPP – Afrigen Biologics, COVID-19 mRNA-Based Vaccines and Therapeutics, Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => mpp-afrigen-biologics-covid-19-mrna-based-vaccines-and-therapeutics-grant-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-08 12:14:30
                            [post_modified_gmt] => 2023-03-08 12:14:30
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=9061
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [115] => WP_Post Object
                        (
                            [ID] => 8462
                            [post_author] => 5
                            [post_date] => 2023-01-10 12:12:52
                            [post_date_gmt] => 2023-01-10 12:12:52
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-10 14:43:22
                            [post_modified_gmt] => 2023-11-10 14:43:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8462
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [116] => WP_Post Object
                        (
                            [ID] => 8447
                            [post_author] => 5
                            [post_date] => 2022-12-15 15:33:22
                            [post_date_gmt] => 2022-12-15 15:33:22
                            [post_content] => 
                            [post_title] => US Government - Ology Bioservices, COVID-19 Plasmid Procurement Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => us-government-ology-bioservices-covid-19-plasmid-procurement-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-16 06:38:29
                            [post_modified_gmt] => 2023-08-16 06:38:29
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8447
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [117] => WP_Post Object
                        (
                            [ID] => 8314
                            [post_author] => 5
                            [post_date] => 2022-12-13 11:46:36
                            [post_date_gmt] => 2022-12-13 11:46:36
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-17
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-29 13:04:09
                            [post_modified_gmt] => 2023-06-29 13:04:09
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8314
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [118] => WP_Post Object
                        (
                            [ID] => 8313
                            [post_author] => 5
                            [post_date] => 2022-12-13 10:48:56
                            [post_date_gmt] => 2022-12-13 10:48:56
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-16
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-29 13:06:48
                            [post_modified_gmt] => 2023-06-29 13:06:48
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8313
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [119] => WP_Post Object
                        (
                            [ID] => 8312
                            [post_author] => 5
                            [post_date] => 2022-12-13 10:35:08
                            [post_date_gmt] => 2022-12-13 10:35:08
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-15
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-10-16 14:15:32
                            [post_modified_gmt] => 2023-10-16 14:15:32
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8312
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [120] => WP_Post Object
                        (
                            [ID] => 8311
                            [post_author] => 5
                            [post_date] => 2022-12-13 10:09:44
                            [post_date_gmt] => 2022-12-13 10:09:44
                            [post_content] => 
                            [post_title] => CEPI - VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-10-16 14:15:39
                            [post_modified_gmt] => 2023-10-16 14:15:39
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8311
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [121] => WP_Post Object
                        (
                            [ID] => 8192
                            [post_author] => 5
                            [post_date] => 2022-12-13 09:04:26
                            [post_date_gmt] => 2022-12-13 09:04:26
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-10 15:08:47
                            [post_modified_gmt] => 2024-04-10 15:08:47
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8192
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [122] => WP_Post Object
                        (
                            [ID] => 8191
                            [post_author] => 5
                            [post_date] => 2022-12-12 16:19:19
                            [post_date_gmt] => 2022-12-12 16:19:19
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-28 17:58:47
                            [post_modified_gmt] => 2023-06-28 17:58:47
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8191
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [123] => WP_Post Object
                        (
                            [ID] => 8190
                            [post_author] => 5
                            [post_date] => 2022-12-12 15:29:46
                            [post_date_gmt] => 2022-12-12 15:29:46
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-01-10 15:15:12
                            [post_modified_gmt] => 2024-01-10 15:15:12
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8190
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [124] => WP_Post Object
                        (
                            [ID] => 8157
                            [post_author] => 5
                            [post_date] => 2022-12-12 15:23:50
                            [post_date_gmt] => 2022-12-12 15:23:50
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-28 18:07:12
                            [post_modified_gmt] => 2023-06-28 18:07:12
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8157
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [125] => WP_Post Object
                        (
                            [ID] => 8152
                            [post_author] => 5
                            [post_date] => 2022-12-12 12:04:21
                            [post_date_gmt] => 2022-12-12 12:04:21
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-28 18:00:35
                            [post_modified_gmt] => 2023-06-28 18:00:35
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8152
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [126] => WP_Post Object
                        (
                            [ID] => 8151
                            [post_author] => 5
                            [post_date] => 2022-12-12 11:56:08
                            [post_date_gmt] => 2022-12-12 11:56:08
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-10-16 14:15:55
                            [post_modified_gmt] => 2023-10-16 14:15:55
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8151
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [127] => WP_Post Object
                        (
                            [ID] => 8150
                            [post_author] => 5
                            [post_date] => 2022-12-12 11:21:26
                            [post_date_gmt] => 2022-12-12 11:21:26
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-10-16 14:16:06
                            [post_modified_gmt] => 2023-10-16 14:16:06
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8150
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [128] => WP_Post Object
                        (
                            [ID] => 8143
                            [post_author] => 5
                            [post_date] => 2022-12-12 11:10:19
                            [post_date_gmt] => 2022-12-12 11:10:19
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-28 17:56:49
                            [post_modified_gmt] => 2023-06-28 17:56:49
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8143
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [129] => WP_Post Object
                        (
                            [ID] => 8142
                            [post_author] => 5
                            [post_date] => 2022-12-12 10:40:31
                            [post_date_gmt] => 2022-12-12 10:40:31
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-10-16 14:16:14
                            [post_modified_gmt] => 2023-10-16 14:16:14
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8142
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [130] => WP_Post Object
                        (
                            [ID] => 8131
                            [post_author] => 5
                            [post_date] => 2022-12-12 09:57:36
                            [post_date_gmt] => 2022-12-12 09:57:36
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-01-10 15:13:52
                            [post_modified_gmt] => 2024-01-10 15:13:52
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8131
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [131] => WP_Post Object
                        (
                            [ID] => 8130
                            [post_author] => 5
                            [post_date] => 2022-12-12 09:34:49
                            [post_date_gmt] => 2022-12-12 09:34:49
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-10-16 14:16:23
                            [post_modified_gmt] => 2023-10-16 14:16:23
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8130
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [132] => WP_Post Object
                        (
                            [ID] => 8129
                            [post_author] => 5
                            [post_date] => 2022-12-12 08:55:53
                            [post_date_gmt] => 2022-12-12 08:55:53
                            [post_content] => 
                            [post_title] => CEPI - VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-01-10 15:17:11
                            [post_modified_gmt] => 2024-01-10 15:17:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8129
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [133] => WP_Post Object
                        (
                            [ID] => 8051
                            [post_author] => 5
                            [post_date] => 2022-12-12 08:39:19
                            [post_date_gmt] => 2022-12-12 08:39:19
                            [post_content] => 
                            [post_title] => CEPI - VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-01-10 15:17:49
                            [post_modified_gmt] => 2024-01-10 15:17:49
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8051
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [134] => WP_Post Object
                        (
                            [ID] => 5808
                            [post_author] => 5
                            [post_date] => 2022-10-04 10:04:03
                            [post_date_gmt] => 2022-10-04 10:04:03
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-16
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-10 17:21:04
                            [post_modified_gmt] => 2023-07-10 17:21:04
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5808
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [135] => WP_Post Object
                        (
                            [ID] => 5782
                            [post_author] => 5
                            [post_date] => 2022-09-16 07:28:56
                            [post_date_gmt] => 2022-09-16 07:28:56
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-22 13:43:22
                            [post_modified_gmt] => 2023-06-22 13:43:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5782
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [136] => WP_Post Object
                        (
                            [ID] => 5653
                            [post_author] => 5
                            [post_date] => 2022-08-25 12:56:30
                            [post_date_gmt] => 2022-08-25 12:56:30
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-22 14:00:47
                            [post_modified_gmt] => 2023-06-22 14:00:47
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5653
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [137] => WP_Post Object
                        (
                            [ID] => 5652
                            [post_author] => 5
                            [post_date] => 2022-08-25 12:26:53
                            [post_date_gmt] => 2022-08-25 12:26:53
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-22 13:48:11
                            [post_modified_gmt] => 2023-06-22 13:48:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5652
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [138] => WP_Post Object
                        (
                            [ID] => 5620
                            [post_author] => 5
                            [post_date] => 2022-08-12 12:05:12
                            [post_date_gmt] => 2022-08-12 12:05:12
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-12 12:05:12
                            [post_modified_gmt] => 2022-08-12 12:05:12
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5620
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [139] => WP_Post Object
                        (
                            [ID] => 5619
                            [post_author] => 5
                            [post_date] => 2022-08-12 12:02:21
                            [post_date_gmt] => 2022-08-12 12:02:21
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 12:48:01
                            [post_modified_gmt] => 2022-10-12 12:48:01
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5619
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [140] => WP_Post Object
                        (
                            [ID] => 5618
                            [post_author] => 5
                            [post_date] => 2022-08-12 11:52:17
                            [post_date_gmt] => 2022-08-12 11:52:17
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-12 11:52:17
                            [post_modified_gmt] => 2022-08-12 11:52:17
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5618
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [141] => WP_Post Object
                        (
                            [ID] => 5617
                            [post_author] => 5
                            [post_date] => 2022-08-12 11:49:46
                            [post_date_gmt] => 2022-08-12 11:49:46
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-12 11:49:46
                            [post_modified_gmt] => 2022-08-12 11:49:46
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5617
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [142] => WP_Post Object
                        (
                            [ID] => 5616
                            [post_author] => 5
                            [post_date] => 2022-08-12 11:45:22
                            [post_date_gmt] => 2022-08-12 11:45:22
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-12 11:45:22
                            [post_modified_gmt] => 2022-08-12 11:45:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5616
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [143] => WP_Post Object
                        (
                            [ID] => 5615
                            [post_author] => 5
                            [post_date] => 2022-08-12 11:40:08
                            [post_date_gmt] => 2022-08-12 11:40:08
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-12 11:40:08
                            [post_modified_gmt] => 2022-08-12 11:40:08
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5615
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [144] => WP_Post Object
                        (
                            [ID] => 5614
                            [post_author] => 5
                            [post_date] => 2022-08-12 11:34:41
                            [post_date_gmt] => 2022-08-12 11:34:41
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-29 11:28:05
                            [post_modified_gmt] => 2022-09-29 11:28:05
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5614
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [145] => WP_Post Object
                        (
                            [ID] => 5612
                            [post_author] => 5
                            [post_date] => 2022-08-12 10:14:31
                            [post_date_gmt] => 2022-08-12 10:14:31
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-14 13:42:46
                            [post_modified_gmt] => 2022-12-14 13:42:46
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5612
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [146] => WP_Post Object
                        (
                            [ID] => 5611
                            [post_author] => 5
                            [post_date] => 2022-08-12 10:05:33
                            [post_date_gmt] => 2022-08-12 10:05:33
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-12 10:05:33
                            [post_modified_gmt] => 2022-08-12 10:05:33
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5611
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [147] => WP_Post Object
                        (
                            [ID] => 5610
                            [post_author] => 5
                            [post_date] => 2022-08-12 09:31:00
                            [post_date_gmt] => 2022-08-12 09:31:00
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-28 14:10:06
                            [post_modified_gmt] => 2023-03-28 14:10:06
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5610
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [148] => WP_Post Object
                        (
                            [ID] => 5609
                            [post_author] => 5
                            [post_date] => 2022-08-12 09:24:43
                            [post_date_gmt] => 2022-08-12 09:24:43
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-12 09:24:43
                            [post_modified_gmt] => 2022-08-12 09:24:43
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5609
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [149] => WP_Post Object
                        (
                            [ID] => 5608
                            [post_author] => 5
                            [post_date] => 2022-08-12 09:09:54
                            [post_date_gmt] => 2022-08-12 09:09:54
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-04-27 08:36:41
                            [post_modified_gmt] => 2023-04-27 08:36:41
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5608
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [150] => WP_Post Object
                        (
                            [ID] => 5599
                            [post_author] => 5
                            [post_date] => 2022-08-11 14:17:45
                            [post_date_gmt] => 2022-08-11 14:17:45
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-05-01 14:23:07
                            [post_modified_gmt] => 2023-05-01 14:23:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5599
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [151] => WP_Post Object
                        (
                            [ID] => 5596
                            [post_author] => 5
                            [post_date] => 2022-08-11 12:52:07
                            [post_date_gmt] => 2022-08-11 12:52:07
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-11-08 18:52:16
                            [post_modified_gmt] => 2022-11-08 18:52:16
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5596
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [152] => WP_Post Object
                        (
                            [ID] => 5595
                            [post_author] => 5
                            [post_date] => 2022-08-11 12:36:15
                            [post_date_gmt] => 2022-08-11 12:36:15
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-11 12:36:15
                            [post_modified_gmt] => 2022-08-11 12:36:15
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5595
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [153] => WP_Post Object
                        (
                            [ID] => 5594
                            [post_author] => 5
                            [post_date] => 2022-08-11 12:13:32
                            [post_date_gmt] => 2022-08-11 12:13:32
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-10 13:53:44
                            [post_modified_gmt] => 2023-11-10 13:53:44
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5594
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [154] => WP_Post Object
                        (
                            [ID] => 5593
                            [post_author] => 5
                            [post_date] => 2022-08-11 11:48:52
                            [post_date_gmt] => 2022-08-11 11:48:52
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-11 12:26:53
                            [post_modified_gmt] => 2022-08-11 12:26:53
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5593
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [155] => WP_Post Object
                        (
                            [ID] => 5592
                            [post_author] => 5
                            [post_date] => 2022-08-11 11:16:19
                            [post_date_gmt] => 2022-08-11 11:16:19
                            [post_content] => 
                            [post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-13 13:12:08
                            [post_modified_gmt] => 2022-10-13 13:12:08
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5592
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [156] => WP_Post Object
                        (
                            [ID] => 5591
                            [post_author] => 5
                            [post_date] => 2022-08-11 10:18:46
                            [post_date_gmt] => 2022-08-11 10:18:46
                            [post_content] => 
                            [post_title] => Gates Foundation - Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-11 10:18:46
                            [post_modified_gmt] => 2022-08-11 10:18:46
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5591
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [157] => WP_Post Object
                        (
                            [ID] => 5429
                            [post_author] => 5
                            [post_date] => 2022-07-25 06:51:00
                            [post_date_gmt] => 2022-07-25 06:51:00
                            [post_content] => 
                            [post_title] => Sanofi – Translate Bio, Influenza and COVID-19 Vaccine Collaboration & License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-translate-bio-influenza-and-covid-19-vaccine-collaboration-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-05-04 12:00:45
                            [post_modified_gmt] => 2023-05-04 12:00:45
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5429
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [158] => WP_Post Object
                        (
                            [ID] => 5123
                            [post_author] => 5
                            [post_date] => 2022-06-29 15:28:35
                            [post_date_gmt] => 2022-06-29 15:28:35
                            [post_content] => 
                            [post_title] => NIH – MPP (C-TAP), COVID-19 Technologies, Patent and Biological Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-10 14:42:31
                            [post_modified_gmt] => 2023-11-10 14:42:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5123
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [159] => WP_Post Object
                        (
                            [ID] => 5122
                            [post_author] => 5
                            [post_date] => 2022-06-29 14:42:34
                            [post_date_gmt] => 2022-06-29 14:42:34
                            [post_content] => 
                            [post_title] => NIH – MPP (C-TAP), COVID-19 Technologies, Patent and Biological Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => 5122
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 11:57:22
                            [post_modified_gmt] => 2023-09-18 11:57:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5122
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [160] => WP_Post Object
                        (
                            [ID] => 5121
                            [post_author] => 5
                            [post_date] => 2022-06-29 14:38:19
                            [post_date_gmt] => 2022-06-29 14:38:19
                            [post_content] => 
                            [post_title] => NIH – MPP (C-TAP), COVID-19 Technologies, Patent and Biological Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 11:57:28
                            [post_modified_gmt] => 2023-09-18 11:57:28
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5121
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [161] => WP_Post Object
                        (
                            [ID] => 5120
                            [post_author] => 5
                            [post_date] => 2022-06-29 14:30:21
                            [post_date_gmt] => 2022-06-29 14:30:21
                            [post_content] => 
                            [post_title] => NIH – MPP (C-TAP), COVID-19 Technologies, Patent and Biological Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 11:56:50
                            [post_modified_gmt] => 2023-09-18 11:56:50
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5120
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [162] => WP_Post Object
                        (
                            [ID] => 5119
                            [post_author] => 5
                            [post_date] => 2022-06-29 14:09:28
                            [post_date_gmt] => 2022-06-29 14:09:28
                            [post_content] => 
                            [post_title] => NIH – MPP (C-TAP), COVID-19 Technologies, Patent and Biological Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 11:56:57
                            [post_modified_gmt] => 2023-09-18 11:56:57
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5119
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [163] => WP_Post Object
                        (
                            [ID] => 5118
                            [post_author] => 5
                            [post_date] => 2022-06-29 14:05:52
                            [post_date_gmt] => 2022-06-29 14:05:52
                            [post_content] => 
                            [post_title] => NIH – MPP (C-TAP), COVID-19 Technologies, Patent and Biological Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 11:57:41
                            [post_modified_gmt] => 2023-09-18 11:57:41
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5118
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [164] => WP_Post Object
                        (
                            [ID] => 5117
                            [post_author] => 5
                            [post_date] => 2022-06-29 14:02:42
                            [post_date_gmt] => 2022-06-29 14:02:42
                            [post_content] => 
                            [post_title] => NIH – MPP (C-TAP), COVID-19 Technologies, Patent and Biological Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 11:57:46
                            [post_modified_gmt] => 2023-09-18 11:57:46
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5117
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [165] => WP_Post Object
                        (
                            [ID] => 5116
                            [post_author] => 5
                            [post_date] => 2022-06-29 14:00:58
                            [post_date_gmt] => 2022-06-29 14:00:58
                            [post_content] => 
                            [post_title] => NIH – MPP (C-TAP), COVID-19 Technologies, Patent and Biological Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 11:57:51
                            [post_modified_gmt] => 2023-09-18 11:57:51
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5116
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [166] => WP_Post Object
                        (
                            [ID] => 5115
                            [post_author] => 5
                            [post_date] => 2022-06-29 13:52:08
                            [post_date_gmt] => 2022-06-29 13:52:08
                            [post_content] => 
                            [post_title] => NIH – MPP (C-TAP), COVID-19 Technologies, Patent and Biological Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 11:57:56
                            [post_modified_gmt] => 2023-09-18 11:57:56
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5115
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [167] => WP_Post Object
                        (
                            [ID] => 5114
                            [post_author] => 5
                            [post_date] => 2022-06-29 13:46:01
                            [post_date_gmt] => 2022-06-29 13:46:01
                            [post_content] => 
                            [post_title] => NIH – MPP (C-TAP), COVID-19 Technologies, Patent and Biological Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 11:58:00
                            [post_modified_gmt] => 2023-09-18 11:58:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5114
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [168] => WP_Post Object
                        (
                            [ID] => 5113
                            [post_author] => 5
                            [post_date] => 2022-06-29 13:33:56
                            [post_date_gmt] => 2022-06-29 13:33:56
                            [post_content] => 
                            [post_title] => NIH – MPP (C-TAP), COVID-19 Technologies, Patent and Biological Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 11:58:05
                            [post_modified_gmt] => 2023-09-18 11:58:05
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5113
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [169] => WP_Post Object
                        (
                            [ID] => 5112
                            [post_author] => 5
                            [post_date] => 2022-06-29 13:04:55
                            [post_date_gmt] => 2022-06-29 13:04:55
                            [post_content] => 
                            [post_title] => NIH – MPP (C-TAP), COVID-19 Technologies, Patent and Biological Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 11:58:11
                            [post_modified_gmt] => 2023-09-18 11:58:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5112
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [170] => WP_Post Object
                        (
                            [ID] => 5111
                            [post_author] => 5
                            [post_date] => 2022-06-29 12:40:35
                            [post_date_gmt] => 2022-06-29 12:40:35
                            [post_content] => 
                            [post_title] => NIH – MPP (C-TAP), COVID-19 Technologies, Patent and Biological Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-18 11:58:17
                            [post_modified_gmt] => 2023-09-18 11:58:17
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5111
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [171] => WP_Post Object
                        (
                            [ID] => 4808
                            [post_author] => 5
                            [post_date] => 2022-05-24 09:09:54
                            [post_date_gmt] => 2022-05-24 09:09:54
                            [post_content] => 
                            [post_title] => CSIC - MPP (C-TAP), COVID-19 Diagnostic, Patent & Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 10:13:53
                            [post_modified_gmt] => 2023-09-27 10:13:53
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4808
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [172] => WP_Post Object
                        (
                            [ID] => 4807
                            [post_author] => 5
                            [post_date] => 2022-05-24 09:02:55
                            [post_date_gmt] => 2022-05-24 09:02:55
                            [post_content] => 
                            [post_title] => CSIC - MPP (C-TAP), COVID-19 Diagnostic, Patent & Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 11:32:19
                            [post_modified_gmt] => 2023-09-27 11:32:19
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4807
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [173] => WP_Post Object
                        (
                            [ID] => 4806
                            [post_author] => 5
                            [post_date] => 2022-05-24 08:59:08
                            [post_date_gmt] => 2022-05-24 08:59:08
                            [post_content] => 
                            [post_title] => CSIC - MPP (C-TAP), COVID-19 Diagnostic, Patent & Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 10:11:24
                            [post_modified_gmt] => 2023-09-27 10:11:24
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4806
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [174] => WP_Post Object
                        (
                            [ID] => 4805
                            [post_author] => 5
                            [post_date] => 2022-05-24 08:53:12
                            [post_date_gmt] => 2022-05-24 08:53:12
                            [post_content] => 
                            [post_title] => CSIC - MPP (C-TAP), COVID-19 Diagnostic, Patent & Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 11:34:37
                            [post_modified_gmt] => 2023-09-27 11:34:37
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4805
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [175] => WP_Post Object
                        (
                            [ID] => 4804
                            [post_author] => 5
                            [post_date] => 2022-05-24 08:40:15
                            [post_date_gmt] => 2022-05-24 08:40:15
                            [post_content] => 
                            [post_title] => CSIC - MPP (C-TAP), COVID-19 Diagnostic, Patent & Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 11:33:40
                            [post_modified_gmt] => 2023-09-27 11:33:40
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4804
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [176] => WP_Post Object
                        (
                            [ID] => 4802
                            [post_author] => 5
                            [post_date] => 2022-05-24 08:24:23
                            [post_date_gmt] => 2022-05-24 08:24:23
                            [post_content] => 
                            [post_title] => CSIC - MPP (C-TAP), COVID-19 Diagnostic, Patent & Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 11:31:31
                            [post_modified_gmt] => 2023-09-27 11:31:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4802
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [177] => WP_Post Object
                        (
                            [ID] => 4801
                            [post_author] => 5
                            [post_date] => 2022-05-24 08:19:21
                            [post_date_gmt] => 2022-05-24 08:19:21
                            [post_content] => 
                            [post_title] => CSIC - MPP (C-TAP), COVID-19 Diagnostic, Patent & Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 10:15:07
                            [post_modified_gmt] => 2023-09-27 10:15:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4801
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [178] => WP_Post Object
                        (
                            [ID] => 4800
                            [post_author] => 5
                            [post_date] => 2022-05-24 08:07:39
                            [post_date_gmt] => 2022-05-24 08:07:39
                            [post_content] => 
                            [post_title] => CSIC - MPP (C-TAP), COVID-19 Diagnostic, Patent & Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 10:13:19
                            [post_modified_gmt] => 2023-09-27 10:13:19
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4800
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [179] => WP_Post Object
                        (
                            [ID] => 4798
                            [post_author] => 5
                            [post_date] => 2022-05-23 14:11:13
                            [post_date_gmt] => 2022-05-23 14:11:13
                            [post_content] => 
                            [post_title] => CSIC - MPP (C-TAP), COVID-19 Diagnostic, Patent & Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 10:12:22
                            [post_modified_gmt] => 2023-09-27 10:12:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4798
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [180] => WP_Post Object
                        (
                            [ID] => 4797
                            [post_author] => 5
                            [post_date] => 2022-05-23 13:54:57
                            [post_date_gmt] => 2022-05-23 13:54:57
                            [post_content] => 
                            [post_title] => CSIC - MPP (C-TAP), COVID-19 Diagnostic, Patent & Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 11:30:35
                            [post_modified_gmt] => 2023-09-27 11:30:35
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4797
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [181] => WP_Post Object
                        (
                            [ID] => 4796
                            [post_author] => 5
                            [post_date] => 2022-05-23 13:54:05
                            [post_date_gmt] => 2022-05-23 13:54:05
                            [post_content] => 
                            [post_title] => CSIC - MPP (C-TAP), COVID-19 Diagnostic, Patent & Material License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 10:00:31
                            [post_modified_gmt] => 2023-09-27 10:00:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4796
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [182] => WP_Post Object
                        (
                            [ID] => 4661
                            [post_author] => 5
                            [post_date] => 2022-04-20 08:13:06
                            [post_date_gmt] => 2022-04-20 08:13:06
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-16
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-10 15:03:07
                            [post_modified_gmt] => 2023-07-10 15:03:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4661
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [183] => WP_Post Object
                        (
                            [ID] => 4147
                            [post_author] => 5
                            [post_date] => 2022-04-18 12:53:51
                            [post_date_gmt] => 2022-04-18 12:53:51
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-15
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-10 17:20:14
                            [post_modified_gmt] => 2023-07-10 17:20:14
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4147
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [184] => WP_Post Object
                        (
                            [ID] => 4601
                            [post_author] => 5
                            [post_date] => 2022-04-18 10:40:48
                            [post_date_gmt] => 2022-04-18 10:40:48
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-09 08:43:24
                            [post_modified_gmt] => 2024-04-09 08:43:24
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4601
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [185] => WP_Post Object
                        (
                            [ID] => 4148
                            [post_author] => 5
                            [post_date] => 2022-04-12 08:59:45
                            [post_date_gmt] => 2022-04-12 08:59:45
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-10 14:31:45
                            [post_modified_gmt] => 2023-11-10 14:31:45
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4148
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [186] => WP_Post Object
                        (
                            [ID] => 4223
                            [post_author] => 5
                            [post_date] => 2022-03-04 09:43:58
                            [post_date_gmt] => 2022-03-04 09:43:58
                            [post_content] => 
                            [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-09 13:29:51
                            [post_modified_gmt] => 2024-04-09 13:29:51
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4223
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [187] => WP_Post Object
                        (
                            [ID] => 4222
                            [post_author] => 5
                            [post_date] => 2022-03-04 09:14:41
                            [post_date_gmt] => 2022-03-04 09:14:41
                            [post_content] => 
                            [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-20 12:11:49
                            [post_modified_gmt] => 2023-06-20 12:11:49
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4222
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [188] => WP_Post Object
                        (
                            [ID] => 4221
                            [post_author] => 5
                            [post_date] => 2022-03-04 09:05:29
                            [post_date_gmt] => 2022-03-04 09:05:29
                            [post_content] => 
                            [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-20 12:19:35
                            [post_modified_gmt] => 2023-06-20 12:19:35
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4221
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [189] => WP_Post Object
                        (
                            [ID] => 4220
                            [post_author] => 5
                            [post_date] => 2022-03-04 08:47:04
                            [post_date_gmt] => 2022-03-04 08:47:04
                            [post_content] => 
                            [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-20 12:27:40
                            [post_modified_gmt] => 2023-06-20 12:27:40
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4220
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [190] => WP_Post Object
                        (
                            [ID] => 4219
                            [post_author] => 5
                            [post_date] => 2022-03-04 08:02:15
                            [post_date_gmt] => 2022-03-04 08:02:15
                            [post_content] => 
                            [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-20 12:29:24
                            [post_modified_gmt] => 2023-06-20 12:29:24
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4219
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [191] => WP_Post Object
                        (
                            [ID] => 4218
                            [post_author] => 5
                            [post_date] => 2022-03-03 14:17:53
                            [post_date_gmt] => 2022-03-03 14:17:53
                            [post_content] => 
                            [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-20 12:28:01
                            [post_modified_gmt] => 2023-06-20 12:28:01
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4218
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [192] => WP_Post Object
                        (
                            [ID] => 4217
                            [post_author] => 5
                            [post_date] => 2022-03-03 13:59:58
                            [post_date_gmt] => 2022-03-03 13:59:58
                            [post_content] => 
                            [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-20 12:26:19
                            [post_modified_gmt] => 2023-06-20 12:26:19
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4217
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [193] => WP_Post Object
                        (
                            [ID] => 4216
                            [post_author] => 5
                            [post_date] => 2022-03-03 13:45:21
                            [post_date_gmt] => 2022-03-03 13:45:21
                            [post_content] => 
                            [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-20 12:24:42
                            [post_modified_gmt] => 2023-06-20 12:24:42
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4216
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [194] => WP_Post Object
                        (
                            [ID] => 4215
                            [post_author] => 5
                            [post_date] => 2022-03-03 13:31:56
                            [post_date_gmt] => 2022-03-03 13:31:56
                            [post_content] => 
                            [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-20 12:23:22
                            [post_modified_gmt] => 2023-06-20 12:23:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4215
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [195] => WP_Post Object
                        (
                            [ID] => 4214
                            [post_author] => 5
                            [post_date] => 2022-03-03 12:54:33
                            [post_date_gmt] => 2022-03-03 12:54:33
                            [post_content] => 
                            [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-20 12:08:15
                            [post_modified_gmt] => 2023-06-20 12:08:15
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4214
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [196] => WP_Post Object
                        (
                            [ID] => 4213
                            [post_author] => 5
                            [post_date] => 2022-03-03 10:54:01
                            [post_date_gmt] => 2022-03-03 10:54:01
                            [post_content] => 
                            [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-20 12:14:31
                            [post_modified_gmt] => 2023-06-20 12:14:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4213
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [197] => WP_Post Object
                        (
                            [ID] => 4212
                            [post_author] => 5
                            [post_date] => 2022-03-02 14:54:16
                            [post_date_gmt] => 2022-03-02 14:54:16
                            [post_content] => 
                            [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-20 12:18:07
                            [post_modified_gmt] => 2023-06-20 12:18:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4212
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [198] => WP_Post Object
                        (
                            [ID] => 4210
                            [post_author] => 5
                            [post_date] => 2022-03-02 13:14:31
                            [post_date_gmt] => 2022-03-02 13:14:31
                            [post_content] => 
                            [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-20 12:21:57
                            [post_modified_gmt] => 2023-06-20 12:21:57
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4210
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [199] => WP_Post Object
                        (
                            [ID] => 4209
                            [post_author] => 5
                            [post_date] => 2022-03-02 12:07:13
                            [post_date_gmt] => 2022-03-02 12:07:13
                            [post_content] => 
                            [post_title] => Biological E - Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-01-11 10:04:33
                            [post_modified_gmt] => 2024-01-11 10:04:33
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4209
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [200] => WP_Post Object
                        (
                            [ID] => 4205
                            [post_author] => 5
                            [post_date] => 2022-02-28 15:24:19
                            [post_date_gmt] => 2022-02-28 15:24:19
                            [post_content] => 
                            [post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-22 14:01:27
                            [post_modified_gmt] => 2023-06-22 14:01:27
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4205
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [201] => WP_Post Object
                        (
                            [ID] => 4204
                            [post_author] => 5
                            [post_date] => 2022-02-28 14:53:11
                            [post_date_gmt] => 2022-02-28 14:53:11
                            [post_content] => 
                            [post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-22 13:52:02
                            [post_modified_gmt] => 2023-06-22 13:52:02
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4204
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [202] => WP_Post Object
                        (
                            [ID] => 4201
                            [post_author] => 5
                            [post_date] => 2022-02-28 13:33:22
                            [post_date_gmt] => 2022-02-28 13:33:22
                            [post_content] => 
                            [post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-22 14:02:58
                            [post_modified_gmt] => 2023-06-22 14:02:58
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4201
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [203] => WP_Post Object
                        (
                            [ID] => 4200
                            [post_author] => 5
                            [post_date] => 2022-02-28 13:13:29
                            [post_date_gmt] => 2022-02-28 13:13:29
                            [post_content] => 
                            [post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-22 13:54:49
                            [post_modified_gmt] => 2023-06-22 13:54:49
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4200
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [204] => WP_Post Object
                        (
                            [ID] => 4161
                            [post_author] => 5
                            [post_date] => 2022-02-02 13:48:58
                            [post_date_gmt] => 2022-02-02 13:48:58
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-05-31 08:58:23
                            [post_modified_gmt] => 2024-05-31 08:58:23
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4161
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [205] => WP_Post Object
                        (
                            [ID] => 4159
                            [post_author] => 5
                            [post_date] => 2022-02-02 13:10:48
                            [post_date_gmt] => 2022-02-02 13:10:48
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-10 17:32:26
                            [post_modified_gmt] => 2023-07-10 17:32:26
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4159
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [206] => WP_Post Object
                        (
                            [ID] => 4158
                            [post_author] => 5
                            [post_date] => 2022-02-02 13:00:08
                            [post_date_gmt] => 2022-02-02 13:00:08
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-11 07:11:12
                            [post_modified_gmt] => 2023-07-11 07:11:12
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4158
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [207] => WP_Post Object
                        (
                            [ID] => 4157
                            [post_author] => 5
                            [post_date] => 2022-02-02 12:54:56
                            [post_date_gmt] => 2022-02-02 12:54:56
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-11 07:01:00
                            [post_modified_gmt] => 2023-07-11 07:01:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4157
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [208] => WP_Post Object
                        (
                            [ID] => 4156
                            [post_author] => 5
                            [post_date] => 2022-02-02 12:36:42
                            [post_date_gmt] => 2022-02-02 12:36:42
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-11 06:57:27
                            [post_modified_gmt] => 2023-07-11 06:57:27
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4156
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [209] => WP_Post Object
                        (
                            [ID] => 4155
                            [post_author] => 5
                            [post_date] => 2022-02-02 12:19:16
                            [post_date_gmt] => 2022-02-02 12:19:16
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-10 17:39:59
                            [post_modified_gmt] => 2023-07-10 17:39:59
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4155
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [210] => WP_Post Object
                        (
                            [ID] => 4154
                            [post_author] => 5
                            [post_date] => 2022-02-02 12:13:41
                            [post_date_gmt] => 2022-02-02 12:13:41
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-10 17:39:00
                            [post_modified_gmt] => 2023-07-10 17:39:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4154
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [211] => WP_Post Object
                        (
                            [ID] => 4153
                            [post_author] => 5
                            [post_date] => 2022-02-02 12:10:13
                            [post_date_gmt] => 2022-02-02 12:10:13
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-10 17:38:12
                            [post_modified_gmt] => 2023-07-10 17:38:12
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4153
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [212] => WP_Post Object
                        (
                            [ID] => 4152
                            [post_author] => 5
                            [post_date] => 2022-02-02 11:51:54
                            [post_date_gmt] => 2022-02-02 11:51:54
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-11 07:10:01
                            [post_modified_gmt] => 2023-07-11 07:10:01
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4152
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [213] => WP_Post Object
                        (
                            [ID] => 4151
                            [post_author] => 5
                            [post_date] => 2022-02-02 11:39:24
                            [post_date_gmt] => 2022-02-02 11:39:24
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-10 17:33:46
                            [post_modified_gmt] => 2023-07-10 17:33:46
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4151
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [214] => WP_Post Object
                        (
                            [ID] => 4150
                            [post_author] => 5
                            [post_date] => 2022-02-02 10:24:30
                            [post_date_gmt] => 2022-02-02 10:24:30
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-10 17:10:00
                            [post_modified_gmt] => 2023-07-10 17:10:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4150
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [215] => WP_Post Object
                        (
                            [ID] => 4149
                            [post_author] => 5
                            [post_date] => 2022-02-02 10:15:42
                            [post_date_gmt] => 2022-02-02 10:15:42
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-10 17:23:03
                            [post_modified_gmt] => 2023-07-10 17:23:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4149
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [216] => WP_Post Object
                        (
                            [ID] => 4146
                            [post_author] => 5
                            [post_date] => 2022-02-02 07:28:42
                            [post_date_gmt] => 2022-02-02 07:28:42
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-10 17:36:14
                            [post_modified_gmt] => 2023-07-10 17:36:14
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4146
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [217] => WP_Post Object
                        (
                            [ID] => 4141
                            [post_author] => 5
                            [post_date] => 2022-01-31 14:31:23
                            [post_date_gmt] => 2022-01-31 14:31:23
                            [post_content] => 
                            [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-10 14:30:55
                            [post_modified_gmt] => 2024-04-10 14:30:55
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4141
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [218] => WP_Post Object
                        (
                            [ID] => 4140
                            [post_author] => 5
                            [post_date] => 2022-01-31 14:22:03
                            [post_date_gmt] => 2022-01-31 14:22:03
                            [post_content] => 
                            [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-22 13:00:51
                            [post_modified_gmt] => 2023-06-22 13:00:51
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4140
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [219] => WP_Post Object
                        (
                            [ID] => 4139
                            [post_author] => 5
                            [post_date] => 2022-01-31 14:18:32
                            [post_date_gmt] => 2022-01-31 14:18:32
                            [post_content] => 
                            [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-22 13:20:55
                            [post_modified_gmt] => 2023-06-22 13:20:55
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4139
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [220] => WP_Post Object
                        (
                            [ID] => 4138
                            [post_author] => 5
                            [post_date] => 2022-01-31 14:09:33
                            [post_date_gmt] => 2022-01-31 14:09:33
                            [post_content] => 
                            [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-22 13:26:07
                            [post_modified_gmt] => 2023-06-22 13:26:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4138
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [221] => WP_Post Object
                        (
                            [ID] => 4137
                            [post_author] => 5
                            [post_date] => 2022-01-31 13:53:37
                            [post_date_gmt] => 2022-01-31 13:53:37
                            [post_content] => 
                            [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-22 13:30:50
                            [post_modified_gmt] => 2023-06-22 13:30:50
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4137
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [222] => WP_Post Object
                        (
                            [ID] => 4136
                            [post_author] => 5
                            [post_date] => 2022-01-31 13:42:47
                            [post_date_gmt] => 2022-01-31 13:42:47
                            [post_content] => 
                            [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-22 13:29:44
                            [post_modified_gmt] => 2023-06-22 13:29:44
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4136
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [223] => WP_Post Object
                        (
                            [ID] => 4135
                            [post_author] => 5
                            [post_date] => 2022-01-31 13:25:08
                            [post_date_gmt] => 2022-01-31 13:25:08
                            [post_content] => 
                            [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-22 13:22:47
                            [post_modified_gmt] => 2023-06-22 13:22:47
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4135
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [224] => WP_Post Object
                        (
                            [ID] => 4134
                            [post_author] => 5
                            [post_date] => 2022-01-31 12:56:28
                            [post_date_gmt] => 2022-01-31 12:56:28
                            [post_content] => 
                            [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-22 13:21:33
                            [post_modified_gmt] => 2023-06-22 13:21:33
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4134
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [225] => WP_Post Object
                        (
                            [ID] => 4133
                            [post_author] => 5
                            [post_date] => 2022-01-31 12:22:56
                            [post_date_gmt] => 2022-01-31 12:22:56
                            [post_content] => 
                            [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-22 13:16:39
                            [post_modified_gmt] => 2023-06-22 13:16:39
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4133
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [226] => WP_Post Object
                        (
                            [ID] => 4131
                            [post_author] => 5
                            [post_date] => 2022-01-29 16:21:19
                            [post_date_gmt] => 2022-01-29 16:21:19
                            [post_content] => 
                            [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-22 13:18:58
                            [post_modified_gmt] => 2023-06-22 13:18:58
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4131
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [227] => WP_Post Object
                        (
                            [ID] => 4130
                            [post_author] => 5
                            [post_date] => 2022-01-29 15:34:50
                            [post_date_gmt] => 2022-01-29 15:34:50
                            [post_content] => 
                            [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-22 13:20:03
                            [post_modified_gmt] => 2023-06-22 13:20:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4130
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [228] => WP_Post Object
                        (
                            [ID] => 4129
                            [post_author] => 5
                            [post_date] => 2022-01-28 14:43:06
                            [post_date_gmt] => 2022-01-28 14:43:06
                            [post_content] => 
                            [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-10 13:58:31
                            [post_modified_gmt] => 2023-11-10 13:58:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4129
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [229] => WP_Post Object
                        (
                            [ID] => 4128
                            [post_author] => 5
                            [post_date] => 2022-01-28 13:38:44
                            [post_date_gmt] => 2022-01-28 13:38:44
                            [post_content] => 
                            [post_title] => CEPI - Dynavax, COVID-19 Material Reservation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-dynavax-covid-19-material-reservation-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-21 12:55:24
                            [post_modified_gmt] => 2023-06-21 12:55:24
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4128
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [230] => WP_Post Object
                        (
                            [ID] => 4058
                            [post_author] => 5
                            [post_date] => 2022-01-04 14:25:52
                            [post_date_gmt] => 2022-01-04 14:25:52
                            [post_content] => 
                            [post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => european-commission-curevac-covid-19-vaccine-advance-purchase-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-09 07:58:35
                            [post_modified_gmt] => 2024-04-09 07:58:35
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4058
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [231] => WP_Post Object
                        (
                            [ID] => 4054
                            [post_author] => 5
                            [post_date] => 2022-01-03 11:45:52
                            [post_date_gmt] => 2022-01-03 11:45:52
                            [post_content] => 
                            [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-20
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-01-11 10:07:47
                            [post_modified_gmt] => 2024-01-11 10:07:47
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4054
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [232] => WP_Post Object
                        (
                            [ID] => 4051
                            [post_author] => 5
                            [post_date] => 2022-01-03 11:01:41
                            [post_date_gmt] => 2022-01-03 11:01:41
                            [post_content] => 
                            [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-17
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-05-01 14:38:45
                            [post_modified_gmt] => 2023-05-01 14:38:45
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4051
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [233] => WP_Post Object
                        (
                            [ID] => 4050
                            [post_author] => 5
                            [post_date] => 2022-01-03 10:49:32
                            [post_date_gmt] => 2022-01-03 10:49:32
                            [post_content] => 
                            [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-16
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-01-03 10:56:55
                            [post_modified_gmt] => 2022-01-03 10:56:55
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4050
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [234] => WP_Post Object
                        (
                            [ID] => 4047
                            [post_author] => 5
                            [post_date] => 2021-12-27 17:17:36
                            [post_date_gmt] => 2021-12-27 17:17:36
                            [post_content] => 
                            [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-15
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-04 16:05:43
                            [post_modified_gmt] => 2023-01-04 16:05:43
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4047
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [235] => WP_Post Object
                        (
                            [ID] => 4046
                            [post_author] => 5
                            [post_date] => 2021-12-27 17:10:47
                            [post_date_gmt] => 2021-12-27 17:10:47
                            [post_content] => 
                            [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-04 15:13:16
                            [post_modified_gmt] => 2023-01-04 15:13:16
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4046
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [236] => WP_Post Object
                        (
                            [ID] => 4045
                            [post_author] => 5
                            [post_date] => 2021-12-27 17:07:25
                            [post_date_gmt] => 2021-12-27 17:07:25
                            [post_content] => 
                            [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-04-27 11:30:11
                            [post_modified_gmt] => 2023-04-27 11:30:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4045
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [237] => WP_Post Object
                        (
                            [ID] => 4043
                            [post_author] => 5
                            [post_date] => 2021-12-27 16:47:54
                            [post_date_gmt] => 2021-12-27 16:47:54
                            [post_content] => 
                            [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-12-27 16:47:54
                            [post_modified_gmt] => 2021-12-27 16:47:54
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4043
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [238] => WP_Post Object
                        (
                            [ID] => 4042
                            [post_author] => 5
                            [post_date] => 2021-12-27 16:41:56
                            [post_date_gmt] => 2021-12-27 16:41:56
                            [post_content] => 
                            [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-29 12:25:56
                            [post_modified_gmt] => 2022-09-29 12:25:56
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4042
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [239] => WP_Post Object
                        (
                            [ID] => 4041
                            [post_author] => 5
                            [post_date] => 2021-12-27 16:28:21
                            [post_date_gmt] => 2021-12-27 16:28:21
                            [post_content] => 
                            [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-02 15:55:03
                            [post_modified_gmt] => 2023-08-02 15:55:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4041
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [240] => WP_Post Object
                        (
                            [ID] => 4040
                            [post_author] => 5
                            [post_date] => 2021-12-27 15:24:04
                            [post_date_gmt] => 2021-12-27 15:24:04
                            [post_content] => 
                            [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-21 11:34:34
                            [post_modified_gmt] => 2023-03-21 11:34:34
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4040
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [241] => WP_Post Object
                        (
                            [ID] => 4038
                            [post_author] => 5
                            [post_date] => 2021-12-27 15:08:30
                            [post_date_gmt] => 2021-12-27 15:08:30
                            [post_content] => 
                            [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-04-05 12:35:46
                            [post_modified_gmt] => 2023-04-05 12:35:46
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4038
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [242] => WP_Post Object
                        (
                            [ID] => 4036
                            [post_author] => 5
                            [post_date] => 2021-12-26 17:01:45
                            [post_date_gmt] => 2021-12-26 17:01:45
                            [post_content] => 
                            [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-03-21 11:31:29
                            [post_modified_gmt] => 2023-03-21 11:31:29
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4036
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [243] => WP_Post Object
                        (
                            [ID] => 4035
                            [post_author] => 5
                            [post_date] => 2021-12-26 16:47:36
                            [post_date_gmt] => 2021-12-26 16:47:36
                            [post_content] => 
                            [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-16 13:28:18
                            [post_modified_gmt] => 2022-12-16 13:28:18
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4035
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [244] => WP_Post Object
                        (
                            [ID] => 4032
                            [post_author] => 5
                            [post_date] => 2021-12-26 16:32:27
                            [post_date_gmt] => 2021-12-26 16:32:27
                            [post_content] => 
                            [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-05-01 14:37:25
                            [post_modified_gmt] => 2023-05-01 14:37:25
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4032
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [245] => WP_Post Object
                        (
                            [ID] => 4029
                            [post_author] => 5
                            [post_date] => 2021-12-21 12:22:08
                            [post_date_gmt] => 2021-12-21 12:22:08
                            [post_content] => 
                            [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-04-05 12:36:19
                            [post_modified_gmt] => 2023-04-05 12:36:19
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4029
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [246] => WP_Post Object
                        (
                            [ID] => 4028
                            [post_author] => 5
                            [post_date] => 2021-12-21 11:55:28
                            [post_date_gmt] => 2021-12-21 11:55:28
                            [post_content] => 
                            [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-04-05 12:35:05
                            [post_modified_gmt] => 2023-04-05 12:35:05
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4028
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [247] => WP_Post Object
                        (
                            [ID] => 4024
                            [post_author] => 5
                            [post_date] => 2021-12-15 15:33:17
                            [post_date_gmt] => 2021-12-15 15:33:17
                            [post_content] => 
                            [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-22
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-08 12:25:41
                            [post_modified_gmt] => 2024-04-08 12:25:41
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4024
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [248] => WP_Post Object
                        (
                            [ID] => 4022
                            [post_author] => 5
                            [post_date] => 2021-12-15 14:49:36
                            [post_date_gmt] => 2021-12-15 14:49:36
                            [post_content] => 
                            [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-20
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-08 12:45:30
                            [post_modified_gmt] => 2024-04-08 12:45:30
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4022
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [249] => WP_Post Object
                        (
                            [ID] => 4021
                            [post_author] => 5
                            [post_date] => 2021-12-15 14:31:00
                            [post_date_gmt] => 2021-12-15 14:31:00
                            [post_content] => 
                            [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-19
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-08 12:47:16
                            [post_modified_gmt] => 2024-04-08 12:47:16
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4021
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [250] => WP_Post Object
                        (
                            [ID] => 4020
                            [post_author] => 5
                            [post_date] => 2021-12-15 14:24:47
                            [post_date_gmt] => 2021-12-15 14:24:47
                            [post_content] => 
                            [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-18
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-08 12:46:03
                            [post_modified_gmt] => 2024-04-08 12:46:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4020
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [251] => WP_Post Object
                        (
                            [ID] => 4017
                            [post_author] => 5
                            [post_date] => 2021-12-15 13:22:49
                            [post_date_gmt] => 2021-12-15 13:22:49
                            [post_content] => 
                            [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-16
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-08 12:27:29
                            [post_modified_gmt] => 2024-04-08 12:27:29
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4017
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [252] => WP_Post Object
                        (
                            [ID] => 4016
                            [post_author] => 5
                            [post_date] => 2021-12-15 13:20:07
                            [post_date_gmt] => 2021-12-15 13:20:07
                            [post_content] => 
                            [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-15
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-08 12:24:47
                            [post_modified_gmt] => 2024-04-08 12:24:47
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4016
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [253] => WP_Post Object
                        (
                            [ID] => 4014
                            [post_author] => 5
                            [post_date] => 2021-12-15 12:33:09
                            [post_date_gmt] => 2021-12-15 12:33:09
                            [post_content] => 
                            [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 14:58:11
                            [post_modified_gmt] => 2023-09-27 14:58:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4014
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [254] => WP_Post Object
                        (
                            [ID] => 4013
                            [post_author] => 5
                            [post_date] => 2021-12-15 12:16:20
                            [post_date_gmt] => 2021-12-15 12:16:20
                            [post_content] => 
                            [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 12:14:58
                            [post_modified_gmt] => 2023-09-27 12:14:58
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4013
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [255] => WP_Post Object
                        (
                            [ID] => 4011
                            [post_author] => 5
                            [post_date] => 2021-12-14 15:21:54
                            [post_date_gmt] => 2021-12-14 15:21:54
                            [post_content] => 
                            [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 15:31:35
                            [post_modified_gmt] => 2023-09-27 15:31:35
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4011
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [256] => WP_Post Object
                        (
                            [ID] => 4009
                            [post_author] => 5
                            [post_date] => 2021-12-14 15:10:51
                            [post_date_gmt] => 2021-12-14 15:10:51
                            [post_content] => 
                            [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-and-gsk-collaboration-and-license-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 11:47:52
                            [post_modified_gmt] => 2023-09-27 11:47:52
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4009
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [257] => WP_Post Object
                        (
                            [ID] => 4007
                            [post_author] => 5
                            [post_date] => 2021-12-14 08:51:32
                            [post_date_gmt] => 2021-12-14 08:51:32
                            [post_content] => 
                            [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-11 12:17:33
                            [post_modified_gmt] => 2024-04-11 12:17:33
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4007
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [258] => WP_Post Object
                        (
                            [ID] => 4006
                            [post_author] => 5
                            [post_date] => 2021-12-14 08:16:01
                            [post_date_gmt] => 2021-12-14 08:16:01
                            [post_content] => 
                            [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 15:02:09
                            [post_modified_gmt] => 2023-09-27 15:02:09
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4006
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [259] => WP_Post Object
                        (
                            [ID] => 4004
                            [post_author] => 5
                            [post_date] => 2021-12-14 07:57:41
                            [post_date_gmt] => 2021-12-14 07:57:41
                            [post_content] => 
                            [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 11:52:42
                            [post_modified_gmt] => 2023-09-27 11:52:42
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4004
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [260] => WP_Post Object
                        (
                            [ID] => 4003
                            [post_author] => 5
                            [post_date] => 2021-12-13 18:36:53
                            [post_date_gmt] => 2021-12-13 18:36:53
                            [post_content] => 
                            [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 14:52:45
                            [post_modified_gmt] => 2023-09-27 14:52:45
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4003
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [261] => WP_Post Object
                        (
                            [ID] => 4002
                            [post_author] => 5
                            [post_date] => 2021-12-13 18:28:05
                            [post_date_gmt] => 2021-12-13 18:28:05
                            [post_content] => 
                            [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-11 12:02:18
                            [post_modified_gmt] => 2024-04-11 12:02:18
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4002
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [262] => WP_Post Object
                        (
                            [ID] => 4001
                            [post_author] => 5
                            [post_date] => 2021-12-13 14:55:46
                            [post_date_gmt] => 2021-12-13 14:55:46
                            [post_content] => 
                            [post_title] => CureVac - GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 15:20:07
                            [post_modified_gmt] => 2023-09-27 15:20:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4001
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [263] => WP_Post Object
                        (
                            [ID] => 3997
                            [post_author] => 5
                            [post_date] => 2021-12-13 14:24:49
                            [post_date_gmt] => 2021-12-13 14:24:49
                            [post_content] => 
                            [post_title] => CureVac - GSK, COVID-19 Vaccine Collaboration and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 15:35:24
                            [post_modified_gmt] => 2023-09-27 15:35:24
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3997
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [264] => WP_Post Object
                        (
                            [ID] => 3869
                            [post_author] => 5
                            [post_date] => 2021-11-19 12:55:06
                            [post_date_gmt] => 2021-11-19 12:55:06
                            [post_content] => 
                            [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-17
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-05-04 11:40:05
                            [post_modified_gmt] => 2023-05-04 11:40:05
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3869
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [265] => WP_Post Object
                        (
                            [ID] => 3886
                            [post_author] => 5
                            [post_date] => 2021-11-18 16:36:37
                            [post_date_gmt] => 2021-11-18 16:36:37
                            [post_content] => 
                            [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-16
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-15 15:00:13
                            [post_modified_gmt] => 2022-12-15 15:00:13
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3886
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [266] => WP_Post Object
                        (
                            [ID] => 3884
                            [post_author] => 5
                            [post_date] => 2021-11-18 16:17:51
                            [post_date_gmt] => 2021-11-18 16:17:51
                            [post_content] => 
                            [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-05-01 14:31:52
                            [post_modified_gmt] => 2023-05-01 14:31:52
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3884
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [267] => WP_Post Object
                        (
                            [ID] => 3883
                            [post_author] => 5
                            [post_date] => 2021-11-18 16:10:24
                            [post_date_gmt] => 2021-11-18 16:10:24
                            [post_content] => 
                            [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-03 12:53:31
                            [post_modified_gmt] => 2023-01-03 12:53:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3883
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [268] => WP_Post Object
                        (
                            [ID] => 3882
                            [post_author] => 5
                            [post_date] => 2021-11-18 16:01:06
                            [post_date_gmt] => 2021-11-18 16:01:06
                            [post_content] => 
                            [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-05-05 08:10:55
                            [post_modified_gmt] => 2023-05-05 08:10:55
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3882
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [269] => WP_Post Object
                        (
                            [ID] => 3881
                            [post_author] => 5
                            [post_date] => 2021-11-18 15:52:45
                            [post_date_gmt] => 2021-11-18 15:52:45
                            [post_content] => 
                            [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-04 15:15:40
                            [post_modified_gmt] => 2023-01-04 15:15:40
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3881
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [270] => WP_Post Object
                        (
                            [ID] => 3880
                            [post_author] => 5
                            [post_date] => 2021-11-18 15:50:26
                            [post_date_gmt] => 2021-11-18 15:50:26
                            [post_content] => 
                            [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-11-18 15:50:26
                            [post_modified_gmt] => 2021-11-18 15:50:26
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3880
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [271] => WP_Post Object
                        (
                            [ID] => 3878
                            [post_author] => 5
                            [post_date] => 2021-11-18 15:08:19
                            [post_date_gmt] => 2021-11-18 15:08:19
                            [post_content] => 
                            [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-11-18 15:08:19
                            [post_modified_gmt] => 2021-11-18 15:08:19
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3878
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [272] => WP_Post Object
                        (
                            [ID] => 3877
                            [post_author] => 5
                            [post_date] => 2021-11-18 15:05:16
                            [post_date_gmt] => 2021-11-18 15:05:16
                            [post_content] => 
                            [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-29 11:45:57
                            [post_modified_gmt] => 2022-09-29 11:45:57
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3877
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [273] => WP_Post Object
                        (
                            [ID] => 3876
                            [post_author] => 5
                            [post_date] => 2021-11-18 14:51:40
                            [post_date_gmt] => 2021-11-18 14:51:40
                            [post_content] => 
                            [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-05-01 14:31:10
                            [post_modified_gmt] => 2023-05-01 14:31:10
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3876
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [274] => WP_Post Object
                        (
                            [ID] => 3875
                            [post_author] => 5
                            [post_date] => 2021-11-18 14:43:39
                            [post_date_gmt] => 2021-11-18 14:43:39
                            [post_content] => 
                            [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-05-01 14:30:10
                            [post_modified_gmt] => 2023-05-01 14:30:10
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3875
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [275] => WP_Post Object
                        (
                            [ID] => 3874
                            [post_author] => 5
                            [post_date] => 2021-11-18 14:29:06
                            [post_date_gmt] => 2021-11-18 14:29:06
                            [post_content] => 
                            [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-05-01 14:29:46
                            [post_modified_gmt] => 2023-05-01 14:29:46
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3874
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [276] => WP_Post Object
                        (
                            [ID] => 3873
                            [post_author] => 5
                            [post_date] => 2021-11-18 14:05:12
                            [post_date_gmt] => 2021-11-18 14:05:12
                            [post_content] => 
                            [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-05-04 11:38:53
                            [post_modified_gmt] => 2023-05-04 11:38:53
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3873
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [277] => WP_Post Object
                        (
                            [ID] => 3870
                            [post_author] => 5
                            [post_date] => 2021-11-18 12:58:35
                            [post_date_gmt] => 2021-11-18 12:58:35
                            [post_content] => 
                            [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-05-04 11:37:06
                            [post_modified_gmt] => 2023-05-04 11:37:06
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3870
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [278] => WP_Post Object
                        (
                            [ID] => 3863
                            [post_author] => 5
                            [post_date] => 2021-11-05 14:19:38
                            [post_date_gmt] => 2021-11-05 14:19:38
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-19
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-12 13:40:07
                            [post_modified_gmt] => 2024-04-12 13:40:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3863
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [279] => WP_Post Object
                        (
                            [ID] => 3861
                            [post_author] => 5
                            [post_date] => 2021-11-05 13:59:54
                            [post_date_gmt] => 2021-11-05 13:59:54
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-17
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-09 09:10:18
                            [post_modified_gmt] => 2024-04-09 09:10:18
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3861
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [280] => WP_Post Object
                        (
                            [ID] => 3860
                            [post_author] => 5
                            [post_date] => 2021-11-05 13:51:48
                            [post_date_gmt] => 2021-11-05 13:51:48
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-16
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-09 09:32:01
                            [post_modified_gmt] => 2024-04-09 09:32:01
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3860
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [281] => WP_Post Object
                        (
                            [ID] => 3859
                            [post_author] => 5
                            [post_date] => 2021-11-05 13:44:47
                            [post_date_gmt] => 2021-11-05 13:44:47
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-15
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-09 09:33:15
                            [post_modified_gmt] => 2024-04-09 09:33:15
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3859
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [282] => WP_Post Object
                        (
                            [ID] => 3858
                            [post_author] => 5
                            [post_date] => 2021-11-05 13:39:37
                            [post_date_gmt] => 2021-11-05 13:39:37
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-09 09:33:41
                            [post_modified_gmt] => 2024-04-09 09:33:41
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3858
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [283] => WP_Post Object
                        (
                            [ID] => 3857
                            [post_author] => 5
                            [post_date] => 2021-11-05 13:37:12
                            [post_date_gmt] => 2021-11-05 13:37:12
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-09 09:30:22
                            [post_modified_gmt] => 2024-04-09 09:30:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3857
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [284] => WP_Post Object
                        (
                            [ID] => 3856
                            [post_author] => 5
                            [post_date] => 2021-11-05 13:12:38
                            [post_date_gmt] => 2021-11-05 13:12:38
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-09 09:21:02
                            [post_modified_gmt] => 2024-04-09 09:21:02
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3856
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [285] => WP_Post Object
                        (
                            [ID] => 3855
                            [post_author] => 5
                            [post_date] => 2021-11-05 13:10:25
                            [post_date_gmt] => 2021-11-05 13:10:25
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-09 08:56:42
                            [post_modified_gmt] => 2024-04-09 08:56:42
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3855
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [286] => WP_Post Object
                        (
                            [ID] => 3854
                            [post_author] => 5
                            [post_date] => 2021-11-05 13:03:41
                            [post_date_gmt] => 2021-11-05 13:03:41
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-09 09:23:49
                            [post_modified_gmt] => 2024-04-09 09:23:49
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3854
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [287] => WP_Post Object
                        (
                            [ID] => 3852
                            [post_author] => 5
                            [post_date] => 2021-11-05 12:43:57
                            [post_date_gmt] => 2021-11-05 12:43:57
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-09 09:21:35
                            [post_modified_gmt] => 2024-04-09 09:21:35
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3852
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [288] => WP_Post Object
                        (
                            [ID] => 3851
                            [post_author] => 5
                            [post_date] => 2021-11-05 12:41:54
                            [post_date_gmt] => 2021-11-05 12:41:54
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-09 09:13:39
                            [post_modified_gmt] => 2024-04-09 09:13:39
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3851
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [289] => WP_Post Object
                        (
                            [ID] => 3849
                            [post_author] => 5
                            [post_date] => 2021-11-05 12:30:09
                            [post_date_gmt] => 2021-11-05 12:30:09
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-09 08:45:45
                            [post_modified_gmt] => 2024-04-09 08:45:45
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3849
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [290] => WP_Post Object
                        (
                            [ID] => 3848
                            [post_author] => 5
                            [post_date] => 2021-11-05 12:27:44
                            [post_date_gmt] => 2021-11-05 12:27:44
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-04-27 08:13:29
                            [post_modified_gmt] => 2023-04-27 08:13:29
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3848
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [291] => WP_Post Object
                        (
                            [ID] => 3847
                            [post_author] => 5
                            [post_date] => 2021-11-05 12:25:40
                            [post_date_gmt] => 2021-11-05 12:25:40
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-09 09:35:44
                            [post_modified_gmt] => 2024-04-09 09:35:44
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3847
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [292] => WP_Post Object
                        (
                            [ID] => 3846
                            [post_author] => 5
                            [post_date] => 2021-11-05 12:14:17
                            [post_date_gmt] => 2021-11-05 12:14:17
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-09 09:29:27
                            [post_modified_gmt] => 2024-04-09 09:29:27
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3846
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [293] => WP_Post Object
                        (
                            [ID] => 3812
                            [post_author] => 5
                            [post_date] => 2021-09-10 12:44:57
                            [post_date_gmt] => 2021-09-10 12:44:57
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-17
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-10 17:01:51
                            [post_modified_gmt] => 2023-07-10 17:01:51
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3812
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [294] => WP_Post Object
                        (
                            [ID] => 3810
                            [post_author] => 5
                            [post_date] => 2021-09-10 12:21:33
                            [post_date_gmt] => 2021-09-10 12:21:33
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-15
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-10 14:55:36
                            [post_modified_gmt] => 2023-07-10 14:55:36
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3810
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [295] => WP_Post Object
                        (
                            [ID] => 3809
                            [post_author] => 5
                            [post_date] => 2021-09-10 12:11:12
                            [post_date_gmt] => 2021-09-10 12:11:12
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-10 14:59:00
                            [post_modified_gmt] => 2023-07-10 14:59:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3809
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [296] => WP_Post Object
                        (
                            [ID] => 3808
                            [post_author] => 5
                            [post_date] => 2021-09-10 11:59:11
                            [post_date_gmt] => 2021-09-10 11:59:11
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-01-11 11:35:57
                            [post_modified_gmt] => 2024-01-11 11:35:57
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3808
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [297] => WP_Post Object
                        (
                            [ID] => 3807
                            [post_author] => 5
                            [post_date] => 2021-09-10 11:55:25
                            [post_date_gmt] => 2021-09-10 11:55:25
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-10 14:51:15
                            [post_modified_gmt] => 2023-07-10 14:51:15
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3807
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [298] => WP_Post Object
                        (
                            [ID] => 3806
                            [post_author] => 5
                            [post_date] => 2021-09-10 11:47:18
                            [post_date_gmt] => 2021-09-10 11:47:18
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-01-10 15:20:35
                            [post_modified_gmt] => 2024-01-10 15:20:35
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3806
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [299] => WP_Post Object
                        (
                            [ID] => 3805
                            [post_author] => 5
                            [post_date] => 2021-09-10 11:33:53
                            [post_date_gmt] => 2021-09-10 11:33:53
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-10 17:07:02
                            [post_modified_gmt] => 2023-07-10 17:07:02
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3805
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [300] => WP_Post Object
                        (
                            [ID] => 3804
                            [post_author] => 5
                            [post_date] => 2021-09-10 11:20:59
                            [post_date_gmt] => 2021-09-10 11:20:59
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-10 17:08:42
                            [post_modified_gmt] => 2023-07-10 17:08:42
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3804
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [301] => WP_Post Object
                        (
                            [ID] => 3803
                            [post_author] => 5
                            [post_date] => 2021-09-10 10:54:42
                            [post_date_gmt] => 2021-09-10 10:54:42
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-10 16:58:31
                            [post_modified_gmt] => 2023-07-10 16:58:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3803
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [302] => WP_Post Object
                        (
                            [ID] => 3802
                            [post_author] => 5
                            [post_date] => 2021-09-10 10:45:57
                            [post_date_gmt] => 2021-09-10 10:45:57
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-10 15:08:48
                            [post_modified_gmt] => 2023-07-10 15:08:48
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3802
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [303] => WP_Post Object
                        (
                            [ID] => 3801
                            [post_author] => 5
                            [post_date] => 2021-09-10 10:36:30
                            [post_date_gmt] => 2021-09-10 10:36:30
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-10 14:57:56
                            [post_modified_gmt] => 2023-07-10 14:57:56
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3801
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [304] => WP_Post Object
                        (
                            [ID] => 3800
                            [post_author] => 5
                            [post_date] => 2021-09-10 10:25:59
                            [post_date_gmt] => 2021-09-10 10:25:59
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-10 15:05:04
                            [post_modified_gmt] => 2023-07-10 15:05:04
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3800
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [305] => WP_Post Object
                        (
                            [ID] => 3799
                            [post_author] => 5
                            [post_date] => 2021-09-10 10:07:18
                            [post_date_gmt] => 2021-09-10 10:07:18
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-10 15:01:09
                            [post_modified_gmt] => 2023-07-10 15:01:09
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3799
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [306] => WP_Post Object
                        (
                            [ID] => 3798
                            [post_author] => 5
                            [post_date] => 2021-09-10 10:02:07
                            [post_date_gmt] => 2021-09-10 10:02:07
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-10 15:08:15
                            [post_modified_gmt] => 2023-07-10 15:08:15
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3798
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [307] => WP_Post Object
                        (
                            [ID] => 3797
                            [post_author] => 5
                            [post_date] => 2021-09-10 09:54:44
                            [post_date_gmt] => 2021-09-10 09:54:44
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-10 15:07:04
                            [post_modified_gmt] => 2023-07-10 15:07:04
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3797
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [308] => WP_Post Object
                        (
                            [ID] => 3796
                            [post_author] => 5
                            [post_date] => 2021-09-10 09:03:43
                            [post_date_gmt] => 2021-09-10 09:03:43
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-01-10 15:22:21
                            [post_modified_gmt] => 2024-01-10 15:22:21
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3796
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [309] => WP_Post Object
                        (
                            [ID] => 3792
                            [post_author] => 5
                            [post_date] => 2021-09-09 14:23:13
                            [post_date_gmt] => 2021-09-09 14:23:13
                            [post_content] => 
                            [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-14 13:24:00
                            [post_modified_gmt] => 2022-12-14 13:24:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3792
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [310] => WP_Post Object
                        (
                            [ID] => 3791
                            [post_author] => 5
                            [post_date] => 2021-09-09 14:18:44
                            [post_date_gmt] => 2021-09-09 14:18:44
                            [post_content] => 
                            [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-03 13:14:39
                            [post_modified_gmt] => 2023-01-03 13:14:39
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3791
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [311] => WP_Post Object
                        (
                            [ID] => 3789
                            [post_author] => 5
                            [post_date] => 2021-09-09 14:07:30
                            [post_date_gmt] => 2021-09-09 14:07:30
                            [post_content] => 
                            [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-29 12:32:36
                            [post_modified_gmt] => 2022-09-29 12:32:36
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3789
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [312] => WP_Post Object
                        (
                            [ID] => 3788
                            [post_author] => 5
                            [post_date] => 2021-09-09 14:00:40
                            [post_date_gmt] => 2021-09-09 14:00:40
                            [post_content] => 
                            [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-11-04 09:02:12
                            [post_modified_gmt] => 2021-11-04 09:02:12
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3788
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [313] => WP_Post Object
                        (
                            [ID] => 3786
                            [post_author] => 5
                            [post_date] => 2021-09-09 13:20:21
                            [post_date_gmt] => 2021-09-09 13:20:21
                            [post_content] => 
                            [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-01-09 13:48:44
                            [post_modified_gmt] => 2024-01-09 13:48:44
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3786
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [314] => WP_Post Object
                        (
                            [ID] => 3784
                            [post_author] => 5
                            [post_date] => 2021-09-09 13:03:52
                            [post_date_gmt] => 2021-09-09 13:03:52
                            [post_content] => 
                            [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-16 12:52:03
                            [post_modified_gmt] => 2022-12-16 12:52:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3784
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [315] => WP_Post Object
                        (
                            [ID] => 3783
                            [post_author] => 5
                            [post_date] => 2021-09-09 12:41:47
                            [post_date_gmt] => 2021-09-09 12:41:47
                            [post_content] => 
                            [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-11 09:17:03
                            [post_modified_gmt] => 2023-08-11 09:17:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3783
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [316] => WP_Post Object
                        (
                            [ID] => 3782
                            [post_author] => 5
                            [post_date] => 2021-09-09 12:36:36
                            [post_date_gmt] => 2021-09-09 12:36:36
                            [post_content] => 
                            [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-01-09 13:49:10
                            [post_modified_gmt] => 2024-01-09 13:49:10
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3782
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [317] => WP_Post Object
                        (
                            [ID] => 3781
                            [post_author] => 5
                            [post_date] => 2021-09-09 12:29:54
                            [post_date_gmt] => 2021-09-09 12:29:54
                            [post_content] => 
                            [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-15 15:06:09
                            [post_modified_gmt] => 2022-12-15 15:06:09
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3781
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [318] => WP_Post Object
                        (
                            [ID] => 3778
                            [post_author] => 5
                            [post_date] => 2021-09-09 11:52:53
                            [post_date_gmt] => 2021-09-09 11:52:53
                            [post_content] => 
                            [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-11 09:16:10
                            [post_modified_gmt] => 2023-08-11 09:16:10
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3778
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [319] => WP_Post Object
                        (
                            [ID] => 3765
                            [post_author] => 5
                            [post_date] => 2021-09-01 14:09:03
                            [post_date_gmt] => 2021-09-01 14:09:03
                            [post_content] => 
                            [post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ati-regeneron-covid-19-antibodies-manufacturing-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-02 15:59:35
                            [post_modified_gmt] => 2023-08-02 15:59:35
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3765
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [320] => WP_Post Object
                        (
                            [ID] => 3764
                            [post_author] => 5
                            [post_date] => 2021-09-01 12:17:32
                            [post_date_gmt] => 2021-09-01 12:17:32
                            [post_content] => 
                            [post_title] => BARDA – Moderna, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => barda-moderna-covid-19-vaccine-development-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-14 14:25:34
                            [post_modified_gmt] => 2023-08-14 14:25:34
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3764
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [321] => WP_Post Object
                        (
                            [ID] => 3758
                            [post_author] => 5
                            [post_date] => 2021-08-26 12:04:03
                            [post_date_gmt] => 2021-08-26 12:04:03
                            [post_content] => 
                            [post_title] => BARDA - Moderna, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => barda-moderna-covid-19-vaccine-development-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-01-09 13:50:07
                            [post_modified_gmt] => 2024-01-09 13:50:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3758
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [322] => WP_Post Object
                        (
                            [ID] => 3741
                            [post_author] => 5
                            [post_date] => 2021-08-24 09:13:39
                            [post_date_gmt] => 2021-08-24 09:13:39
                            [post_content] => 
                            [post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => european-commission-curevac-covid-19-vaccine-advance-purchase-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-09 07:52:34
                            [post_modified_gmt] => 2024-04-09 07:52:34
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3741
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [323] => WP_Post Object
                        (
                            [ID] => 3696
                            [post_author] => 5
                            [post_date] => 2021-08-19 14:23:22
                            [post_date_gmt] => 2021-08-19 14:23:22
                            [post_content] => 
                            [post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => ati-regeneron-covid-19-antibodies-manufacturing-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-02 16:03:12
                            [post_modified_gmt] => 2023-08-02 16:03:12
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3696
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [324] => WP_Post Object
                        (
                            [ID] => 3495
                            [post_author] => 5
                            [post_date] => 2021-08-10 13:06:45
                            [post_date_gmt] => 2021-08-10 13:06:45
                            [post_content] => 
                            [post_title] => US Department of Defense – Moderna, COVID-19 Vaccine Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => dod-moderna-covid-19-vaccine-supply-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-02 14:45:12
                            [post_modified_gmt] => 2023-08-02 14:45:12
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3495
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [325] => WP_Post Object
                        (
                            [ID] => 3493
                            [post_author] => 5
                            [post_date] => 2021-08-10 11:15:39
                            [post_date_gmt] => 2021-08-10 11:15:39
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-22 13:58:36
                            [post_modified_gmt] => 2023-06-22 13:58:36
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3493
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [326] => WP_Post Object
                        (
                            [ID] => 3436
                            [post_author] => 6
                            [post_date] => 2021-07-01 03:48:49
                            [post_date_gmt] => 2021-07-01 03:48:49
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-09 08:41:21
                            [post_modified_gmt] => 2024-04-09 08:41:21
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3436
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [327] => WP_Post Object
                        (
                            [ID] => 3434
                            [post_author] => 6
                            [post_date] => 2021-07-01 03:44:18
                            [post_date_gmt] => 2021-07-01 03:44:18
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-09 08:17:53
                            [post_modified_gmt] => 2024-04-09 08:17:53
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3434
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [328] => WP_Post Object
                        (
                            [ID] => 3433
                            [post_author] => 6
                            [post_date] => 2021-07-01 03:41:21
                            [post_date_gmt] => 2021-07-01 03:41:21
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-09 08:17:26
                            [post_modified_gmt] => 2024-04-09 08:17:26
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3433
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [329] => WP_Post Object
                        (
                            [ID] => 3431
                            [post_author] => 6
                            [post_date] => 2021-07-01 03:38:49
                            [post_date_gmt] => 2021-07-01 03:38:49
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-09 08:44:52
                            [post_modified_gmt] => 2024-04-09 08:44:52
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3431
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [330] => WP_Post Object
                        (
                            [ID] => 3430
                            [post_author] => 6
                            [post_date] => 2021-07-01 03:27:51
                            [post_date_gmt] => 2021-07-01 03:27:51
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-09 08:42:39
                            [post_modified_gmt] => 2024-04-09 08:42:39
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3430
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [331] => WP_Post Object
                        (
                            [ID] => 3428
                            [post_author] => 6
                            [post_date] => 2021-07-01 03:24:00
                            [post_date_gmt] => 2021-07-01 03:24:00
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-09 08:18:28
                            [post_modified_gmt] => 2024-04-09 08:18:28
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3428
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [332] => WP_Post Object
                        (
                            [ID] => 3427
                            [post_author] => 6
                            [post_date] => 2021-07-01 03:22:23
                            [post_date_gmt] => 2021-07-01 03:22:23
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-09 08:16:49
                            [post_modified_gmt] => 2024-04-09 08:16:49
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3427
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [333] => WP_Post Object
                        (
                            [ID] => 3426
                            [post_author] => 6
                            [post_date] => 2021-07-01 03:06:23
                            [post_date_gmt] => 2021-07-01 03:06:23
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-09 08:43:48
                            [post_modified_gmt] => 2024-04-09 08:43:48
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3426
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [334] => WP_Post Object
                        (
                            [ID] => 3424
                            [post_author] => 6
                            [post_date] => 2021-07-01 03:03:57
                            [post_date_gmt] => 2021-07-01 03:03:57
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-12 13:36:11
                            [post_modified_gmt] => 2024-04-12 13:36:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3424
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [335] => WP_Post Object
                        (
                            [ID] => 3422
                            [post_author] => 6
                            [post_date] => 2021-07-01 02:58:21
                            [post_date_gmt] => 2021-07-01 02:58:21
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-09 08:40:04
                            [post_modified_gmt] => 2024-04-09 08:40:04
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3422
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [336] => WP_Post Object
                        (
                            [ID] => 3421
                            [post_author] => 6
                            [post_date] => 2021-07-01 02:56:30
                            [post_date_gmt] => 2021-07-01 02:56:30
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-09 08:20:36
                            [post_modified_gmt] => 2024-04-09 08:20:36
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3421
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [337] => WP_Post Object
                        (
                            [ID] => 3420
                            [post_author] => 6
                            [post_date] => 2021-07-01 02:52:05
                            [post_date_gmt] => 2021-07-01 02:52:05
                            [post_content] => 
                            [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-01-10 15:24:32
                            [post_modified_gmt] => 2024-01-10 15:24:32
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3420
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [338] => WP_Post Object
                        (
                            [ID] => 3372
                            [post_author] => 5
                            [post_date] => 2021-06-30 15:06:19
                            [post_date_gmt] => 2021-06-30 15:06:19
                            [post_content] => 
                            [post_title] => US Government - Ology Bioservices, COVID-19 Plasmid Procurement Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 13:46:34
                            [post_modified_gmt] => 2022-10-12 13:46:34
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3372
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [339] => WP_Post Object
                        (
                            [ID] => 3370
                            [post_author] => 5
                            [post_date] => 2021-06-30 15:01:06
                            [post_date_gmt] => 2021-06-30 15:01:06
                            [post_content] => 
                            [post_title] => US Government - Ology Bioservices, COVID-19 Plasmid Procurement Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 13:46:41
                            [post_modified_gmt] => 2022-10-12 13:46:41
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3370
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [340] => WP_Post Object
                        (
                            [ID] => 3368
                            [post_author] => 5
                            [post_date] => 2021-06-30 14:58:39
                            [post_date_gmt] => 2021-06-30 14:58:39
                            [post_content] => 
                            [post_title] => US Government - Ology Bioservices, COVID-19 Plasmid Procurement Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-11 07:41:53
                            [post_modified_gmt] => 2023-08-11 07:41:53
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3368
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [341] => WP_Post Object
                        (
                            [ID] => 3366
                            [post_author] => 5
                            [post_date] => 2021-06-30 14:53:53
                            [post_date_gmt] => 2021-06-30 14:53:53
                            [post_content] => 
                            [post_title] => US Government - Ology Bioservices, COVID-19 Plasmid Procurement Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-14 13:52:34
                            [post_modified_gmt] => 2023-08-14 13:52:34
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3366
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [342] => WP_Post Object
                        (
                            [ID] => 3364
                            [post_author] => 5
                            [post_date] => 2021-06-30 14:47:34
                            [post_date_gmt] => 2021-06-30 14:47:34
                            [post_content] => 
                            [post_title] => US Government - Ology Bioservices, COVID-19 Plasmid Procurement Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-16 13:44:44
                            [post_modified_gmt] => 2022-12-16 13:44:44
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3364
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [343] => WP_Post Object
                        (
                            [ID] => 3361
                            [post_author] => 5
                            [post_date] => 2021-06-30 14:30:51
                            [post_date_gmt] => 2021-06-30 14:30:51
                            [post_content] => 
                            [post_title] => US Government - Ology Bioservices, COVID-19 Plasmid Procurement Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-04-06 11:29:48
                            [post_modified_gmt] => 2023-04-06 11:29:48
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3361
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [344] => WP_Post Object
                        (
                            [ID] => 3360
                            [post_author] => 5
                            [post_date] => 2021-06-30 14:28:40
                            [post_date_gmt] => 2021-06-30 14:28:40
                            [post_content] => 
                            [post_title] => US Government - Ology Bioservices, COVID-19 Plasmid Procurement Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-11 07:25:57
                            [post_modified_gmt] => 2023-08-11 07:25:57
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3360
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [345] => WP_Post Object
                        (
                            [ID] => 3356
                            [post_author] => 5
                            [post_date] => 2021-06-30 13:53:23
                            [post_date_gmt] => 2021-06-30 13:53:23
                            [post_content] => 
                            [post_title] => US Government - Ology Bioservices, COVID-19 Plasmid Procurement Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-03 15:24:04
                            [post_modified_gmt] => 2023-01-03 15:24:04
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3356
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [346] => WP_Post Object
                        (
                            [ID] => 3354
                            [post_author] => 5
                            [post_date] => 2021-06-30 13:29:21
                            [post_date_gmt] => 2021-06-30 13:29:21
                            [post_content] => 
                            [post_title] => US Government - Ology Bioservices, COVID-19 Plasmid Procurement Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-04-27 11:52:50
                            [post_modified_gmt] => 2023-04-27 11:52:50
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3354
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [347] => WP_Post Object
                        (
                            [ID] => 3352
                            [post_author] => 5
                            [post_date] => 2021-06-30 13:24:49
                            [post_date_gmt] => 2021-06-30 13:24:49
                            [post_content] => 
                            [post_title] => US Government - Ology Bioservices, COVID-19 Plasmid Procurement Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-02 15:25:27
                            [post_modified_gmt] => 2023-08-02 15:25:27
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3352
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [348] => WP_Post Object
                        (
                            [ID] => 3221
                            [post_author] => 6
                            [post_date] => 2021-06-28 12:23:49
                            [post_date_gmt] => 2021-06-28 12:23:49
                            [post_content] => 
                            [post_title] => Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-27 09:47:45
                            [post_modified_gmt] => 2022-09-27 09:47:45
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3221
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [349] => WP_Post Object
                        (
                            [ID] => 3220
                            [post_author] => 6
                            [post_date] => 2021-06-28 12:22:09
                            [post_date_gmt] => 2021-06-28 12:22:09
                            [post_content] => 
                            [post_title] => Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 12:22:07
                            [post_modified_gmt] => 2022-10-12 12:22:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3220
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [350] => WP_Post Object
                        (
                            [ID] => 3219
                            [post_author] => 6
                            [post_date] => 2021-06-28 12:19:29
                            [post_date_gmt] => 2021-06-28 12:19:29
                            [post_content] => 
                            [post_title] => Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-29 12:28:41
                            [post_modified_gmt] => 2022-09-29 12:28:41
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3219
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [351] => WP_Post Object
                        (
                            [ID] => 3218
                            [post_author] => 6
                            [post_date] => 2021-06-28 12:16:20
                            [post_date_gmt] => 2021-06-28 12:16:20
                            [post_content] => 
                            [post_title] => Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 14:31:28
                            [post_modified_gmt] => 2022-10-12 14:31:28
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3218
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [352] => WP_Post Object
                        (
                            [ID] => 3217
                            [post_author] => 6
                            [post_date] => 2021-06-28 12:14:37
                            [post_date_gmt] => 2021-06-28 12:14:37
                            [post_content] => 
                            [post_title] => Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-02 15:57:23
                            [post_modified_gmt] => 2023-08-02 15:57:23
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3217
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [353] => WP_Post Object
                        (
                            [ID] => 3215
                            [post_author] => 6
                            [post_date] => 2021-06-28 12:07:55
                            [post_date_gmt] => 2021-06-28 12:07:55
                            [post_content] => 
                            [post_title] => Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-07-13 11:33:05
                            [post_modified_gmt] => 2022-07-13 11:33:05
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3215
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [354] => WP_Post Object
                        (
                            [ID] => 3127
                            [post_author] => 6
                            [post_date] => 2021-06-03 15:08:41
                            [post_date_gmt] => 2021-06-03 15:08:41
                            [post_content] => 
                            [post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-08 13:04:06
                            [post_modified_gmt] => 2024-04-08 13:04:06
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3127
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [355] => WP_Post Object
                        (
                            [ID] => 3126
                            [post_author] => 6
                            [post_date] => 2021-06-03 15:05:40
                            [post_date_gmt] => 2021-06-03 15:05:40
                            [post_content] => 
                            [post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-04 15:38:12
                            [post_modified_gmt] => 2023-01-04 15:38:12
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3126
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [356] => WP_Post Object
                        (
                            [ID] => 3125
                            [post_author] => 6
                            [post_date] => 2021-06-03 15:03:17
                            [post_date_gmt] => 2021-06-03 15:03:17
                            [post_content] => 
                            [post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 12:22:26
                            [post_modified_gmt] => 2022-10-12 12:22:26
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3125
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [357] => WP_Post Object
                        (
                            [ID] => 3123
                            [post_author] => 6
                            [post_date] => 2021-06-03 14:51:22
                            [post_date_gmt] => 2021-06-03 14:51:22
                            [post_content] => 
                            [post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-08 13:07:37
                            [post_modified_gmt] => 2024-04-08 13:07:37
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3123
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [358] => WP_Post Object
                        (
                            [ID] => 3122
                            [post_author] => 6
                            [post_date] => 2021-06-03 14:45:44
                            [post_date_gmt] => 2021-06-03 14:45:44
                            [post_content] => 
                            [post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-10-12 14:32:30
                            [post_modified_gmt] => 2022-10-12 14:32:30
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3122
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [359] => WP_Post Object
                        (
                            [ID] => 3121
                            [post_author] => 6
                            [post_date] => 2021-06-03 14:26:32
                            [post_date_gmt] => 2021-06-03 14:26:32
                            [post_content] => 
                            [post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-08 12:56:23
                            [post_modified_gmt] => 2024-04-08 12:56:23
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3121
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [360] => WP_Post Object
                        (
                            [ID] => 3120
                            [post_author] => 6
                            [post_date] => 2021-06-03 14:24:03
                            [post_date_gmt] => 2021-06-03 14:24:03
                            [post_content] => 
                            [post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-02 15:56:21
                            [post_modified_gmt] => 2023-08-02 15:56:21
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3120
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [361] => WP_Post Object
                        (
                            [ID] => 3119
                            [post_author] => 6
                            [post_date] => 2021-06-03 14:21:50
                            [post_date_gmt] => 2021-06-03 14:21:50
                            [post_content] => 
                            [post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-08 13:04:29
                            [post_modified_gmt] => 2024-04-08 13:04:29
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3119
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [362] => WP_Post Object
                        (
                            [ID] => 2956
                            [post_author] => 6
                            [post_date] => 2021-05-28 18:56:15
                            [post_date_gmt] => 2021-05-28 18:56:15
                            [post_content] => 
                            [post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-06 11:04:14
                            [post_modified_gmt] => 2023-06-06 11:04:14
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2956
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [363] => WP_Post Object
                        (
                            [ID] => 2961
                            [post_author] => 6
                            [post_date] => 2021-05-28 18:55:47
                            [post_date_gmt] => 2021-05-28 18:55:47
                            [post_content] => 
                            [post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-04 16:36:28
                            [post_modified_gmt] => 2023-01-04 16:36:28
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2961
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [364] => WP_Post Object
                        (
                            [ID] => 2965
                            [post_author] => 6
                            [post_date] => 2021-05-28 18:55:12
                            [post_date_gmt] => 2021-05-28 18:55:12
                            [post_content] => 
                            [post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-09 12:33:07
                            [post_modified_gmt] => 2024-04-09 12:33:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2965
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [365] => WP_Post Object
                        (
                            [ID] => 2947
                            [post_author] => 6
                            [post_date] => 2021-05-28 18:54:17
                            [post_date_gmt] => 2021-05-28 18:54:17
                            [post_content] => 
                            [post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-14 15:51:47
                            [post_modified_gmt] => 2022-12-14 15:51:47
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2947
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [366] => WP_Post Object
                        (
                            [ID] => 2960
                            [post_author] => 6
                            [post_date] => 2021-05-28 18:53:36
                            [post_date_gmt] => 2021-05-28 18:53:36
                            [post_content] => 
                            [post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-04 15:39:20
                            [post_modified_gmt] => 2023-01-04 15:39:20
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2960
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [367] => WP_Post Object
                        (
                            [ID] => 2964
                            [post_author] => 6
                            [post_date] => 2021-05-28 18:53:11
                            [post_date_gmt] => 2021-05-28 18:53:11
                            [post_content] => 
                            [post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-15 16:44:06
                            [post_modified_gmt] => 2022-12-15 16:44:06
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2964
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [368] => WP_Post Object
                        (
                            [ID] => 2958
                            [post_author] => 6
                            [post_date] => 2021-05-28 18:52:54
                            [post_date_gmt] => 2021-05-28 18:52:54
                            [post_content] => 
                            [post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-09 12:26:13
                            [post_modified_gmt] => 2024-04-09 12:26:13
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2958
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [369] => WP_Post Object
                        (
                            [ID] => 2949
                            [post_author] => 6
                            [post_date] => 2021-05-28 18:52:06
                            [post_date_gmt] => 2021-05-28 18:52:06
                            [post_content] => 
                            [post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-02 14:34:47
                            [post_modified_gmt] => 2023-08-02 14:34:47
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2949
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [370] => WP_Post Object
                        (
                            [ID] => 2957
                            [post_author] => 6
                            [post_date] => 2021-05-28 18:51:39
                            [post_date_gmt] => 2021-05-28 18:51:39
                            [post_content] => 
                            [post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-29 09:29:34
                            [post_modified_gmt] => 2022-09-29 09:29:34
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2957
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [371] => WP_Post Object
                        (
                            [ID] => 2962
                            [post_author] => 6
                            [post_date] => 2021-05-28 18:50:18
                            [post_date_gmt] => 2021-05-28 18:50:18
                            [post_content] => 
                            [post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-03 15:39:44
                            [post_modified_gmt] => 2023-01-03 15:39:44
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2962
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [372] => WP_Post Object
                        (
                            [ID] => 2945
                            [post_author] => 6
                            [post_date] => 2021-05-28 14:03:27
                            [post_date_gmt] => 2021-05-28 14:03:27
                            [post_content] => 
                            [post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-07-13 09:09:43
                            [post_modified_gmt] => 2022-07-13 09:09:43
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2945
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [373] => WP_Post Object
                        (
                            [ID] => 2909
                            [post_author] => 6
                            [post_date] => 2021-05-19 15:13:58
                            [post_date_gmt] => 2021-05-19 15:13:58
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-22 14:45:09
                            [post_modified_gmt] => 2023-06-22 14:45:09
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2909
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [374] => WP_Post Object
                        (
                            [ID] => 2908
                            [post_author] => 6
                            [post_date] => 2021-05-19 15:08:05
                            [post_date_gmt] => 2021-05-19 15:08:05
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-22 14:37:32
                            [post_modified_gmt] => 2023-06-22 14:37:32
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2908
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [375] => WP_Post Object
                        (
                            [ID] => 2907
                            [post_author] => 6
                            [post_date] => 2021-05-19 14:46:20
                            [post_date_gmt] => 2021-05-19 14:46:20
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-22 14:40:14
                            [post_modified_gmt] => 2023-06-22 14:40:14
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2907
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [376] => WP_Post Object
                        (
                            [ID] => 2893
                            [post_author] => 6
                            [post_date] => 2021-05-19 14:40:45
                            [post_date_gmt] => 2021-05-19 14:40:45
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-22 14:34:03
                            [post_modified_gmt] => 2023-06-22 14:34:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2893
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [377] => WP_Post Object
                        (
                            [ID] => 2892
                            [post_author] => 6
                            [post_date] => 2021-05-14 19:30:23
                            [post_date_gmt] => 2021-05-14 19:30:23
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-22 13:41:02
                            [post_modified_gmt] => 2023-06-22 13:41:02
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2892
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [378] => WP_Post Object
                        (
                            [ID] => 2890
                            [post_author] => 6
                            [post_date] => 2021-05-14 19:14:07
                            [post_date_gmt] => 2021-05-14 19:14:07
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-22 14:34:52
                            [post_modified_gmt] => 2023-06-22 14:34:52
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2890
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [379] => WP_Post Object
                        (
                            [ID] => 2889
                            [post_author] => 6
                            [post_date] => 2021-05-14 19:09:07
                            [post_date_gmt] => 2021-05-14 19:09:07
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-22 13:53:11
                            [post_modified_gmt] => 2023-06-22 13:53:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2889
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [380] => WP_Post Object
                        (
                            [ID] => 2885
                            [post_author] => 5
                            [post_date] => 2021-05-14 18:17:37
                            [post_date_gmt] => 2021-05-14 18:17:37
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-22 14:36:43
                            [post_modified_gmt] => 2023-06-22 14:36:43
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2885
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [381] => WP_Post Object
                        (
                            [ID] => 2824
                            [post_author] => 5
                            [post_date] => 2021-04-16 16:39:49
                            [post_date_gmt] => 2021-04-16 16:39:49
                            [post_content] => 
                            [post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-02 16:04:12
                            [post_modified_gmt] => 2023-08-02 16:04:12
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2824
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [382] => WP_Post Object
                        (
                            [ID] => 2822
                            [post_author] => 5
                            [post_date] => 2021-04-16 16:09:31
                            [post_date_gmt] => 2021-04-16 16:09:31
                            [post_content] => 
                            [post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-15 15:49:41
                            [post_modified_gmt] => 2022-12-15 15:49:41
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2822
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [383] => WP_Post Object
                        (
                            [ID] => 2820
                            [post_author] => 5
                            [post_date] => 2021-04-16 12:44:14
                            [post_date_gmt] => 2021-04-16 12:44:14
                            [post_content] => 
                            [post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-01-09 13:53:49
                            [post_modified_gmt] => 2024-01-09 13:53:49
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2820
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [384] => WP_Post Object
                        (
                            [ID] => 2744
                            [post_author] => 5
                            [post_date] => 2021-03-30 15:12:35
                            [post_date_gmt] => 2021-03-30 15:12:35
                            [post_content] => 
                            [post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-03 15:41:14
                            [post_modified_gmt] => 2023-01-03 15:41:14
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2744
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [385] => WP_Post Object
                        (
                            [ID] => 2749
                            [post_author] => 5
                            [post_date] => 2021-03-30 15:10:16
                            [post_date_gmt] => 2021-03-30 15:10:16
                            [post_content] => 
                            [post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-04-27 11:51:19
                            [post_modified_gmt] => 2023-04-27 11:51:19
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2749
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [386] => WP_Post Object
                        (
                            [ID] => 2748
                            [post_author] => 5
                            [post_date] => 2021-03-30 15:05:46
                            [post_date_gmt] => 2021-03-30 15:05:46
                            [post_content] => 
                            [post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => 2748
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-04 15:41:58
                            [post_modified_gmt] => 2023-01-04 15:41:58
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2748
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [387] => WP_Post Object
                        (
                            [ID] => 2743
                            [post_author] => 5
                            [post_date] => 2021-03-24 15:11:40
                            [post_date_gmt] => 2021-03-24 15:11:40
                            [post_content] => 
                            [post_title] => US Department of Defense – Novavax, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-09-29 12:36:08
                            [post_modified_gmt] => 2022-09-29 12:36:08
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2743
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [388] => WP_Post Object
                        (
                            [ID] => 2742
                            [post_author] => 5
                            [post_date] => 2021-03-24 13:37:07
                            [post_date_gmt] => 2021-03-24 13:37:07
                            [post_content] => 
                            [post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-08-12 12:28:13
                            [post_modified_gmt] => 2021-08-12 12:28:13
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2742
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [389] => WP_Post Object
                        (
                            [ID] => 2741
                            [post_author] => 5
                            [post_date] => 2021-03-24 13:32:55
                            [post_date_gmt] => 2021-03-24 13:32:55
                            [post_content] => 
                            [post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-11 08:20:09
                            [post_modified_gmt] => 2023-08-11 08:20:09
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2741
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [390] => WP_Post Object
                        (
                            [ID] => 2739
                            [post_author] => 5
                            [post_date] => 2021-03-24 13:12:14
                            [post_date_gmt] => 2021-03-24 13:12:14
                            [post_content] => 
                            [post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-01 10:34:52
                            [post_modified_gmt] => 2023-09-01 10:34:52
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2739
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [391] => WP_Post Object
                        (
                            [ID] => 2737
                            [post_author] => 5
                            [post_date] => 2021-03-24 13:00:46
                            [post_date_gmt] => 2021-03-24 13:00:46
                            [post_content] => 
                            [post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-02 15:52:21
                            [post_modified_gmt] => 2023-08-02 15:52:21
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2737
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [392] => WP_Post Object
                        (
                            [ID] => 2736
                            [post_author] => 5
                            [post_date] => 2021-03-23 18:15:15
                            [post_date_gmt] => 2021-03-23 18:15:15
                            [post_content] => 
                            [post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-11 08:18:03
                            [post_modified_gmt] => 2023-08-11 08:18:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2736
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [393] => WP_Post Object
                        (
                            [ID] => 2734
                            [post_author] => 5
                            [post_date] => 2021-03-23 18:01:22
                            [post_date_gmt] => 2021-03-23 18:01:22
                            [post_content] => 
                            [post_title] => US Department of Defense – Novavax, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-08-31 10:53:46
                            [post_modified_gmt] => 2022-08-31 10:53:46
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2734
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [394] => WP_Post Object
                        (
                            [ID] => 2543
                            [post_author] => 5
                            [post_date] => 2021-03-12 18:15:58
                            [post_date_gmt] => 2021-03-12 18:15:58
                            [post_content] => 
                            [post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-08 14:44:44
                            [post_modified_gmt] => 2024-04-08 14:44:44
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2543
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [395] => WP_Post Object
                        (
                            [ID] => 2540
                            [post_author] => 5
                            [post_date] => 2021-03-12 18:12:48
                            [post_date_gmt] => 2021-03-12 18:12:48
                            [post_content] => 
                            [post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-08 14:45:16
                            [post_modified_gmt] => 2024-04-08 14:45:16
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2540
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [396] => WP_Post Object
                        (
                            [ID] => 2541
                            [post_author] => 5
                            [post_date] => 2021-03-12 18:11:14
                            [post_date_gmt] => 2021-03-12 18:11:14
                            [post_content] => 
                            [post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-09 11:56:06
                            [post_modified_gmt] => 2024-04-09 11:56:06
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2541
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [397] => WP_Post Object
                        (
                            [ID] => 2542
                            [post_author] => 5
                            [post_date] => 2021-03-12 14:21:07
                            [post_date_gmt] => 2021-03-12 14:21:07
                            [post_content] => 
                            [post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-08 14:50:26
                            [post_modified_gmt] => 2024-04-08 14:50:26
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2542
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [398] => WP_Post Object
                        (
                            [ID] => 2544
                            [post_author] => 5
                            [post_date] => 2021-03-12 14:16:06
                            [post_date_gmt] => 2021-03-12 14:16:06
                            [post_content] => 
                            [post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-08 14:46:26
                            [post_modified_gmt] => 2024-04-08 14:46:26
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2544
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [399] => WP_Post Object
                        (
                            [ID] => 2545
                            [post_author] => 5
                            [post_date] => 2021-03-12 14:14:38
                            [post_date_gmt] => 2021-03-12 14:14:38
                            [post_content] => 
                            [post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-08 14:47:00
                            [post_modified_gmt] => 2024-04-08 14:47:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2545
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [400] => WP_Post Object
                        (
                            [ID] => 2547
                            [post_author] => 5
                            [post_date] => 2021-03-12 13:58:55
                            [post_date_gmt] => 2021-03-12 13:58:55
                            [post_content] => 
                            [post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-08 14:49:19
                            [post_modified_gmt] => 2024-04-08 14:49:19
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2547
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [401] => WP_Post Object
                        (
                            [ID] => 2549
                            [post_author] => 5
                            [post_date] => 2021-03-12 13:50:41
                            [post_date_gmt] => 2021-03-12 13:50:41
                            [post_content] => 
                            [post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-08 14:48:07
                            [post_modified_gmt] => 2024-04-08 14:48:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2549
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [402] => WP_Post Object
                        (
                            [ID] => 2553
                            [post_author] => 5
                            [post_date] => 2021-03-12 13:47:42
                            [post_date_gmt] => 2021-03-12 13:47:42
                            [post_content] => 
                            [post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-08 14:52:33
                            [post_modified_gmt] => 2024-04-08 14:52:33
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2553
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [403] => WP_Post Object
                        (
                            [ID] => 2457
                            [post_author] => 5
                            [post_date] => 2021-02-25 15:25:57
                            [post_date_gmt] => 2021-02-25 15:25:57
                            [post_content] => 
                            [post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-12 11:10:03
                            [post_modified_gmt] => 2023-09-12 11:10:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2457
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [404] => WP_Post Object
                        (
                            [ID] => 2461
                            [post_author] => 5
                            [post_date] => 2021-02-25 15:23:35
                            [post_date_gmt] => 2021-02-25 15:23:35
                            [post_content] => 
                            [post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-14 08:34:20
                            [post_modified_gmt] => 2023-08-14 08:34:20
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2461
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [405] => WP_Post Object
                        (
                            [ID] => 2462
                            [post_author] => 5
                            [post_date] => 2021-02-25 15:23:19
                            [post_date_gmt] => 2021-02-25 15:23:19
                            [post_content] => 
                            [post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-14 08:38:00
                            [post_modified_gmt] => 2023-08-14 08:38:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2462
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [406] => WP_Post Object
                        (
                            [ID] => 2463
                            [post_author] => 5
                            [post_date] => 2021-02-25 15:22:52
                            [post_date_gmt] => 2021-02-25 15:22:52
                            [post_content] => 
                            [post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-14 08:29:37
                            [post_modified_gmt] => 2023-08-14 08:29:37
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2463
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [407] => WP_Post Object
                        (
                            [ID] => 2464
                            [post_author] => 5
                            [post_date] => 2021-02-25 15:21:51
                            [post_date_gmt] => 2021-02-25 15:21:51
                            [post_content] => 
                            [post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-14 08:33:41
                            [post_modified_gmt] => 2023-08-14 08:33:41
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2464
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [408] => WP_Post Object
                        (
                            [ID] => 2465
                            [post_author] => 5
                            [post_date] => 2021-02-25 15:21:32
                            [post_date_gmt] => 2021-02-25 15:21:32
                            [post_content] => 
                            [post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-14 08:39:58
                            [post_modified_gmt] => 2023-08-14 08:39:58
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2465
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [409] => WP_Post Object
                        (
                            [ID] => 2466
                            [post_author] => 5
                            [post_date] => 2021-02-25 15:20:40
                            [post_date_gmt] => 2021-02-25 15:20:40
                            [post_content] => 
                            [post_title] => US Department of Defense - Sanofi, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-01-09 13:55:12
                            [post_modified_gmt] => 2024-01-09 13:55:12
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2466
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [410] => WP_Post Object
                        (
                            [ID] => 2467
                            [post_author] => 5
                            [post_date] => 2021-02-25 15:20:15
                            [post_date_gmt] => 2021-02-25 15:20:15
                            [post_content] => 
                            [post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-14 08:32:07
                            [post_modified_gmt] => 2023-08-14 08:32:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2467
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [411] => WP_Post Object
                        (
                            [ID] => 2470
                            [post_author] => 5
                            [post_date] => 2021-01-25 13:24:13
                            [post_date_gmt] => 2021-01-25 13:24:13
                            [post_content] => 
                            [post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-08 14:55:11
                            [post_modified_gmt] => 2024-04-08 14:55:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2470
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [412] => WP_Post Object
                        (
                            [ID] => 2473
                            [post_author] => 5
                            [post_date] => 2021-01-25 13:21:58
                            [post_date_gmt] => 2021-01-25 13:21:58
                            [post_content] => 
                            [post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-09 11:53:04
                            [post_modified_gmt] => 2024-04-09 11:53:04
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2473
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [413] => WP_Post Object
                        (
                            [ID] => 2474
                            [post_author] => 5
                            [post_date] => 2021-01-25 13:19:34
                            [post_date_gmt] => 2021-01-25 13:19:34
                            [post_content] => 
                            [post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-09 07:56:43
                            [post_modified_gmt] => 2024-04-09 07:56:43
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2474
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [414] => WP_Post Object
                        (
                            [ID] => 2475
                            [post_author] => 5
                            [post_date] => 2021-01-25 13:18:53
                            [post_date_gmt] => 2021-01-25 13:18:53
                            [post_content] => 
                            [post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-08 14:57:42
                            [post_modified_gmt] => 2024-04-08 14:57:42
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2475
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [415] => WP_Post Object
                        (
                            [ID] => 2476
                            [post_author] => 5
                            [post_date] => 2021-01-25 13:18:09
                            [post_date_gmt] => 2021-01-25 13:18:09
                            [post_content] => 
                            [post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-09 07:54:07
                            [post_modified_gmt] => 2024-04-09 07:54:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2476
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [416] => WP_Post Object
                        (
                            [ID] => 2477
                            [post_author] => 5
                            [post_date] => 2021-01-25 13:16:23
                            [post_date_gmt] => 2021-01-25 13:16:23
                            [post_content] => 
                            [post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-08 14:56:25
                            [post_modified_gmt] => 2024-04-08 14:56:25
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2477
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [417] => WP_Post Object
                        (
                            [ID] => 2479
                            [post_author] => 5
                            [post_date] => 2021-01-25 13:12:32
                            [post_date_gmt] => 2021-01-25 13:12:32
                            [post_content] => 
                            [post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-09 07:54:52
                            [post_modified_gmt] => 2024-04-09 07:54:52
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2479
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [418] => WP_Post Object
                        (
                            [ID] => 2481
                            [post_author] => 5
                            [post_date] => 2021-01-25 13:11:08
                            [post_date_gmt] => 2021-01-25 13:11:08
                            [post_content] => 
                            [post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-08 14:59:21
                            [post_modified_gmt] => 2024-04-08 14:59:21
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2481
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [419] => WP_Post Object
                        (
                            [ID] => 2482
                            [post_author] => 5
                            [post_date] => 2021-01-25 13:09:37
                            [post_date_gmt] => 2021-01-25 13:09:37
                            [post_content] => 
                            [post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-09 07:59:48
                            [post_modified_gmt] => 2024-04-09 07:59:48
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2482
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [420] => WP_Post Object
                        (
                            [ID] => 2471
                            [post_author] => 5
                            [post_date] => 2021-01-25 13:08:02
                            [post_date_gmt] => 2021-01-25 13:08:02
                            [post_content] => 
                            [post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-08 14:54:15
                            [post_modified_gmt] => 2024-04-08 14:54:15
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2471
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [421] => WP_Post Object
                        (
                            [ID] => 2452
                            [post_author] => 5
                            [post_date] => 2021-01-19 11:41:19
                            [post_date_gmt] => 2021-01-19 11:41:19
                            [post_content] => 
                            [post_title] => US Department of Defense – Moderna, COVID-19 Vaccine Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-dod-supply-agreement-for-mrna-vaccine-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-02 14:36:20
                            [post_modified_gmt] => 2023-08-02 14:36:20
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2452
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [422] => WP_Post Object
                        (
                            [ID] => 2450
                            [post_author] => 5
                            [post_date] => 2021-01-19 11:04:23
                            [post_date_gmt] => 2021-01-19 11:04:23
                            [post_content] => 
                            [post_title] => US Department of Defense - Moderna, COVID-19 Vaccine Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-dod-supply-agreement-for-mrna-vaccine-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-02 14:49:16
                            [post_modified_gmt] => 2023-08-02 14:49:16
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2450
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [423] => WP_Post Object
                        (
                            [ID] => 2449
                            [post_author] => 5
                            [post_date] => 2021-01-19 10:47:27
                            [post_date_gmt] => 2021-01-19 10:47:27
                            [post_content] => 
                            [post_title] => US Department of Defense - Moderna, COVID-19 Vaccine Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-dod-supply-agreement-for-mrna-vaccine-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-04-09 12:58:57
                            [post_modified_gmt] => 2024-04-09 12:58:57
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2449
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [424] => WP_Post Object
                        (
                            [ID] => 2448
                            [post_author] => 5
                            [post_date] => 2021-01-19 10:24:45
                            [post_date_gmt] => 2021-01-19 10:24:45
                            [post_content] => 
                            [post_title] => US Department of Defense - Moderna, COVID-19 Vaccine Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-dod-supply-agreement-for-mrna-vaccine
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-02 14:47:07
                            [post_modified_gmt] => 2023-08-02 14:47:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2448
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [425] => WP_Post Object
                        (
                            [ID] => 2444
                            [post_author] => 5
                            [post_date] => 2021-01-19 09:27:20
                            [post_date_gmt] => 2021-01-19 09:27:20
                            [post_content] => 
                            [post_title] => BARDA – Moderna, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-20 10:42:15
                            [post_modified_gmt] => 2023-06-20 10:42:15
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2444
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [426] => WP_Post Object
                        (
                            [ID] => 2443
                            [post_author] => 5
                            [post_date] => 2021-01-19 09:14:03
                            [post_date_gmt] => 2021-01-19 09:14:03
                            [post_content] => 
                            [post_title] => BARDA – Moderna, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-20 10:46:42
                            [post_modified_gmt] => 2023-06-20 10:46:42
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2443
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [427] => WP_Post Object
                        (
                            [ID] => 2442
                            [post_author] => 5
                            [post_date] => 2021-01-19 06:56:32
                            [post_date_gmt] => 2021-01-19 06:56:32
                            [post_content] => 
                            [post_title] => BARDA - Moderna, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-01-09 13:56:25
                            [post_modified_gmt] => 2024-01-09 13:56:25
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2442
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [428] => WP_Post Object
                        (
                            [ID] => 2441
                            [post_author] => 5
                            [post_date] => 2021-01-19 06:48:04
                            [post_date_gmt] => 2021-01-19 06:48:04
                            [post_content] => 
                            [post_title] => BARDA – Moderna, COVID-19 Vaccine Development Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-20 10:51:31
                            [post_modified_gmt] => 2023-06-20 10:51:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2441
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [429] => WP_Post Object
                        (
                            [ID] => 2426
                            [post_author] => 5
                            [post_date] => 2020-12-14 15:02:08
                            [post_date_gmt] => 2020-12-14 15:02:08
                            [post_content] => 
                            [post_title] => Sanofi – Translate Bio, Influenza and COVID-19 Vaccine Collaboration & License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-translate-bio-collaboration-and-license-agreement-as-amended-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-20 14:38:47
                            [post_modified_gmt] => 2023-07-20 14:38:47
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2426
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [430] => WP_Post Object
                        (
                            [ID] => 2424
                            [post_author] => 5
                            [post_date] => 2020-12-14 15:01:40
                            [post_date_gmt] => 2020-12-14 15:01:40
                            [post_content] => 
                            [post_title] => Sanofi – Translate Bio, Influenza and COVID-19 Vaccine Collaboration & License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => sanofi-translate-bio-collaboration-and-license-agreement-as-amended-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-05-04 11:56:17
                            [post_modified_gmt] => 2023-05-04 11:56:17
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2424
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [431] => WP_Post Object
                        (
                            [ID] => 3910
                            [post_author] => 5
                            [post_date] => 2022-12-15 14:44:16
                            [post_date_gmt] => 2022-12-15 14:44:16
                            [post_content] => 
                            [post_title] => Merck – MPP, Molnupiravir License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => msd-mpp-molnupiravir-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-02 15:21:46
                            [post_modified_gmt] => 2023-08-02 15:21:46
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3910
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [432] => WP_Post Object
                        (
                            [ID] => 3909
                            [post_author] => 5
                            [post_date] => 2021-11-22 13:29:28
                            [post_date_gmt] => 2021-11-22 13:29:28
                            [post_content] => 
                            [post_title] => Merck – MPP, Molnupiravir License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => msd-mpp-molnupiravir-license-agreement-17
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-27 14:48:06
                            [post_modified_gmt] => 2023-01-27 14:48:06
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3909
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [433] => WP_Post Object
                        (
                            [ID] => 3908
                            [post_author] => 5
                            [post_date] => 2021-11-22 13:20:09
                            [post_date_gmt] => 2021-11-22 13:20:09
                            [post_content] => 
                            [post_title] => Merck – MPP, Molnupiravir License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => msd-mpp-molnupiravir-license-agreement-16
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-27 14:48:24
                            [post_modified_gmt] => 2023-01-27 14:48:24
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3908
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [434] => WP_Post Object
                        (
                            [ID] => 3907
                            [post_author] => 5
                            [post_date] => 2021-11-22 13:07:49
                            [post_date_gmt] => 2021-11-22 13:07:49
                            [post_content] => 
                            [post_title] => Merck – MPP, Molnupiravir License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => msd-mpp-molnupiravir-license-agreement-15
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-27 14:48:44
                            [post_modified_gmt] => 2023-01-27 14:48:44
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3907
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [435] => WP_Post Object
                        (
                            [ID] => 3906
                            [post_author] => 5
                            [post_date] => 2021-11-22 12:57:50
                            [post_date_gmt] => 2021-11-22 12:57:50
                            [post_content] => 
                            [post_title] => Merck – MPP, Molnupiravir License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => msd-mpp-molnupiravir-license-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-27 14:49:01
                            [post_modified_gmt] => 2023-01-27 14:49:01
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3906
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [436] => WP_Post Object
                        (
                            [ID] => 3904
                            [post_author] => 5
                            [post_date] => 2021-11-22 12:20:20
                            [post_date_gmt] => 2021-11-22 12:20:20
                            [post_content] => 
                            [post_title] => Merck – MPP, Molnupiravir License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => msd-mpp-molnupiravir-license-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-27 14:47:28
                            [post_modified_gmt] => 2023-01-27 14:47:28
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3904
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [437] => WP_Post Object
                        (
                            [ID] => 3903
                            [post_author] => 5
                            [post_date] => 2021-11-22 12:04:07
                            [post_date_gmt] => 2021-11-22 12:04:07
                            [post_content] => 
                            [post_title] => Merck – MPP, Molnupiravir License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => msd-mpp-molnupiravir-license-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-27 14:49:54
                            [post_modified_gmt] => 2023-01-27 14:49:54
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3903
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [438] => WP_Post Object
                        (
                            [ID] => 3901
                            [post_author] => 5
                            [post_date] => 2021-11-22 11:42:55
                            [post_date_gmt] => 2021-11-22 11:42:55
                            [post_content] => 
                            [post_title] => Merck – MPP, Molnupiravir License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => msd-mpp-molnupiravir-license-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-27 14:50:40
                            [post_modified_gmt] => 2023-01-27 14:50:40
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3901
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [439] => WP_Post Object
                        (
                            [ID] => 3900
                            [post_author] => 5
                            [post_date] => 2021-11-22 11:35:10
                            [post_date_gmt] => 2021-11-22 11:35:10
                            [post_content] => 
                            [post_title] => Merck – MPP, Molnupiravir License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => msd-mpp-molnupiravir-license-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-27 14:51:19
                            [post_modified_gmt] => 2023-01-27 14:51:19
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3900
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [440] => WP_Post Object
                        (
                            [ID] => 3899
                            [post_author] => 5
                            [post_date] => 2021-11-22 11:24:36
                            [post_date_gmt] => 2021-11-22 11:24:36
                            [post_content] => 
                            [post_title] => Merck – MPP, Molnupiravir License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => msd-mpp-molnupiravir-license-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-02 15:17:52
                            [post_modified_gmt] => 2023-08-02 15:17:52
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3899
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [441] => WP_Post Object
                        (
                            [ID] => 3898
                            [post_author] => 5
                            [post_date] => 2021-11-22 11:02:44
                            [post_date_gmt] => 2021-11-22 11:02:44
                            [post_content] => 
                            [post_title] => Merck – MPP, Molnupiravir License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => msd-mpp-molnupiravir-license-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-27 14:52:13
                            [post_modified_gmt] => 2023-01-27 14:52:13
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3898
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [442] => WP_Post Object
                        (
                            [ID] => 3897
                            [post_author] => 5
                            [post_date] => 2021-11-22 10:34:34
                            [post_date_gmt] => 2021-11-22 10:34:34
                            [post_content] => 
                            [post_title] => Merck – MPP, Molnupiravir License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => msd-mpp-molnupiravir-license-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-27 14:52:36
                            [post_modified_gmt] => 2023-01-27 14:52:36
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3897
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [443] => WP_Post Object
                        (
                            [ID] => 3896
                            [post_author] => 5
                            [post_date] => 2021-11-22 10:27:28
                            [post_date_gmt] => 2021-11-22 10:27:28
                            [post_content] => 
                            [post_title] => Merck – MPP, Molnupiravir License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => msd-mpp-molnupiravir-license-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-27 14:52:57
                            [post_modified_gmt] => 2023-01-27 14:52:57
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3896
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [444] => WP_Post Object
                        (
                            [ID] => 3895
                            [post_author] => 5
                            [post_date] => 2021-11-22 10:20:20
                            [post_date_gmt] => 2021-11-22 10:20:20
                            [post_content] => 
                            [post_title] => Merck – MPP, Molnupiravir License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => msd-mpp-molnupiravir-license-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-10 14:41:01
                            [post_modified_gmt] => 2023-11-10 14:41:01
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3895
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [445] => WP_Post Object
                        (
                            [ID] => 3892
                            [post_author] => 5
                            [post_date] => 2021-11-19 13:53:26
                            [post_date_gmt] => 2021-11-19 13:53:26
                            [post_content] => 
                            [post_title] => Merck – MPP, Molnupiravir License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => msd-mpp-molnupiravir-license-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-18 11:44:42
                            [post_modified_gmt] => 2023-07-18 11:44:42
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3892
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [446] => WP_Post Object
                        (
                            [ID] => 3891
                            [post_author] => 5
                            [post_date] => 2021-11-19 13:11:12
                            [post_date_gmt] => 2021-11-19 13:11:12
                            [post_content] => 
                            [post_title] => Merck – MPP, Molnupiravir License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => msd-mpp-molnupiravir-license-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-01-27 14:54:03
                            [post_modified_gmt] => 2023-01-27 14:54:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3891
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [447] => WP_Post Object
                        (
                            [ID] => 3406
                            [post_author] => 5
                            [post_date] => 2021-06-30 18:25:58
                            [post_date_gmt] => 2021-06-30 18:25:58
                            [post_content] => 
                            [post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-29 13:06:12
                            [post_modified_gmt] => 2023-08-29 13:06:12
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3406
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [448] => WP_Post Object
                        (
                            [ID] => 2873
                            [post_author] => 6
                            [post_date] => 2021-05-11 15:17:08
                            [post_date_gmt] => 2021-05-11 15:17:08
                            [post_content] => 
                            [post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-01-10 16:28:18
                            [post_modified_gmt] => 2024-01-10 16:28:18
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2873
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [449] => WP_Post Object
                        (
                            [ID] => 2872
                            [post_author] => 6
                            [post_date] => 2021-05-11 15:14:24
                            [post_date_gmt] => 2021-05-11 15:14:24
                            [post_content] => 
                            [post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-01-10 16:29:16
                            [post_modified_gmt] => 2024-01-10 16:29:16
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2872
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [450] => WP_Post Object
                        (
                            [ID] => 2870
                            [post_author] => 6
                            [post_date] => 2021-05-11 15:07:59
                            [post_date_gmt] => 2021-05-11 15:07:59
                            [post_content] => 
                            [post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-01-10 16:29:53
                            [post_modified_gmt] => 2024-01-10 16:29:53
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2870
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [451] => WP_Post Object
                        (
                            [ID] => 2869
                            [post_author] => 6
                            [post_date] => 2021-05-11 14:53:04
                            [post_date_gmt] => 2021-05-11 14:53:04
                            [post_content] => 
                            [post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-01-10 16:30:26
                            [post_modified_gmt] => 2024-01-10 16:30:26
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2869
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [452] => WP_Post Object
                        (
                            [ID] => 2867
                            [post_author] => 6
                            [post_date] => 2021-05-11 14:28:02
                            [post_date_gmt] => 2021-05-11 14:28:02
                            [post_content] => 
                            [post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => 2867
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-01-10 16:31:37
                            [post_modified_gmt] => 2024-01-10 16:31:37
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2867
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                )

            [post_count] => 453
            [current_post] => -1
            [before_loop] => 1
            [in_the_loop] => 
            [post] => WP_Post Object
                (
                    [ID] => 11750
                    [post_author] => 5
                    [post_date] => 2024-04-11 10:21:23
                    [post_date_gmt] => 2024-04-11 10:21:23
                    [post_content] => 
                    [post_title] => NIAID – AbCellera, COVID-19 Exclusive Patent License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => niaid-abcellera-covid-19-exclusive-patent-license-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-04-11 11:41:21
                    [post_modified_gmt] => 2024-04-11 11:41:21
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11750
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [comment_count] => 0
            [current_comment] => -1
            [found_posts] => 453
            [max_num_pages] => 0
            [max_num_comment_pages] => 0
            [is_single] => 
            [is_preview] => 
            [is_page] => 
            [is_archive] => 1
            [is_date] => 
            [is_year] => 
            [is_month] => 
            [is_day] => 
            [is_time] => 
            [is_author] => 
            [is_category] => 
            [is_tag] => 
            [is_tax] => 
            [is_search] => 1
            [is_feed] => 
            [is_comment_feed] => 
            [is_trackback] => 
            [is_home] => 
            [is_privacy_policy] => 
            [is_404] => 
            [is_embed] => 
            [is_paged] => 
            [is_admin] => 
            [is_attachment] => 
            [is_singular] => 
            [is_robots] => 
            [is_favicon] => 
            [is_posts_page] => 
            [is_post_type_archive] => 1
            [query_vars_hash:WP_Query:private] => ce3f9be18c942e640a2917b3fef17f46
            [query_vars_changed:WP_Query:private] => 1
            [thumbnails_cached] => 
            [allow_query_attachment_by_filename:protected] => 
            [stopwords:WP_Query:private] => Array
                (
                    [0] => about
                    [1] => an
                    [2] => are
                    [3] => as
                    [4] => at
                    [5] => be
                    [6] => by
                    [7] => com
                    [8] => for
                    [9] => from
                    [10] => how
                    [11] => in
                    [12] => is
                    [13] => it
                    [14] => of
                    [15] => on
                    [16] => or
                    [17] => that
                    [18] => the
                    [19] => this
                    [20] => to
                    [21] => was
                    [22] => what
                    [23] => when
                    [24] => where
                    [25] => who
                    [26] => will
                    [27] => with
                    [28] => www
                )

            [compat_fields:WP_Query:private] => Array
                (
                    [0] => query_vars_hash
                    [1] => query_vars_changed
                )

            [compat_methods:WP_Query:private] => Array
                (
                    [0] => init_query_flags
                    [1] => parse_tax_query
                )

        )

    [provisions] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 11750
                    [post_author] => 5
                    [post_date] => 2024-04-11 10:21:23
                    [post_date_gmt] => 2024-04-11 10:21:23
                    [post_content] => 
                    [post_title] => NIAID – AbCellera, COVID-19 Exclusive Patent License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => niaid-abcellera-covid-19-exclusive-patent-license-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-04-11 11:41:21
                    [post_modified_gmt] => 2024-04-11 11:41:21
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11750
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [1] => WP_Post Object
                (
                    [ID] => 11749
                    [post_author] => 5
                    [post_date] => 2024-04-11 10:01:28
                    [post_date_gmt] => 2024-04-11 10:01:28
                    [post_content] => 
                    [post_title] => NIAID – AbCellera, COVID-19 Exclusive Patent License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => niaid-abcellera-covid-19-exclusive-patent-license-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-04-11 11:41:05
                    [post_modified_gmt] => 2024-04-11 11:41:05
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11749
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [2] => WP_Post Object
                (
                    [ID] => 11748
                    [post_author] => 5
                    [post_date] => 2024-04-11 09:57:21
                    [post_date_gmt] => 2024-04-11 09:57:21
                    [post_content] => 
                    [post_title] => NIAID – AbCellera, COVID-19 Exclusive Patent License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => niaid-abcellera-covid-19-exclusive-patent-license-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-04-11 11:40:50
                    [post_modified_gmt] => 2024-04-11 11:40:50
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11748
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [3] => WP_Post Object
                (
                    [ID] => 11747
                    [post_author] => 5
                    [post_date] => 2024-04-11 09:54:19
                    [post_date_gmt] => 2024-04-11 09:54:19
                    [post_content] => 
                    [post_title] => NIAID – AbCellera, COVID-19 Exclusive Patent License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => niaid-abcellera-covid-19-exclusive-patent-license-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-04-11 11:40:37
                    [post_modified_gmt] => 2024-04-11 11:40:37
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11747
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [4] => WP_Post Object
                (
                    [ID] => 11746
                    [post_author] => 5
                    [post_date] => 2024-04-11 09:49:49
                    [post_date_gmt] => 2024-04-11 09:49:49
                    [post_content] => 
                    [post_title] => NIAID – AbCellera, COVID-19 Exclusive Patent License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => niaid-abcellera-covid-19-exclusive-patent-license-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-04-11 11:39:04
                    [post_modified_gmt] => 2024-04-11 11:39:04
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11746
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [5] => WP_Post Object
                (
                    [ID] => 11745
                    [post_author] => 5
                    [post_date] => 2024-04-11 09:44:15
                    [post_date_gmt] => 2024-04-11 09:44:15
                    [post_content] => 
                    [post_title] => NIAID – AbCellera, COVID-19 Exclusive Patent License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => niaid-abcellera-covid-19-exclusive-patent-license-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-04-11 11:39:36
                    [post_modified_gmt] => 2024-04-11 11:39:36
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11745
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [6] => WP_Post Object
                (
                    [ID] => 11744
                    [post_author] => 5
                    [post_date] => 2024-04-11 09:20:26
                    [post_date_gmt] => 2024-04-11 09:20:26
                    [post_content] => 
                    [post_title] => NIAID – AbCellera, COVID-19 Exclusive Patent License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => niaid-abcellera-covid-19-exclusive-patent-license-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-04-11 11:39:50
                    [post_modified_gmt] => 2024-04-11 11:39:50
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11744
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [7] => WP_Post Object
                (
                    [ID] => 11743
                    [post_author] => 5
                    [post_date] => 2024-04-11 09:11:35
                    [post_date_gmt] => 2024-04-11 09:11:35
                    [post_content] => 
                    [post_title] => NIAID – AbCellera, COVID-19 Exclusive Patent License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => niaid-abcellera-covid-19-exclusive-patent-license-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-04-11 11:39:22
                    [post_modified_gmt] => 2024-04-11 11:39:22
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11743
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [8] => WP_Post Object
                (
                    [ID] => 11742
                    [post_author] => 5
                    [post_date] => 2024-04-11 08:51:35
                    [post_date_gmt] => 2024-04-11 08:51:35
                    [post_content] => 
                    [post_title] => NIAID - AbCellera, COVID-19 Exclusive Patent License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => niaid-abcellera-covid-19-exclusive-patent-license-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-04-11 11:38:49
                    [post_modified_gmt] => 2024-04-11 11:38:49
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11742
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [9] => WP_Post Object
                (
                    [ID] => 11741
                    [post_author] => 5
                    [post_date] => 2024-04-11 08:26:17
                    [post_date_gmt] => 2024-04-11 08:26:17
                    [post_content] => 
                    [post_title] => NIAID - AbCellera, COVID-19 Exclusive Patent License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => niaid-abcellera-covid-19-exclusive-patent-license-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-04-11 11:38:34
                    [post_modified_gmt] => 2024-04-11 11:38:34
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11741
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [10] => WP_Post Object
                (
                    [ID] => 11740
                    [post_author] => 5
                    [post_date] => 2024-04-11 08:08:15
                    [post_date_gmt] => 2024-04-11 08:08:15
                    [post_content] => 
                    [post_title] => NIAID - AbCellera, COVID-19 Exclusive Patent License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => niaid-abcellera-covid-19-exclusive-patent-license-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-04-11 11:40:23
                    [post_modified_gmt] => 2024-04-11 11:40:23
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11740
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [11] => WP_Post Object
                (
                    [ID] => 11724
                    [post_author] => 5
                    [post_date] => 2024-04-11 07:44:23
                    [post_date_gmt] => 2024-04-11 07:44:23
                    [post_content] => 
                    [post_title] => NIAID - AbCellera, COVID-19 Exclusive Patent License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => niaid-abcellera-covid-19-exclusive-patent-license-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-04-11 11:40:05
                    [post_modified_gmt] => 2024-04-11 11:40:05
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11724
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [12] => WP_Post Object
                (
                    [ID] => 11610
                    [post_author] => 5
                    [post_date] => 2024-01-25 09:11:37
                    [post_date_gmt] => 2024-01-25 09:11:37
                    [post_content] => 
                    [post_title] => MPP (C-TAP) - Biotech Africa, COVID-19 Diagnostic, Patent & Material Sublicense Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-c-tap-biotech-africa-covid-19-diagnostic-patent-material-sublicense-agreement-13
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-01-25 09:11:37
                    [post_modified_gmt] => 2024-01-25 09:11:37
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11610
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [13] => WP_Post Object
                (
                    [ID] => 11609
                    [post_author] => 5
                    [post_date] => 2024-01-25 09:10:44
                    [post_date_gmt] => 2024-01-25 09:10:44
                    [post_content] => 
                    [post_title] => MPP (C-TAP) - Biotech Africa, COVID-19 Diagnostic, Patent & Material Sublicense Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-c-tap-biotech-africa-covid-19-diagnostic-patent-material-sublicense-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-01-25 09:10:44
                    [post_modified_gmt] => 2024-01-25 09:10:44
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11609
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [14] => WP_Post Object
                (
                    [ID] => 11606
                    [post_author] => 5
                    [post_date] => 2024-01-25 09:10:25
                    [post_date_gmt] => 2024-01-25 09:10:25
                    [post_content] => 
                    [post_title] => MPP (C-TAP) - Biotech Africa, COVID-19 Diagnostic, Patent & Material Sublicense Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-c-tap-biotech-africa-covid-19-diagnostic-patent-material-sublicense-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-01-25 09:10:25
                    [post_modified_gmt] => 2024-01-25 09:10:25
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11606
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [15] => WP_Post Object
                (
                    [ID] => 11605
                    [post_author] => 5
                    [post_date] => 2024-01-25 09:10:18
                    [post_date_gmt] => 2024-01-25 09:10:18
                    [post_content] => 
                    [post_title] => MPP (C-TAP) - Biotech Africa, COVID-19 Diagnostic, Patent & Material Sublicense Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-c-tap-biotech-africa-covid-19-diagnostic-patent-material-sublicense-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-01-25 09:35:04
                    [post_modified_gmt] => 2024-01-25 09:35:04
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11605
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [16] => WP_Post Object
                (
                    [ID] => 11604
                    [post_author] => 5
                    [post_date] => 2024-01-25 09:10:10
                    [post_date_gmt] => 2024-01-25 09:10:10
                    [post_content] => 
                    [post_title] => MPP (C-TAP) - Biotech Africa, COVID-19 Diagnostic, Patent & Material Sublicense Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-c-tap-biotech-africa-covid-19-diagnostic-patent-material-sublicense-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-01-25 09:10:10
                    [post_modified_gmt] => 2024-01-25 09:10:10
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11604
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [17] => WP_Post Object
                (
                    [ID] => 11618
                    [post_author] => 5
                    [post_date] => 2024-01-25 09:09:21
                    [post_date_gmt] => 2024-01-25 09:09:21
                    [post_content] => 
                    [post_title] => MPP (C-TAP) – Biotech Africa, COVID-19 Diagnostic, Patent & Material Sublicense Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-c-tap-biotech-africa-covid-19-diagnostic-patent-material-sublicense-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-01-25 09:09:21
                    [post_modified_gmt] => 2024-01-25 09:09:21
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11618
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [18] => WP_Post Object
                (
                    [ID] => 11613
                    [post_author] => 5
                    [post_date] => 2024-01-25 09:08:27
                    [post_date_gmt] => 2024-01-25 09:08:27
                    [post_content] => 
                    [post_title] => MPP (C-TAP) – Biotech Africa, COVID-19 Diagnostic, Patent & Material Sublicense Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-c-tap-biotech-africa-covid-19-diagnostic-patent-material-sublicense-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-01-25 09:08:27
                    [post_modified_gmt] => 2024-01-25 09:08:27
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11613
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [19] => WP_Post Object
                (
                    [ID] => 11611
                    [post_author] => 5
                    [post_date] => 2024-01-25 08:54:37
                    [post_date_gmt] => 2024-01-25 08:54:37
                    [post_content] => 
                    [post_title] => MPP (C-TAP) – Biotech Africa, COVID-19 Diagnostic, Patent & Material Sublicense Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-c-tap-biotech-africa-covid-19-diagnostic-patent-material-sublicense-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-01-25 08:54:37
                    [post_modified_gmt] => 2024-01-25 08:54:37
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11611
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [20] => WP_Post Object
                (
                    [ID] => 11602
                    [post_author] => 5
                    [post_date] => 2024-01-25 08:54:11
                    [post_date_gmt] => 2024-01-25 08:54:11
                    [post_content] => 
                    [post_title] => MPP (C-TAP) - Biotech Africa, COVID-19 Diagnostic, Patent & Material Sublicense Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-c-tap-biotech-africa-covid-19-diagnostic-patent-material-sublicense-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-01-25 09:36:08
                    [post_modified_gmt] => 2024-01-25 09:36:08
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11602
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [21] => WP_Post Object
                (
                    [ID] => 11617
                    [post_author] => 5
                    [post_date] => 2024-01-25 08:50:16
                    [post_date_gmt] => 2024-01-25 08:50:16
                    [post_content] => 
                    [post_title] => MPP (C-TAP) – Biotech Africa, COVID-19 Diagnostic, Patent & Material Sublicense Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-c-tap-biotech-africa-covid-19-diagnostic-patent-material-sublicense-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-01-25 08:50:16
                    [post_modified_gmt] => 2024-01-25 08:50:16
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11617
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [22] => WP_Post Object
                (
                    [ID] => 11616
                    [post_author] => 5
                    [post_date] => 2024-01-25 08:45:04
                    [post_date_gmt] => 2024-01-25 08:45:04
                    [post_content] => 
                    [post_title] => MPP (C-TAP) – Biotech Africa, COVID-19 Diagnostic, Patent & Material Sublicense Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-c-tap-biotech-africa-covid-19-diagnostic-patent-material-sublicense-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-01-25 08:45:04
                    [post_modified_gmt] => 2024-01-25 08:45:04
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11616
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [23] => WP_Post Object
                (
                    [ID] => 11614
                    [post_author] => 5
                    [post_date] => 2024-01-25 08:38:38
                    [post_date_gmt] => 2024-01-25 08:38:38
                    [post_content] => 
                    [post_title] => MPP (C-TAP) – Biotech Africa, COVID-19 Diagnostic, Patent & Material Sublicense Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-c-tap-biotech-africa-covid-19-diagnostic-patent-material-sublicense-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-01-25 08:38:38
                    [post_modified_gmt] => 2024-01-25 08:38:38
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11614
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [24] => WP_Post Object
                (
                    [ID] => 11607
                    [post_author] => 5
                    [post_date] => 2024-01-23 14:07:35
                    [post_date_gmt] => 2024-01-23 14:07:35
                    [post_content] => 
                    [post_title] => MPP (C-TAP) - Biotech Africa, COVID-19 Diagnostic, Patent & Material Sublicense Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-c-tap-biotech-africa-covid-19-diagnostic-patent-material-sublicense-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-01-25 09:10:31
                    [post_modified_gmt] => 2024-01-25 09:10:31
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11607
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [25] => WP_Post Object
                (
                    [ID] => 11361
                    [post_author] => 5
                    [post_date] => 2023-10-11 15:17:51
                    [post_date_gmt] => 2023-10-11 15:17:51
                    [post_content] => 
                    [post_title] => Medigen - MPP (C-TAP), COVID-19 Vaccine, Patent and Know How License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-15
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-10-11 16:01:11
                    [post_modified_gmt] => 2023-10-11 16:01:11
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11361
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [26] => WP_Post Object
                (
                    [ID] => 11360
                    [post_author] => 5
                    [post_date] => 2023-10-11 15:03:54
                    [post_date_gmt] => 2023-10-11 15:03:54
                    [post_content] => 
                    [post_title] => Medigen - MPP (C-TAP), COVID-19 Vaccine, Patent and Know How License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-14
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-10-11 16:02:40
                    [post_modified_gmt] => 2023-10-11 16:02:40
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11360
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [27] => WP_Post Object
                (
                    [ID] => 11359
                    [post_author] => 5
                    [post_date] => 2023-10-11 14:14:13
                    [post_date_gmt] => 2023-10-11 14:14:13
                    [post_content] => 
                    [post_title] => Medigen - MPP (C-TAP), COVID-19 Vaccine, Patent and Know How License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-13
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-10-11 16:00:13
                    [post_modified_gmt] => 2023-10-11 16:00:13
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11359
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [28] => WP_Post Object
                (
                    [ID] => 11358
                    [post_author] => 5
                    [post_date] => 2023-10-11 13:57:27
                    [post_date_gmt] => 2023-10-11 13:57:27
                    [post_content] => 
                    [post_title] => Medigen - MPP (C-TAP), COVID-19 Vaccine, Patent and Know How License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-10-11 15:59:35
                    [post_modified_gmt] => 2023-10-11 15:59:35
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11358
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [29] => WP_Post Object
                (
                    [ID] => 11357
                    [post_author] => 5
                    [post_date] => 2023-10-11 13:42:17
                    [post_date_gmt] => 2023-10-11 13:42:17
                    [post_content] => 
                    [post_title] => Medigen - MPP (C-TAP), COVID-19 Vaccine, Patent and Know How License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-10-11 15:59:14
                    [post_modified_gmt] => 2023-10-11 15:59:14
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11357
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [30] => WP_Post Object
                (
                    [ID] => 11356
                    [post_author] => 5
                    [post_date] => 2023-10-11 13:32:54
                    [post_date_gmt] => 2023-10-11 13:32:54
                    [post_content] => 
                    [post_title] => Medigen - MPP (C-TAP), COVID-19 Vaccine, Patent and Know How License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-10-11 15:51:52
                    [post_modified_gmt] => 2023-10-11 15:51:52
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11356
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [31] => WP_Post Object
                (
                    [ID] => 11354
                    [post_author] => 5
                    [post_date] => 2023-10-11 12:48:35
                    [post_date_gmt] => 2023-10-11 12:48:35
                    [post_content] => 
                    [post_title] => Medigen - MPP (C-TAP), COVID-19 Vaccine, Patent and Know How License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-10-11 15:52:44
                    [post_modified_gmt] => 2023-10-11 15:52:44
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11354
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [32] => WP_Post Object
                (
                    [ID] => 11353
                    [post_author] => 5
                    [post_date] => 2023-10-11 12:44:32
                    [post_date_gmt] => 2023-10-11 12:44:32
                    [post_content] => 
                    [post_title] => Medigen - MPP (C-TAP), COVID-19 Vaccine, Patent and Know How License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-10-11 15:53:24
                    [post_modified_gmt] => 2023-10-11 15:53:24
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11353
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [33] => WP_Post Object
                (
                    [ID] => 11351
                    [post_author] => 5
                    [post_date] => 2023-10-11 12:30:03
                    [post_date_gmt] => 2023-10-11 12:30:03
                    [post_content] => 
                    [post_title] => Medigen - MPP (C-TAP), COVID-19 Vaccine, Patent and Know How License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-10-11 15:56:38
                    [post_modified_gmt] => 2023-10-11 15:56:38
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11351
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [34] => WP_Post Object
                (
                    [ID] => 11350
                    [post_author] => 5
                    [post_date] => 2023-10-10 14:05:08
                    [post_date_gmt] => 2023-10-10 14:05:08
                    [post_content] => 
                    [post_title] => Medigen - MPP (C-TAP), COVID-19 Vaccine, Patent and Know How License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-10-11 15:54:46
                    [post_modified_gmt] => 2023-10-11 15:54:46
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11350
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [35] => WP_Post Object
                (
                    [ID] => 11349
                    [post_author] => 5
                    [post_date] => 2023-10-10 13:26:39
                    [post_date_gmt] => 2023-10-10 13:26:39
                    [post_content] => 
                    [post_title] => Medigen - MPP (C-TAP), COVID-19 Vaccine, Patent and Know How License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-10-11 15:54:08
                    [post_modified_gmt] => 2023-10-11 15:54:08
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11349
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [36] => WP_Post Object
                (
                    [ID] => 11347
                    [post_author] => 5
                    [post_date] => 2023-10-10 13:10:51
                    [post_date_gmt] => 2023-10-10 13:10:51
                    [post_content] => 
                    [post_title] => Medigen - MPP (C-TAP), COVID-19 Vaccine, Patent and Know How License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-10-11 15:58:36
                    [post_modified_gmt] => 2023-10-11 15:58:36
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11347
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [37] => WP_Post Object
                (
                    [ID] => 11348
                    [post_author] => 5
                    [post_date] => 2023-10-10 12:20:52
                    [post_date_gmt] => 2023-10-10 12:20:52
                    [post_content] => 
                    [post_title] => Medigen - MPP (C-TAP), COVID-19 Vaccine, Patent and Know How License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-10-11 15:52:12
                    [post_modified_gmt] => 2023-10-11 15:52:12
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11348
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [38] => WP_Post Object
                (
                    [ID] => 11346
                    [post_author] => 5
                    [post_date] => 2023-10-10 11:44:01
                    [post_date_gmt] => 2023-10-10 11:44:01
                    [post_content] => 
                    [post_title] => Medigen - MPP (C-TAP), COVID-19 Vaccine, Patent and Know How License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-10-11 15:50:28
                    [post_modified_gmt] => 2023-10-11 15:50:28
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11346
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [39] => WP_Post Object
                (
                    [ID] => 11345
                    [post_author] => 5
                    [post_date] => 2023-10-10 09:45:26
                    [post_date_gmt] => 2023-10-10 09:45:26
                    [post_content] => 
                    [post_title] => Medigen - MPP (C-TAP), COVID-19 Vaccine, Patent and Know How License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => mpp-c-tap-medigen-covid-19-vaccine-patent-and-know-how-license-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-10-11 15:57:28
                    [post_modified_gmt] => 2023-10-11 15:57:28
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11345
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [40] => WP_Post Object
                (
                    [ID] => 11337
                    [post_author] => 5
                    [post_date] => 2023-09-26 13:37:20
                    [post_date_gmt] => 2023-09-26 13:37:20
                    [post_content] => 
                    [post_title] => University of Chile – MPP (C-TAP), COVID-19 Diagnostic Material & Know-How License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => university-of-chile-mpp-c-tap-covid-19-diagnostic-material-know-how-license-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-27 09:20:14
                    [post_modified_gmt] => 2023-09-27 09:20:14
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11337
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [41] => WP_Post Object
                (
                    [ID] => 11336
                    [post_author] => 5
                    [post_date] => 2023-09-26 12:26:24
                    [post_date_gmt] => 2023-09-26 12:26:24
                    [post_content] => 
                    [post_title] => University of Chile – MPP (C-TAP), COVID-19 Diagnostic Material & Know-How License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => university-of-chile-mpp-c-tap-covid-19-diagnostic-material-know-how-license-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-27 09:19:55
                    [post_modified_gmt] => 2023-09-27 09:19:55
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11336
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [42] => WP_Post Object
                (
                    [ID] => 11335
                    [post_author] => 5
                    [post_date] => 2023-09-26 12:23:27
                    [post_date_gmt] => 2023-09-26 12:23:27
                    [post_content] => 
                    [post_title] => University of Chile – MPP (C-TAP), COVID-19 Diagnostic Material & Know-How License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => university-of-chile-mpp-c-tap-covid-19-diagnostic-material-know-how-license-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-27 09:19:29
                    [post_modified_gmt] => 2023-09-27 09:19:29
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11335
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [43] => WP_Post Object
                (
                    [ID] => 11334
                    [post_author] => 5
                    [post_date] => 2023-09-26 12:20:43
                    [post_date_gmt] => 2023-09-26 12:20:43
                    [post_content] => 
                    [post_title] => University of Chile – MPP (C-TAP), COVID-19 Diagnostic Material & Know-How License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => university-of-chile-mpp-c-tap-covid-19-diagnostic-material-know-how-license-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-27 09:17:25
                    [post_modified_gmt] => 2023-09-27 09:17:25
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11334
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [44] => WP_Post Object
                (
                    [ID] => 11333
                    [post_author] => 5
                    [post_date] => 2023-09-26 10:31:42
                    [post_date_gmt] => 2023-09-26 10:31:42
                    [post_content] => 
                    [post_title] => University of Chile – MPP (C-TAP), COVID-19 Diagnostic Material & Know-How License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => university-of-chile-mpp-c-tap-covid-19-diagnostic-material-know-how-license-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-27 09:17:46
                    [post_modified_gmt] => 2023-09-27 09:17:46
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11333
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [45] => WP_Post Object
                (
                    [ID] => 11331
                    [post_author] => 5
                    [post_date] => 2023-09-26 10:25:29
                    [post_date_gmt] => 2023-09-26 10:25:29
                    [post_content] => 
                    [post_title] => University of Chile - MPP (C-TAP), COVID-19 Diagnostic Material & Know-How License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => university-of-chile-mpp-c-tap-covid-19-diagnostic-material-know-how-license-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-27 09:18:47
                    [post_modified_gmt] => 2023-09-27 09:18:47
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11331
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [46] => WP_Post Object
                (
                    [ID] => 11330
                    [post_author] => 5
                    [post_date] => 2023-09-25 16:33:25
                    [post_date_gmt] => 2023-09-25 16:33:25
                    [post_content] => 
                    [post_title] => University of Chile - MPP (C-TAP), COVID-19 Diagnostic Material & Know-How License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => university-of-chile-mpp-c-tap-covid-19-diagnostic-material-know-how-license-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-27 09:18:26
                    [post_modified_gmt] => 2023-09-27 09:18:26
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11330
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [47] => WP_Post Object
                (
                    [ID] => 11329
                    [post_author] => 5
                    [post_date] => 2023-09-25 16:31:48
                    [post_date_gmt] => 2023-09-25 16:31:48
                    [post_content] => 
                    [post_title] => University of Chile - MPP (C-TAP), COVID-19 Diagnostic Material & Know-How License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => university-of-chile-mpp-c-tap-covid-19-diagnostic-material-know-how-license-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-27 09:18:04
                    [post_modified_gmt] => 2023-09-27 09:18:04
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11329
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [48] => WP_Post Object
                (
                    [ID] => 11328
                    [post_author] => 5
                    [post_date] => 2023-09-25 16:22:13
                    [post_date_gmt] => 2023-09-25 16:22:13
                    [post_content] => 
                    [post_title] => University of Chile - MPP (C-TAP), COVID-19 Diagnostic Material & Know-How License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => university-of-chile-mpp-c-tap-covid-19-diagnostic-material-know-how-license-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-27 09:16:55
                    [post_modified_gmt] => 2023-09-27 09:16:55
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11328
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [49] => WP_Post Object
                (
                    [ID] => 11327
                    [post_author] => 5
                    [post_date] => 2023-09-25 16:20:19
                    [post_date_gmt] => 2023-09-25 16:20:19
                    [post_content] => 
                    [post_title] => University of Chile - MPP (C-TAP), COVID-19 Diagnostic Material & Know-How License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => university-of-chile-mpp-c-tap-covid-19-diagnostic-material-know-how-license-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-27 09:19:08
                    [post_modified_gmt] => 2023-09-27 09:19:08
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11327
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [50] => WP_Post Object
                (
                    [ID] => 11260
                    [post_author] => 5
                    [post_date] => 2023-09-18 11:51:39
                    [post_date_gmt] => 2023-09-18 11:51:39
                    [post_content] => 
                    [post_title] => CSIC – MPP (C-TAP), COVID-19 Vaccine, Patent and Material License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-18 11:51:39
                    [post_modified_gmt] => 2023-09-18 11:51:39
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11260
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [51] => WP_Post Object
                (
                    [ID] => 11259
                    [post_author] => 5
                    [post_date] => 2023-09-18 11:17:07
                    [post_date_gmt] => 2023-09-18 11:17:07
                    [post_content] => 
                    [post_title] => CSIC – MPP (C-TAP), COVID-19 Vaccine, Patent and Material License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-18 11:17:07
                    [post_modified_gmt] => 2023-09-18 11:17:07
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11259
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [52] => WP_Post Object
                (
                    [ID] => 11258
                    [post_author] => 5
                    [post_date] => 2023-09-18 11:14:03
                    [post_date_gmt] => 2023-09-18 11:14:03
                    [post_content] => 
                    [post_title] => CSIC – MPP (C-TAP), COVID-19 Vaccine, Patent and Material License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-18 11:14:03
                    [post_modified_gmt] => 2023-09-18 11:14:03
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11258
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [53] => WP_Post Object
                (
                    [ID] => 11257
                    [post_author] => 5
                    [post_date] => 2023-09-18 10:52:07
                    [post_date_gmt] => 2023-09-18 10:52:07
                    [post_content] => 
                    [post_title] => CSIC – MPP (C-TAP), COVID-19 Vaccine, Patent and Material License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-18 11:52:21
                    [post_modified_gmt] => 2023-09-18 11:52:21
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11257
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [54] => WP_Post Object
                (
                    [ID] => 11256
                    [post_author] => 5
                    [post_date] => 2023-09-18 10:42:58
                    [post_date_gmt] => 2023-09-18 10:42:58
                    [post_content] => 
                    [post_title] => CSIC – MPP (C-TAP), COVID-19 Vaccine, Patent and Material License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-18 10:42:58
                    [post_modified_gmt] => 2023-09-18 10:42:58
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11256
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [55] => WP_Post Object
                (
                    [ID] => 11255
                    [post_author] => 5
                    [post_date] => 2023-09-18 10:36:46
                    [post_date_gmt] => 2023-09-18 10:36:46
                    [post_content] => 
                    [post_title] => CSIC – MPP (C-TAP), COVID-19 Vaccine, Patent and Material License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-18 10:37:13
                    [post_modified_gmt] => 2023-09-18 10:37:13
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11255
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [56] => WP_Post Object
                (
                    [ID] => 11254
                    [post_author] => 5
                    [post_date] => 2023-09-18 09:49:03
                    [post_date_gmt] => 2023-09-18 09:49:03
                    [post_content] => 
                    [post_title] => CSIC – MPP (C-TAP), COVID-19 Vaccine, Patent and Material License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-18 09:49:03
                    [post_modified_gmt] => 2023-09-18 09:49:03
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11254
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [57] => WP_Post Object
                (
                    [ID] => 11252
                    [post_author] => 5
                    [post_date] => 2023-09-18 09:45:34
                    [post_date_gmt] => 2023-09-18 09:45:34
                    [post_content] => 
                    [post_title] => CSIC – MPP (C-TAP), COVID-19 Vaccine, Patent and Material License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-18 09:45:34
                    [post_modified_gmt] => 2023-09-18 09:45:34
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11252
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [58] => WP_Post Object
                (
                    [ID] => 11251
                    [post_author] => 5
                    [post_date] => 2023-09-18 09:38:14
                    [post_date_gmt] => 2023-09-18 09:38:14
                    [post_content] => 
                    [post_title] => CSIC – MPP (C-TAP), COVID-19 Vaccine, Patent and Material License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-18 09:38:14
                    [post_modified_gmt] => 2023-09-18 09:38:14
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11251
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [59] => WP_Post Object
                (
                    [ID] => 11250
                    [post_author] => 5
                    [post_date] => 2023-09-18 09:35:19
                    [post_date_gmt] => 2023-09-18 09:35:19
                    [post_content] => 
                    [post_title] => CSIC – MPP (C-TAP), COVID-19 Vaccine, Patent and Material License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-18 09:35:19
                    [post_modified_gmt] => 2023-09-18 09:35:19
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11250
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [60] => WP_Post Object
                (
                    [ID] => 11248
                    [post_author] => 5
                    [post_date] => 2023-09-18 09:31:07
                    [post_date_gmt] => 2023-09-18 09:31:07
                    [post_content] => 
                    [post_title] => CSIC – MPP (C-TAP), COVID-19 Vaccine, Patent and Material License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => csic-mpp-c-tap-covid-19-vaccine-patent-and-material-license-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-18 09:31:07
                    [post_modified_gmt] => 2023-09-18 09:31:07
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11248
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [61] => WP_Post Object
                (
                    [ID] => 11247
                    [post_author] => 5
                    [post_date] => 2023-09-18 09:17:13
                    [post_date_gmt] => 2023-09-18 09:17:13
                    [post_content] => 
                    [post_title] => CSIC - MPP (C-TAP), COVID-19 Vaccine, Patent and Material License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_passw